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Abstract 
Hyperglycaemia on admission is a frequent finding in acute ischaemic stroke 
patients. This post-stroke hyperglycaemia (PSH) is associated with a poor clinical 
outcome independent of age and stroke severity. Evidence from clinical stroke 
studies indicates that hyperglycaemia is associated with a worse outcome in non-
diabetic compared to diabetic stroke patients, but the mechanisms underlying 
this association are poorly understood. Previous in-house studies reported that 
hyperglycaemia, at clinically-relevant blood glucose levels, exacerbated the 
evolution of early ischaemic damage in a non-diabetic rat stroke model, 
indicating that the detrimental effects of hyperglycaemia occur early following 
the onset of focal cerebral ischaemia. In ischaemic stroke the severity and 
duration of ischaemia are the major determinants of acute brain damage and 
therefore a potential mechanism by which hyperglycaemia exacerbates 
ischaemic damage could be through an influence on tissue perfusion. The studies 
in this thesis aimed to test the hypothesis that hyperglycaemia exacerbates early 
ischemic damage by increasing the severity of the cerebral blood flow (CBF) 
deficit. Initial studies were performed to optimise a rodent model with clinically 
relevant blood glucose levels before and after focal cerebral ischaemia induced 
by permanent middle cerebral artery occlusion (MCAO).  This animal model was 
then used in subsequent studies to assess the effect of hyperglycaemia on the 
CBF deficit after MCAO. The CBF deficit was assessed using two different 
methods: 99mTc-HMPAO blood flow autoradiography and MRI perfusion imaging. 
Each method offered its own advantages, for example, 99mTc-HMPAO 
autoradiography produces blood flow images with high spatial resolution 
enabling detailed semi-quantitative region of interest analysis and MRI perfusion 
imaging allowed repeated, quantitative CBF measurements at multiple time 
points after stroke. In addition, the use of MRI enabled concurrent diffusion 
weighted images to be acquired in order to assess the evolution of acute 
ischaemic damage and final T2 defined infarct volume.  The results demonstrate 
that hyperglycaemia exacerbates acute ischaemic damage induced by MCAO but 
not the perfusion deficit as measured by both 99mTc-HMPAO autoradiography and 
MRI.  These findings suggest that the primary mechanism of hyperglycaemia-
associated ischaemic damage is not mediated by an increase in the severity of 
ischaemia. Alternatively, the harmful effects of hyperglycaemia may  
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be predominantly mediated in the brain parenchyma. However Western blot 
analysis of ischaemic brain tissue showed that glucose treatment resulted in only 
minor changes in the levels of the calpain substrates MAP2 and αII-spectrin. 
Thus, the predominant mechanism exacerbated by hyperglycaemia does not 
appear to be calpain-mediated proteolysis, raising the possibility that 
hyperglycaemia affects many different mechanisms simultaneously. 
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Chapter 1 - Introduction
1 
 
1. Introduction 
1.1 Stroke 
1.1.1 Incidence and classification  
Stroke is the fourth most common cause of death in the UK and the second 
worldwide. In the UK there are approximately 152,000 strokes per year which 
leads to approximately 40,000 deaths (Stroke.org.uk, 2015).  The death rate 
from stroke varies between countries and regions, with parts of Scotland having 
some of the highest in the UK (Townsend et al., 2014).  Between 1990 and 2010, 
the incidence of stroke fell across the UK, in part due to improvements in stroke 
prevention and increasing awareness of healthy living (Krishnamurthi et al., 
2013). However, it is projected that the incidence of stroke will increase in the 
coming decades in developed countries due to the ageing population and 
expected increase in population size (Truelsen et al., 2006). 
The majority of strokes are not fatal and as a result stroke is the largest cause of 
severe disability.  More than half of stroke survivors are left with a disability and 
a third are dependent on others for tasks of daily living (Stroke.org.uk, 2015).   
Stroke is therefore a huge burden on the National Health Service (NHS) and 
economy.  From the most recent academic and National Audit office’s analyses, 
the estimated health and social care costs of stroke to the UK are approximately 
£4.4 billion per year (Stroke.org.uk, 2015). When taking into account informal 
care costs and those to the wider economy this figure approaches £9 billion 
(Saka et al., 2009). Despite the huge economic burden of stroke, stroke research 
in the UK is extremely underfunded compared to diseases with similar economic 
burden such as cancer and heart disease. For example, the social and healthcare 
costs of coronary heart disease and stroke were similar in 2012 yet the UK 
research spend for stroke was less than a third of that on coronary heart disease 
(Luengo-Fernandez et al., 2015). 
The World Health Organisation’s definition of stroke is: “rapidly developing 
clinical signs of focal (or global) disturbance of cerebral function, lasting more 
than 24 hours or leading to death, with no apparent cause other than that of 
vascular origin” (WHO, 1988). Transient ischaemic attacks (TIA) have the same 
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clinical features of stroke but symptoms can resolve within 24 hours.  A TIA 
should be considered as a warning sign of stroke or other cardiovascular 
complications given that 15 to 30% of cerebral infarctions are preceded by a TIA 
(Hankey and Warlow, 1999, Rothwell and Warlow, 2005). 
The vascular mechanisms leading to stroke can be classified as ischaemic and 
haemorrhagic. Haemorrhagic strokes account for 15% of all cases of stroke and 
occur when a blood vessel ruptures either within the brain (intracerebral 
haemorrhage) or on the surface of the brain (subarachnoid haemorrhage).  Due 
to the leakage of blood into the brain tissue at high pressures, haemorrhagic 
strokes are generally more severe and are associated with a higher rate of 
mortality compared with ischaemic strokes ((SSNAP), 2014).   
Ischaemic strokes are more common than haemorrhagic strokes, accounting for 
85% of all stroke cases. Ischaemic stroke results from a sudden reduction in 
blood flow to an area of the brain.  The reduction in cerebral blood flow (CBF) 
results from the formation of a blood clot which can arise in one of two ways: 
associated with an atherosclerotic plaque in a damaged artery within or leading 
to the brain (thrombotic stroke), or a clot that forms elsewhere in the body 
which then travels to the brain where it blocks a cerebral artery (embolic 
stroke).  Blood clots (emboli) which form in the heart account for 18-25% of all 
ischaemic strokes (Figure 1.1) (Arboix, 2014). The cause of the cardiac embolus 
is most commonly atrial fibrillation but can also arise in many other conditions 
including; dilated cardiomyopathy, endocarditis and patent foramen ovale 
(Arboix, 2010). Compared with other ischaemic stroke subtypes, cardioembolic 
stroke has the highest rate of in-hospital mortality (Murtagh and Smalling, 2006, 
Arboix, 2014). 
Ischaemic stroke arising from an atherosclerotic plaque is the most common, 
accounting for approximately 50% of all ischaemic strokes (Warlow et al., 2003). 
Atherosclerotic plaques develop when the inner lining of a blood vessel, the 
endothelium, becomes damaged due to underlying factors such as hypertension 
or hypercholesterolemia. Damage to the endothelium eventually leads to 
endothelial dysfunction and the accumulation of substances such as cholesterol, 
fats and cellular debris at the site of damage.  This initiates an inflammatory 
response and leads to the infiltration of inflammatory cells that interact with  
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Figure 1.1.  Ischaemic stroke arising from a cardiac embolus.  Stroke arising from a cardiac 
embolus accounts for around a quarter of all cases of ischaemic stroke.  Cardiac emboli can 
result from a number of conditions including: atrial fibrillation, dilated cardiomyopathy, 
endocarditis and patent foramen ovale.  Reproduced with permission from (Go, 2009), 
Copyright Massachusetts Medical Society. 
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low density lipoprotein (LDL) cholesterol and are converted into macrophages.  
The macrophages engulf LDL and by doing so are transformed into foam cells 
which accumulate and form the basis of the atherosclerotic plaque. Over time, 
plaques can increase in size, narrowing the blood vessel and restricting the flow 
of blood (Figure 1.2).  The atherosclerotic plaque can rupture, leading to the 
formation of a thrombus, which can occlude the vessel and prevent the flow of 
blood (Figure 1.2).   
Ischaemic strokes can also arise from lacunar or small vessel occlusions. This 
subtype of stroke accounts for a quarter of all ischaemic stroke cases and results 
from the occlusion of one of the deep penetrating arteries by microatheroma or 
lipohyalinosis (Jickling et al., 2011). These vessels are small and highly 
susceptible to damage induced by conditions such as hypertension. Brain injury 
from lacunar strokes is smaller than other stroke subtypes and as such they are 
generally associated with more favourable outcomes (Petty et al., 2000).  
The signs and symptoms of ischaemic stroke can vary depending of the vascular 
territory affected. The most common, visible signs of stroke include: facial 
weakness, hemiparesis of the left or right limbs (upper and lower) and slurred 
speech.  These signs are featured in the acronym, FAST- Face Arm Speech Time 
established in the UK to inform the public on how to recognize the signs of 
stroke and to understand the importance of emergency treatment. Other 
symptoms of stroke include: a sudden severe headache, blurred vision or loss of 
sight, and sudden confusion.   
1.1.2 Risk factors 
1.1.2.1 Non-modifiable Risk factors  
Age, gender, race and ethnicity are examples of non-modifiable risk factors for 
stroke.  Whilst it is not possible to modify such factors, they can be used to 
identify those patients that are most at risk and who might benefit from 
preventative treatment.  
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Figure 1.2. Ischaemic stroke arising from an atherosclerotic plaque.  The top image 
illustrates a normal artery with normal CBF. Damage to the endothelium initiates an 
inflammatory process which ultimately leads to the formation of a fibrous atherosclerotic 
plaque within the vessel wall. The plaque causes the artery to become narrowed and 
restricts blood flow (middle image). Over time, the plaque can continue to grow and occlude 
the vessel itself or it can rupture resulting in the formation of a thrombus.  The thrombus 
can occlude the artery which will obstruct the flow of blood resulting in an ischaemic stroke 
(bottom image) (Adapted (with permission) from (Stroke.org.uk, 2015)). 
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Age is the most important risk factor for stroke.  The chance of having a stroke 
doubles for each decade after the age of 55 in both men and woman (AHA/ASA, 
2012, Stroke.org.uk, 2015).  Estimates from the Framingham study, a long-term 
ongoing cardiovascular study, show that by the age of 75, 1 in 5 women and 1 in 
6 men will have a stroke (Seshadri et al., 2006).  Men have a 25% risk of having a 
stroke at an earlier age compared to women, but because women live longer 
than men there are more total incidences of stroke in women (Stroke.org.uk, 
2015).   
1.1.2.2 Modifiable risk factors. 
A larger number of risk factors for stroke are potentially modifiable (Figure 1.3).  
A recent study found that modifiable risk factors accounted for more than 80% of 
all strokes (O'Donnell et al., 2010). Hypertension is the leading modifiable risk 
factor for stroke, contributing to over 50% of strokes. Hypertension is defined as 
systolic/diastolic blood pressures consistently greater than 140/90mmHg and is a 
common problem, affecting approximately 10 million people in the UK 
(Stroke.org.uk, 2015).   
 
Diabetes is another major risk factor for the development of stroke and occurs 
when there is too much glucose in the blood (hyperglycaemia). There are two 
main types of diabetes: type 1 and type 2. Type 1 diabetes occurs when the 
body is not able to produce enough insulin to adequately regulate blood glucose 
levels.  Normally, blood glucose levels range from between 4-6mmol/L when 
fasting.  However in patients with type 1 (and type 2) diabetes fasting blood 
glucose levels are 7.0mmol/L or greater (Diabetes.co.uk).  Type 2 diabetes is 
the most common and occurs when the body is ineffective at using the insulin it 
produces or when it is unable to produce enough insulin.  There are over 3.3 
million people in the UK registered as diabetic and it is estimated that another 
850,000 people have undiagnosed diabetes (Stroke.org.uk, 2015). People who 
have diabetes (type 1 and type 2) are twice as likely to have a stroke compared 
to nondiabetics (Stroke.org.uk, 2015).  
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Figure 1.3.  Potentially modifiable risk factors for stroke. 
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Chronically elevated glucose levels contribute to the build-up of atherosclerotic 
plaques in blood vessels, this can be particularly damaging to small blood 
vessels, including capillaries, and may explain why diabetic patients display a 
greater tendency for lacunar stroke (Hill, 2014). The increased risk of stroke in 
diabetic patients could, in part, be due to an increase in fibrinogen, a 
glycoprotein that is involved in the formation of blood clots.  Increased plasma 
concentrations of fibrinogen have been reported in type 2 diabetic patients 
(Barazzoni et al., 2000) and this hyperfibrinogenemia is associated with an 
increased risk of cardiovascular and cerebrovascular disease (Kannel et al., 
1987).  
Conditions of abnormal glucose metabolism such as: prediabetes, insulin 
resistance and impaired fasting glucose, are also considered as important risk 
factors for stroke and a high incidence of these conditions is reported among 
ischaemic stroke patients (Urabe et al., 2009).    
 
1.1.3 Pathophysiology of ischaemic stroke 
The reduction in blood flow arising from an ischaemic stroke restricts the 
delivery of essential substrates to the territory of the occluded vessel.  This in 
turn initiates a cascade of deleterious biochemical and cellular events which 
converge to mediate brain damage.  The pathological processes in this cascade 
develop over hours and even days after the onset of ischaemia (Figure 1.4). This 
section will focus on the early events in this cascade, which are excitotoxicity, 
oxidative stress and peri-infarct depolarisations.   
1.1.3.1 Bioenergetic failure and excitotoxicity 
The brain has a relatively high energy demand: the weight of the brain makes up 
just 2% of the total body mass but it uses around 20% of the oxygen and 25% of 
the glucose consumed by the entire body.  Despite this, the brain has a limited 
capacity to store energy and is reliant on a continuous blood supply to deliver 
the essential substrates it needs to function.  Consequently, the brain is highly 
vulnerable to ischaemia.  When CBF is reduced during ischaemic stroke the 
delivery of oxygen and glucose is restricted and this leads to the rapid failure of 
the brains normal process for adenosine triphosphate (ATP) production:  
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Figure 1.4.  Simplified temporal profile of the major pathological mechanisms underlying 
focal cerebral ischaemia and their impact on ischaemic damage. Figure adapted from: 
(Dirnagl et al., 1999).  
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oxidative phosphorylation (Dirnagl et al., 1999).  This leads to a profound 
decrease in cellular ATP production and depletion of cellular ATP levels.  In 
addition, the lack of oxygen during focal ischaemia leads to the anaerobic 
metabolism of glucose and the build-up of lactate. An increase in lactate levels 
leads to intracellular acidification and further depletion of ATP.  Diminished ATP 
levels causes the sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) 
pump function to fail. This leads to the rapid loss of ionic gradients and the 
depolarisation of neurons and glia (Martin et al., 1994, Katsura et al., 1994).  
This in turn results in the activation of somatodendritic and presynaptic voltage-
gated calcium channels and the subsequent spontaneous release of excitatory 
amino acids, primarily glutamate, into the extracellular space (Brouns and De 
Deyn, 2009). At the same time, presynaptic reuptake of glutamate is reduced 
which further increases the extracellular concentration of glutamate. The rise in 
extracellular glutamate concentration leads to the pathological activation of 
glutamate receptors, inducing a type of neuronal insult called excitotoxicity.   
There are two main groups of excitatory glutamate receptors - ionotropic NMDA, 
AMPA and kainate receptors and metabotropic glutamate receptors (mGluRs) - in 
the central nervous system (CNS). Ionotropic receptors are named after the 
agonists that activate them: NMDA (N-methyl-D-aspartate), AMPA (α-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate), and kainic acid.  All of the ionotropic 
receptors are nonselective cation channels that allow the influx of sodium ions 
and the efflux of potassium ions.  However, during ischaemia when the Na+/K+-
ATPase fails, the influx of sodium ions is much greater than the efflux of 
potassium which results in the passive inflow of water into the cells leading to 
cytotoxic oedema. This can affect perfusion of brain tissue in surrounding areas 
and may also lead to increases in intracranial pressure and vascular compression 
(Dirnagl et al., 1999). The NMDA family of glutamate receptors are permeable to 
calcium and the excessive activation of NMDA receptors during ischaemia leads 
to the massive influx of calcium (Ca2+) into the cell.  In addition, the activation 
of mGluRs causes calcium to be released from intracellular stores, via 
phospholipase C and Ins(1,4,5)P3 signalling, which contributes to the calcium 
overload during excitotoxicity (Dirnagl et al., 1999). The rise in intracellular 
calcium is toxic to neurons and initiates a series of deleterious events including 
the generation of free radicals and the activation of proteolytic enzymes that 
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degrade proteins, membranes and nucleic acids. These events lead to neuronal 
cell death through necrosis but excitotoxic mechanisms can also induce delayed 
cell death via apoptosis. 
1.1.3.2 Ischaemia-induced activation of calpain 
Activation of the proteolytic enzyme, calpain is one of the key excitotoxic 
events to occur after ischaemia due to calcium overload.  Calpains are a  family 
of ubiquitous calcium sensitive cysteine proteases with a wide range of 
important physiological functions including: cytoskeletal alterations, cell cycle 
and differentiation processes, synaptic function and memory formation (Lynch 
and Baudry, 1984, Chan and Mattson, 1999a, Goll et al., 2003, Denny et al., 
1990). Under normal physiological conditions the activity of calpain is increased 
by transient, localized increases in the concentration of cytosolic calcium and 
tightly regulated by an endogenous inhibitor, calpastatin. However, the 
profound increase in cytosolic calcium, which occurs following the massive 
release of glutamate during ischaemia, overwhelms the endogenous regulation 
of calpain leading to pathological calpain activity and calpain-mediated brain 
injury (Neumar et al., 2001).   
Cleavage of the sodium-calcium exchanger (NCX) is considered to be an 
important mechanism by which the activation of calpain contributes to 
ischaemic damage. Sodium-calcium exchangers are antiporter membrane 
proteins that use the outward sodium gradient generated by the Na+/K+ ATPase 
to transport one calcium ion out of the cell and 3 sodium ions into the cell, and 
in doing so help to maintain the cells normal, low calcium concentration. Using 
an in vitro model of ischaemia, Bano et al (2005), found that calpain-mediated 
cleavage of the NCX inactivated the ionic exchange activity of the pump 
resulting in the retention of intracellular Ca2+, prolonged calpain activation and 
neurotoxicity.  These effects were reversed by over-expression of the calpain 
inhibitor, calpastatin (Bano et al., 2005).  Further to this, studies have shown 
that inhibition of calpain reduces ischaemic damage, indicating that calpains are 
important mediators of ischaemic brain damage (Hong et al., 1994a, Hong et al., 
1994b, Li et al., 1998). 
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1.1.3.3 Oxidative stress 
Oxidative stress has been implicated as an important mediator of neuronal cell 
death after cerebral ischaemia (Niizuma et al., 2009, Sugawara and Chan, 2003, 
Chan, 2001).  Following ischaemia, and in particular reperfusion, free radicals 
such as superoxide, hydrogen peroxide and hydroxyl radicals, are generated via 
a number of different mechanisms (Nakashima et al., 1999, Schaller and Graf, 
2004).  However, reactive oxygen species (ROS) generated from mitochondria 
are considered to be the primary source of free radical generation during 
ischaemia.  In addition to ROS, reactive nitrogen species (RNS) also contribute to 
tissue damage during ischaemia.  High levels of nitric oxide (NO) are produced 
during ischaemia via the calcium-dependent activation of the constitutive 
neuronal nitric oxide synthase and by the activation of inducible nitric oxide 
synthase in inflammatory cells (Castillo et al., 2000). NO reacts with superoxide 
producing the highly reactive peroxynitrite radical. Reactive oxygen and 
nitrogen species induce a wide array of cellular effects including: inactivation of 
enzymes, release of calcium ions from intracellular stores, protein denaturation, 
lipid peroxidation and damage to the cytoskeleton and DNA (Brouns and De 
Deyn, 2009). They can also lead to an increase in blood brain barrier 
permeability through the activation of matrix metalloproteinases (MMP), in 
particular matrix metalloproteinase 9 (Rosenberg et al., 1998, Montaner et al., 
2003), which contributes to the development of vasogenic oedema. 
1.1.3.4 Peri-infarct depolarisations 
Peri-infarct depolarisations (PIDs) are secondary mechanisms that can contribute 
to the expansion of the ischaemic lesion.  In the severely hypoperfused tissue of 
the ischaemic lesion (ischaemic core) cells undergo anoxic depolarisation and 
are unable to repolarise and go on to die.  However, in the moderately 
hypoperfused tissue bordering the ischaemic core, termed the ischaemic 
penumbra, the cells are able to repolarise but at the cost of high energy 
consumption.  Once repolarised, these cells have the ability to depolarise again 
in response to high extracellular glutamate and potassium concentrations.  This 
process can be repeated and repetitive depolarisations are called peri-infarct 
depolarisations.  The occurrence of PIDs has been well documented in animal 
stroke models where an increase in the frequency of PIDs is associated with 
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greater infarct growth (Back et al., 1996, Gill et al., 1992, Strong et al., 2000).  
This phenomenon has also been demonstrated in human stroke patients and may 
contribute to delayed ischaemic damage (Nakamura et al., 2010).  
1.1.3.5 Necrotic and apoptotic cell death 
During ischaemic stroke, brain cells can die via two distinct processes: necrosis 
or apoptosis. There are several factors that govern which process predominates 
including: the severity and nature of the stimulus and cell type and maturity 
(Brouns and De Deyn, 2009).   
Necrotic cell death is the predominant cell death mechanism that occurs in the 
tissue at the core of the ischaemic lesion which suffers the most severe 
reduction in blood flow (Dirnagl et al., 1999). Necrotic cell death in the 
ischaemic core occurs within minutes to hours after stroke onset and when cells 
die through this mechanism they release more glutamate and toxins into the 
extracellular environment which can affect surrounding neuronal and glial cells.  
Apoptosis, or programmed cell death, is the form of cell death which 
predominates in the peri-infarct brain tissue (Dirnagl et al., 1999), occurring 
within hours and can last for days after ischaemia onset.  Apoptosis may be 
initiated by caspase-dependent or caspase-independent pathways although 
caspase-dependent pathways are primarily involved in mediating cell death 
following focal cerebral ischaemia. Caspase-dependent apoptosis is mediated by 
the release of cytochrome C from the mitochondria. This facilitates the 
formation of the apoptosome complex which contains the cytosolic protein Apaf-
1 and procaspase 9.  The formation of the apoptosome complex promotes the 
activation of caspases, a family of cysteine proteases, which upon activation 
cleave a number of downstream substrates, including other “executioner” 
caspases, DNA repair enzymes, and cytoskeletal proteins.  Caspase-3 is one of 
the executioner caspases activated during brain ischaemia and its activation is 
considered to be a critical step in apoptosis. This is supported by the fact that 
pharmacological inhibition or genetic disruption of caspase-3 reduces ischaemic 
injury (Endres et al., 1998, Le et al., 2002).  
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1.1.4 Animal models of ischaemic stroke 
Animal models of stroke provide a valuable tool for studying the complex 
pathophysiology of stroke and for testing novel therapeutic agents.  The middle 
cerebral artery (MCA) is the cerebral vessel most commonly occluded in human 
ischaemic stroke (Treadwell and Thanvi, 2010), and pre-clinical studies reflect 
this as occlusion of the MCA is the most commonly used method to induce 
ischaemic stroke in animals.  The MCA can be occluded using various surgical 
methods which vary in their ability to model human disease.  The two methods 
of middle cerebral artery occlusion (MCAO) which are commonly used to induce 
focal cerebral ischaemia in the rat in our research group are: the intraluminal 
filament (ILF) method and the distal diathermy (DD) MCAO method.   
1.1.4.1 Intraluminal filament method 
The ILF method of MCAO, first described by Koizumi et al (1986) and later 
modified by Longa et al (1989), is the most commonly used method for studying 
ischaemic stroke in rats and mice.  This method involves the exposure of the 
common carotid artery through a midline incision in the neck and dissection and 
exposure of the internal and external carotid arteries.  The MCA is occluded by 
inserting a filament into the internal carotid artery and advancing it until it 
lodges in the narrow proximal anterior cerebral artery blocking the origin of the 
MCA.  Filaments can be made in-house using nylon monofilaments (Dermalon) or 
can be purchased from Doccol Corporation.  Ischaemic damage induced using the 
ILF method can be extensive, causing damage to the caudate nucleus and other 
subcortical structures, as well as significant damage to the cortex.  The typical 
pattern of ischaemic damage induced by the intraluminal filament method is 
shown on the T2-weighted magnetic resonance images in Figure 1.5 (Reid, 2012). 
A major advantage of this method is the potential to induce both permanent and 
transient occlusion of the MCA by leaving the filament in place or removing it 
after a specified.  Also, MCAO surgery using the intraluminal filament method 
does not require a craniotomy and can be done in a high throughput manner.  
The major disadvantage of this method is the low reproducibility in lesion size 
and high rate of subarachnoid haemorrhage development (Schmid-Elsaesser et 
al., 1998).   
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1.1.4.2 Distal diathermy method 
The distal diathermy method of MCAO involves the exposure of the MCA via a 
craniotomy followed by direct occlusion of the MCA using diathermy forceps to 
electrocoagulate the blood within the exposed portion of the vessel, thereby 
disrupting the structural integrity of the artery.  This method of MCAO was 
adapted from work by Robinson et al (1975) and Tamura et al (1981) who 
demonstrated that the extent of ischaemic damage is dependent of the position 
and length of the occluded vessel (Robinson et al., 1975, Tamura et al., 1981a).  
Occluding the distal stem of the MCA (above the lenticulostriate arteries) and its 
main cortical branches produces smaller lesions localised to the cerebral cortex 
in comparison to those induced by proximal MCA occlusion which produces both 
cortical and subcortical ischaemic damage. The smaller lesions produced by 
distal MCAO are advantageous as they are more relevant to human stroke 
(Carmichael, 2005) and also the craniectomy reduces the deleterious 
consequences of brain swelling and thereby reduces post-surgical mortality 
rates. Disadvantages of this method are that the craniotomy requires an 
acquired degree of neurosurgical skill and longer preparation time compared to 
other models.  T2-weighted magnetic resonance images demonstrating the 
typical pattern of ischaemic damage induced by distal diathermy MCAO are 
shown in Figure 1.6. 
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Figure 1.5. MRI RARE T2-weighted coronal brain images depicting ischaemic damage in 
Wistar Kyoto rats 24 hours after permanent MCAO induced by the intraluminal filament 
method. Images: rostral (A) to caudal (H).  Ischaemic damage on T2 images appears 
hyperintense and incorporates both cortical and subcortical brain regions. Images courtesy 
of Dr Emma Reid (Reid, 2012).  
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Figure 1.6.  MRI RARE T2-weighted coronal brain images demonstrating ischaemic damage 
24 hours after permanent MCAO induced by the distal diathermy method in adult, male 
Wistar rats. Images: rostral (A) to caudal (H).  Ischaemic damage on T2 images appears 
hyperintense and is primarily restricted to the cortex.   
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1.2 The ischaemic penumbra 
1.2.1 Cerebral blood flow 
Due to high oxygen consumption, the brain requires tight regulation of blood 
flow for survival.  In normotensive adults CBF is maintained relatively constant 
at around 55ml/100g/min by cerebral autoregulation.  Autoregulation refers to 
the physiological mechanisms (myogenic, neurogenic and metabolic) that 
maintain CBF at a constant level during changes in cerebral perfusion pressure 
(CPP) provided CPP is within the range of 50-150mmHg (Figure 1.7). Above and 
below this limit, autoregulatory mechanisms fail and CBF passively follows 
changes in mean arterial pressure and intracranial pressure.  When CPP falls 
below the lower limit, cerebral ischaemia ensues.  
1.2.2 Cerebral blood flow alteration in focal cerebral ischaemia 
Following stroke there is a topographical gradient of cerebral blood flow 
reduction across the territory of the supplied artery. The end-artery territory 
has the most severe reduction in blood flow and tissue within this region is 
referred to as the ischaemic core.  The profound or complete loss of CBF in the 
ischaemic core leads to irreversible tissue damage and this tissue will rapidly 
progress to infarction. The brain tissue at the periphery of this core - termed the 
ischaemic penumbra, experiences a less severe reduction in CBF as this region 
receives collateral flow from alternative routes, mostly via the circle of Willis or 
leptomeningeal anastomoses (Shuaib et al., 2011). Tissue within the ischaemic 
penumbra is functionally impaired but does not immediately progress to 
infarction and therefore has the capacity to regain normal function if blood flow 
is promptly restored. In addition to the ischaemic core and penumbra, there are 
some areas of tissue which experience a modest reduction in CBF which are not 
expected to become incorporated into the infarct.  This tissue is called benign 
oligaemic tissue and it may not be completely safe from ischaemic damage as 
modest reductions in CBF, in conjunction with pathological conditions such as 
hyperglycaemia or hypotension, could induce progressive damage.  
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Figure 1.7.  Cerebrovascular autoregulation in health and the influence of arterial blood 
gasses and CPP. CBF is maintained at a relatively constant level by autoregulation when 
CPP is within the range of 50-150mmHg. Out with the upper and lower limits of this range, at 
the point of maximal vasodilation and vasoconstriction, autoregulation is lost.  Hypercapnia 
and hypoxia cause blood vessels to dilate, leading to an increase in CBF whereas 
hypocapnia causes vasoconstriction and a decrease in blood flow. PaO2, PaCO2 partial 
pressures of oxygen/carbon dioxide in arterial blood. Figure adapted from (Shardlow and 
Jackson, 2011).  
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CBF thresholds for the ischaemic core and penumbra were first described by 
Lindsay Symon and colleagues in the 1970’s using a baboon model of focal 
cerebral ischaemia. They examined cortical-evoked responses to varying degrees 
of ischaemia and identified three different regions when CBF was progressively 
lowered: 
1. Benign oligaemic tissue in which cerebral function (somato-sensory 
evoked potentials) was normal despite a reduction in CBF from normal. 
2. Ischaemic penumbra tissue, where cerebral function was impaired at 
~20ml/100g/min.  
3. Ischaemic core where cerebral function was abolished at around 6-
10ml/100g/min.  
They also showed that the functional impairment in the ischaemic penumbra 
could be restored with an increase in CBF (Symon et al., 1977).  From these 
experiments the ischaemic penumbra was defined as: a region of functionally 
impaired but structurally intact hypoperfused tissue that is potentially viable.   
The definition of the ischaemic penumbra has evolved over the past 30-40 years 
due to advances in neuroimaging and a revised definition defines it as:  
“Ischaemic tissue which is functionally impaired and is at risk of infarction and 
has the potential to be salvaged by reperfusion and/or other strategies. If it is 
not salvaged this tissue is progressively recruited into the infarct core which will 
expand with time into the maximal volume originally at risk” (Donnan et al., 
2007). 
In addition, Donnan et al (2007) established a set of criteria to define the 
ischaemic penumbra (Figure 1.8)(Donnan et al., 2007). CBF thresholds to define 
the ischaemic core and ischaemic penumbra tissue have also been defined in 
human stroke (Figure 1.9)(Powers et al., 1985, Hakim et al., 1989, Baron et al., 
1984). Some of the brain imaging methods used to identify the ischaemic 
penumbra in human stroke will be discussed in the following section. 
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Figure 1.8.  Criteria for defining the ischaemic penumbra.  (Donnan et al., 2007). 
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Figure 1.9. Ischaemic core and penumbra.  Following occlusion of a cerebral artery, most 
commonly the middle cerebral artery, the region with the most severe reduction in blood 
flow is referred to as the ischaemic core. In humans, this region corresponds to a region 
with CBF below a value of approximately 12ml/100g/min.  At the periphery of this ischaemic 
core there is a region with less severely reduced blood flow termed the ischaemic 
penumbra.  Blood flow within this region can range from 12-22ml/100g/min. Benign 
oligaemic tissue is hypoperfused tissue in which CBF is above 22ml/100g/min that does not 
progress to infarction.  CBF values from: (Heiss, 2000) . 
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1.2.3 Imaging the ischaemic penumbra 
The identification of potentially salvageable penumbra tissue is hugely important 
in clinical and preclinical stroke research. Clinically it can be used to identify 
patients who are most likely to benefit from treatment.  Therapeutics for stroke 
are limited and although many neuroprotective strategies have shown efficacy in 
animal models of stroke there has been a failure to translate these results to the 
clinic. One contributing factor could be that many clinical studies included 
patients with no salvageable tissue, those patients that are least likely to 
benefit from treatment. Therefore identification of potentially viable penumbra 
tissue could allow new stroke therapies to be assessed in comparable patient 
groups, which in turn could aid translation from bench to bedside. Identification 
of the penumbra in preclinical research is equally important as it enables the 
efficacy of new neuroprotective strategies to be assessed.  Magnetic resonance 
imaging (MRI) is the favoured imaging modality in the preclinical setting 
although perfusion computed tomography (PET) is considered to be the gold 
standard for imaging the ischaemic penumbra clinically. However developments 
in MRI have led to an increase in the use of this technique to identify potentially 
viable tissue in the clinical setting.  Computed tomography (CT) is the most 
widely accessible and cost effective technique for diagnosing ischaemic stroke 
and the use of perfusion CT (PCT) to identify the ischaemic penumbra is being 
used increasingly. As such, PCT is likely to become one of the most widely used 
techniques for identifying the penumbra.  The use of these three imaging 
modalities to identify the ischaemic penumbra will be discussed in the following 
sections.  
1.2.3.1 Positron emission tomography 
PET imaging of the penumbra involves the intravenous administration of a 
positron emitting radioisotope bound to a tracer ligand.  The PET system detects 
the gamma rays emitted by the tracer and produces an image of the tracer’s 
distribution in the brain.  The presence of the ischaemic penumbra was first 
demonstrated in ischaemic stroke patients using PET with the 15O inhalation 
technique (Baron et al., 1981).  Using this method the penumbra was defined as 
a region of hypoperfused tissue (CBF>12-22ml/100g/min) with preserved 
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neuronal function (CMRO2 >65µmol/100g/min) and increased oxygen extraction 
fraction (80-100% above the normal 40%)(Heiss, 2003).  
The penumbra is a dynamic process and the flow values within the tissue 
deemed the ischaemic penumbra may vary depending on the time elapsed since 
stroke onset.  This stressed the need for a marker of neuronal integrity that 
could be used to distinguish between irreversibly damaged and potentially viable 
tissue regardless of variations in CBF over time.  This led to the use of 11C-
flumazenil (FMZ), a ligand for the benzodiazepine receptor subunit of the GABAA 
receptor, that was found to be a useful marker of neuronal integrity since GABAA 
receptors are abundant in neuronal tissue and are sensitive to ischaemic damage 
(Alicke and Schwartz-Bloom, 1995).  FMZ-PET imaging studies have demonstrated 
that the FMZ ligand can be reliably used to distinguish between irreversibly 
damaged (decreased FMZ binding) and penumbra (preserved FMZ 
binding/morphological integrity) tissue early after acute stroke (Heiss et al., 
2000). Other PET tracers such as 18F-fluromisonidazole have also been used to 
identify penumbra tissue. 18F-fluromisonidazole is a hypoxia tracer and the 
uptake of the tracer specifically occurs in viable hypoxic tissue (Read et al., 
1998).   
Although PET is an effective tool for imaging the ischaemic penumbra it has a 
number of disadvantages which make it impractical for clinical use.  Firstly, PET 
requires arterial cannulation for tracer administration and arterial blood 
sampling is necessary for CBF quantitation, both of which can restrict its use 
when thrombolytic therapy is planned. Secondly, the radioactive dose used 
limits the amount of times a patient can undergo PET imaging and therefore it is 
not suitable for studies requiring repeated measurements. Lastly, PET imaging is 
expensive and therefore it is not available in many stroke units around the 
world. Consequently, MRI and CT perfusion imaging are the preferred imaging 
modalities for imaging the ischaemic penumbra in the clinical setting. 
1.2.3.2 Perfusion computed tomography  
Perfusion computed tomography is the most widely accessible imaging tool for 
identifying the ischaemic penumbra and its advantages over other imaging 
methods include short imaging times and lower costs. PCT involves the 
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intravenous administration of an iodinated contrast agent and defines the 
penumbra based on changes in cerebral blood volume (CBV), CBF and mean 
transit time (MTT).  CBV is defined as the volume of flowing blood for a given 
volume of brain and is measured in units of ml per 100g of tissue.  MTT is 
measured in seconds and defines the mean time it takes for a volume of blood to 
transit a given volume of tissue. In normally perfused tissue perfusion is 
symmetrical with higher CBF and CBV in grey compared to white matter.  During 
ischaemic stroke the severe reduction in CBF, and loss of autoregulation, leads 
to a decrease in CBV and a prolonged MTT in the core of the ischaemic lesion. 
The tissue at the periphery of the ischaemic core also has a prolonged MTT but 
only moderately reduced CBF and almost normal or increased CBV (due to 
preserved cerebral autoregulation). Various definitions have been proposed to 
estimate the ischaemic penumbra using different CBF, CBV and MTT thresholds.  
A systematic review of all three PCT parameters found that a CBV threshold of 
2ml/100g most accurately defined the infarct core and a MTT  threshold ≥145% 
of normal most accurately describes the tissue at risk of infarction (Wintermark 
et al., 2006). Using these thresholds, the ability of PCT to identify the ischaemic 
penumbra has been validated against MRI measurements of perfusion-diffusion 
mismatch (Schaefer et al., 2008).  Therefore although MR is currently the 
preferred imaging method to evaluate core and penumbra, PCT is likely to 
become one of the most widely used imaging modalities due the high 
accessibility to computed tomography in stroke care units. 
1.2.3.3 Identifying the penumbra using MRI perfusion-diffusion mismatch 
Diffusion weighted imaging (DWI) is an established MRI technique that can 
accurately identify ischaemic tissue injury within minutes after stroke onset 
(Moseley et al., 1990, Yoneda et al., 1999).  DWI of acute stroke is based on the 
restricted diffusion of water molecules caused by ischaemia induced membrane 
dysfunction and cytotoxic oedema.  The restricted diffusion of protons leads to 
high signal intensity on DWI maps and can be quantitatively assessed using the 
apparent diffusion coefficient (ADC). ADC is a physiological measure of the rate 
of water movement through the brain tissue and is measured in units of 
mm2/sec. On ADC maps, regions of restricted diffusion have lower ADC values 
compared to regions with normal diffusion and appear hypointense.  MRI 
Perfusion imaging (PI) measures capillary blood flow and can be performed by a 
26 
 
bolus contrast technique or an arterial spin labelling (ASL) technique (Figure 
1.10).  The latter technique is less invasive as it does not require the 
administration of a contrast agent and instead uses electromagnetically labelled 
arterial blood water as an endogenous blood flow tracer. However it is not as 
widely used as it is more difficult to perform.  The mismatch between regions of 
diffusion and perfusion abnormality during acute ischaemic stroke has been used 
to estimate the ischaemic penumbra.  This perfusion-diffusion mismatch (PI-DWI 
mismatch) model developed from the observation that the diffusion lesion 
evolved over time to encompass the PI defined lesion in the absence of 
reperfusion (Baird et al., 1997, Warach et al., 2000). According to the PI-DWI 
mismatch model, the DWI lesion is taken to represent the ischaemic core, tissue 
that will progress to infarction regardless of reperfusion. The PI lesion, which is 
typically larger than the DWI lesion, represents hypoperfused tissue and the 
mismatch between them, is taken to represent the ischaemic penumbra.   
The PI-DWI mismatch model has been widely used to identify the ischaemic 
penumbra in acute ischaemic stroke patients. Darby et al (1999) reported that 
approximately 70% of patients studied within 24 hours of symptom onset had a 
PI-DWI mismatch (Darby et al., 1999).  Serial MRI studies have demonstrated the 
presence of mismatch tissue beyond 24 hours after stroke in some patients 
(Markus et al., 2004, Heiss et al., 1992), indicating that the time-window 
available for salvage of this tissue may be longer than the originally proposed 
time window of 3-6 hours.  
Several clinical studies have shown that patients with PI-DWI mismatch benefit 
from acute thrombolytic therapy (DIAS, DEFUSE, DEFUSE 2, EPITHET, DEDAS). 
The phase II Desmoteplase in acute ischaemic stroke trial (DIAS) recruited only 
patients that had at least a 20% PI-DWI mismatch. Using this criterion they found 
that patients treated with Desmoteplase within 9 hours of symptom onset had a 
higher rate of reperfusion and significantly improved clinical outcome compared 
to placebo treatment (Hacke et al., 2005). In the diffusion and perfusion imaging 
evaluation for understanding stroke evolution (DEFUSE) study, patients were not 
selected based on PI-DWI mismatch.  However this study showed that early 
reperfusion (within 3-6 hours after symptom onset) with intravenous alteplase 
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Figure 1.10. Diagram showing a summary of the arterial spin labelling technique. This 
technique uses electromagnetically labelled arterial blood water as an endogenous blood 
flow tracer. Two separate images are captured, one with magnetic labelling of arterial blood 
water (labelled image) and one without (control image).  Subtraction of labelled images from 
control images removes the signal from the static tissue leaving only the signal from the 
magnetically labelled blood which provides a relative measure of perfusion that is 
proportional to blood flow.  Figure adapted from: http://fmri.research.umich.edu. 
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was associated with favourable clinical outcomes in patients with mismatch 
tissue compared to those without (Albers et al., 2006). These studies 
demonstrate that the PI-DWI mismatch model can be successfully used to 
identify potentially salvageable tissue and in turn, those patients that are likely 
to benefit from thrombolytic therapy. However it may not always be reliable.  
There is evidence from animal studies and cases in humans reporting that the 
diffusion lesion can be temporarily or completely reversed following early 
reperfusion with thrombolytic therapy (Kidwell et al., 2000, Hasegawa et al., 
1994).  Thus, the diffusion lesion may not only include irreversibly damaged 
tissue, as defined by the mismatch model. There is also evidence that the 
perfusion lesion includes some benign oligaemic tissue and therefore does not 
always correctly identify tissue at risk of infarction (Rose et al., 2004, Sobesky 
et al., 2005). In order to address this problem, attempts have been made to 
establish diffusion and perfusion viability thresholds that can differentiate 
between regions that will proceed to infarction and salvageable penumbral 
tissue.  However, at present there is no clear consensus on where to set 
perfusion and diffusion thresholds in order to define mismatch tissue in both 
clinical and preclinical studies (Campbell and Macrae, 2015).   
The MRI PI-DWI mismatch model has also been used to assess the temporal 
evolution of ischaemic penumbra tissue in animal models of focal cerebral 
ischaemia. In a rodent model of permanent MCAO, Meng et al (2004) examined 
the temporal evolution of the PI-DWI mismatch.  They showed that the diffusion 
lesion expands over time to incorporate the larger perfusion lesion and that this 
corresponded with a reduction in the volume of PI-DWI mismatch tissue over 
time (Meng et al., 2004).  Meng and colleagues found that by 3 hours after 
permanent MCAO the ADC-derived lesion had fully evolved suggesting that the 
time window for penumbral salvage is short. The same group also examined the 
temporal evolution of PI-DWI mismatch tissue following transient MCAO (60 
minute occlusion period). They found that the infarct volume measured 24 hours 
after transient MCAO was significantly smaller than the acute diffusion lesion 
measured 3 hours after MCAO (Meng et al., 2004). This indicated that 
reperfusion following transient MCAO may have successfully salvaged penumbral 
tissue. The animals used by Meng and colleagues were normotensive Sprague 
Dawley rats but similar studies have also been performed in hypertensive rat 
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strains (Reid et al., 2012, McCabe et al., 2009, Letourneur et al., 2011).  
Compared to control Wistar Kyoto (WKY) rats, the size of the initial diffusion 
lesion was significantly greater in spontaneously hypertensive stroke prone 
(SHRSP) rats resulting in smaller volumes of PI-DWI mismatch tissue early after 
the onset of permanent MCAO. 
1.2.4 Salvaging the ischaemic penumbra 
Since the discovery of the penumbra and the potential to halt or even reverse 
neurological damage the main goal of ischaemic stroke therapy has been to 
salvage this tissue.  Tissue in the penumbra can be salvaged by restoring blood 
flow to the affected tissue and improving collateral flow.  Current therapies for 
stroke are limited and the available recanalization strategies include: blood clot 
thrombolysis with intravenous recombinant tissue plasminogen activator (rt-PA, 
alteplase), or surgical clot removal with endovascular devices (mechanical 
thrombectomy).  The latter is a highly specialised treatment that is not widely 
available as it is only performed in hospitals which have experience in using 
these devices.  However, in cases where this method has been used, substantial 
neurological improvements have been documented (Pereira et al., 2013, San 
Roman et al., 2012, Rohde et al., 2011). 
 
Thrombolysis with rt-PA is the most effective treatment for ischaemic stroke but 
despite this, less than 10% of all stroke patients currently receive it 
(ISD_Scotland, 2014).  This is mainly due to the narrow window of opportunity 
for treatment and the increased risk of haemorrhage with rt-PA use. In the first 
instance, thrombolysis treatment with rt-PA was licensed for use within 3 hours 
of stroke onset after the National Institute of Neurological Disorders and Stroke 
(NINDS) trial found that patients that received rt-PA within 3 hours of stroke 
symptom onset had improved clinical outcomes compared to placebo treated 
patients (NINDS, 1995).  The time window for rt-PA therapy has since been 
extended out to 4.5 hours after stroke onset (Hacke et al., 2008), but the 
number of patients receiving it remains low. Attempts have been made to 
improve this figure for example, the advertising campaign FAST, which aims to 
educate the public on identifying stroke symptoms and stresses the importance 
of seeking emergency treatment, has led to an increase in the number of 
patients arriving within the therapeutic time window (ISD_Scotland, 2014).  In 
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addition, the number of patients receiving rt-PA could be improved by the use of 
imaging techniques, rather than relying on the time from symptom onset, to 
identify those patients with penumbral tissue - those who are most likely to 
benefit from treatment. Indeed, the potential for selecting patients who might 
benefit from thrombolysis treatment beyond the 4.5 hour time window has been 
demonstrated clinically (Albers et al., 2006, Davis et al., 2008, Lansberg et al., 
2012). At present, the use of MRI PI-DWI mismatch to select patients that may 
benefit from rt-PA administered 4.5-9 hours after stroke onset or in patients 
with wake-up stroke is being tested in a phase 3 clinical trial (ECAS4-ExTEND). 
Extending the time window for thrombolysis treatment is an important method 
by which clinical outcomes may be improved. Ischaemic stroke is a highly 
heterogeneous disease and therefore each patient’s time window for treatment 
can vary. Furthermore, imaging studies have demonstrated the presence of 
potentially salvageable tissue up to 48 hours after symptom onset in some 
patients (Markus et al., 2004, Read et al., 2000, Heiss et al., 1992).  
 
As well as recanalisation therapy, these patients may also benefit from 
neuroprotective interventions.  Neuroprotective agents have been developed in 
an attempt to save neurons from irreversible injury, thereby preserving the 
ischaemic penumbra and extending the therapeutic time window for reperfusion 
therapies.  However, despite numerous neuroprotective strategies showing 
efficacy in animal models of focal cerebral ischaemia, at present no 
neuroprotective therapies have demonstrated efficacy in human stroke. There 
are a number of experimental factors which could have contributed to the 
failure of neuroprotective agents to translate from animal models to the clinic.  
One such factor is the use of mostly young, healthy animals in preclinical 
studies. This is not representative of the clinical stroke population, in which the 
majority of patients are elderly and have any number of underlying medical 
conditions such as diabetes and hypertension that can influence prognosis. 
Hyperglycaemia can also influence prognosis and is a potential target for 
therapeutic intervention. 
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1.3 Hyperglycaemia and Stroke 
Hyperglycaemia is a frequent finding in patients admitted to hospital with a 
suspected stroke:  arising in over 60% of stroke patients with no previous history 
of diabetes and in 90% of diabetics (Muir et al., 2011).  This post-stroke 
hyperglycaemia (PSH) is recognised as a predictor of mortality and disability 
independent of age, stroke type and severity.  Melamed and colleagues were one 
of the first groups to report on the significance of hyperglycaemia in acute 
stroke, demonstrating that hyperglycaemia was associated with significantly 
higher in-hospital mortality rates compared to normoglycaemic stroke patients 
(Melamed, 1976). Many more clinical stroke studies have also reported a similar 
association between hyperglycaemia and worse clinical outcomes (Table 
1.1)(Berger and Hakim, 1986, Weir et al., 1997, Melamed, 1976, Kiers et al., 
1992b, Baird et al., 2003, Parsons et al., 2002). This association was reviewed in 
a meta-analysis which reported that hyperglycaemia was associated with an 
increased relative risk of in-hospital mortality and poor functional outcomes 
after stroke (Capes et al., 2001).  Interestingly, the results from this meta-
analysis revealed that the unadjusted relative risk of in-hospital mortality and 
poor functional outcome was higher in non-diabetic stroke patients compared to 
those with a known history of the condition.  A more recent study also found 
that hyperglycaemia was independently associated with infarct growth and 
neurological deterioration in non-diabetic but not diabetic stroke patients 
(Shimoyama et al., 2014). Thus the adverse effects of hyperglycaemia may vary 
between diabetic and non-diabetic stroke patients. This is interesting as it 
suggests that there may be differences in the injury mechanisms induced by 
acute hyperglycaemia at the time of stroke onset compared to chronic 
hyperglycaemia (as in the case of diabetes).  Understanding these mechanisms 
will be important in terms of the future management and treatment of patients 
with PSH, as well as the identification of new therapeutic targets.  
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Table 1.1. Clinical studies demonstrating an association between hyperglycaemia and 
worse clinical outcomes. 
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The temporal profile of blood glucose levels after stroke is complex and varies 
from patient to patient. For example in some patients blood glucose levels are 
only elevated on admission, returning to normal after 24 hours. In others, 
hyperglycaemia may not be present on admission but may occur at some point 
during the first 72 hours after stroke (Allport et al., 2006). In addition, patients 
can show persistent hyperglycaemia, in which blood glucose levels are elevated 
on admission and remain elevated at 24 hours or longer after stroke (Yong and 
Kaste, 2008).  The outcome from stroke may vary depending on the temporal 
profile of blood glucose levels.  For example, Yong et al (2008) found that 
persistent hyperglycaemia was associated with worse neurological outcomes and 
an increased risk of mortality at 90 days, whereas hyperglycaemia only on 
admission was not associated with any parameters of worse outcome. This will 
have an impact on the design of any future clinical trials for the treatment of 
PSH, as this data indicates that only patients with persistent hyperglycaemia 
may benefit from treatment.  
1.3.1 Etiology of post-stroke hyperglycaemia 
Although hyperglycaemia is associated with increased mortality and disability in 
ischaemic stroke patients the underlying etiology of PSH is not fully understood.  
Many initial studies proposed that hyperglycaemia after acute ischaemic stroke 
arises from a stress reaction following a more severe stroke, leading to the 
activation of the hypothalamic-pituitary-adrenal axis and the subsequent release 
of stress hormones such as cortisol and catecholamines (O'Neill et al., 1991, 
Tracey et al., 1993, Tracey and Stout, 1994).  However, the stress response is 
disputed since later studies failed to demonstrate an association between 
hyperglycaemia, stress hormone levels and stroke severity (van Kooten et al., 
1993, Allport et al., 2006). The neuroanatomical location of the infarct has also 
been associated with elevated glucose levels after ischaemic stroke.  Allport et 
al (2004) reported that infarcts affecting the insular cortex predicted PSH 
(Allport et al., 2004), whilst others do not support an association between PSH 
and a neuroanatomical trigger for PSH (Moreton et al., 2007, Kiers et al., 
1992a). PSH might also be explained by the uncovering of underlying latent 
diabetes or a form of dysglycaemia as it has been reported that over 50% of 
stroke survivors diagnosed as having PSH were diabetic or had impaired glucose 
tolerance or metabolic syndrome  12 weeks after stroke (Gray et al., 2004).  
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1.3.2 Management of hyperglycaemia in ischaemic stroke 
There are no firm guidelines for the management of hyperglycaemia in acute 
ischaemic stroke.  Guidelines from the European Stroke Initiative recommend 
intervention with insulin when blood glucose levels exceed 10mmol/L.  However 
the optimum strategy will vary depending on the individual patient and the 
characteristics of the care-unit setting. Insulin treatment regimens are 
considered labour intensive, requiring consistent bedside glucose monitoring due 
to the potential for hypoglycaemia (Gray et al., 2007), which should be avoided 
as severe hypoglycaemia can exacerbate ischaemic damage (Zhu and Auer, 
2004). 
Some clinical trials have reported that tight glycaemic control (TGC) with 
intensive insulin regimens leads to better long-term outcomes in patients with 
myocardial infarction or other critical illnesses (Malmberg et al., 1995, Gibson et 
al., 2009).   However, others such as NICE-SUGAR found that TGC in critically ill 
patients can increase the risk of adverse events (Finfer et al., 2009). Relatively 
few clinical trials have examined the effectiveness of TGC protocols in the acute 
stroke setting and currently there is no significant evidence that TGC improves 
patient outcome (Ntaios et al., 2014).  The largest clinical trial to date is the UK 
Glucose Insulin in Stroke Trial (GIST-UK). GIST-UK investigated the effects of 
TGC with glucose-potassium-insulin (GKI) infusion therapy versus saline infusion 
in hyperglycaemic patients presenting within 24 hours of stroke onset with blood 
glucose levels between 6.0-17.0mmol/L. The data from GIST-UK indicate that 
there was no improvement in mortality rates or secondary outcome measures in 
patients treated with GKI compared to saline, however the results were 
inconclusive (Gray et al., 2007).  This is because the study failed to recruit the 
number of patients it set out to (only 933 out of 2355) and was therefore 
underpowered to be able to make accurate conclusions about clinical outcome.  
In addition, although the reduction in blood glucose levels between insulin and 
saline groups was clinically significant, the reduction was small: mean blood 
glucose was 0.57mmol/L lower than control.  However, the extent of the blood 
glucose reduction may not influence patient outcome  because in a smaller 
study, the treatment of hyperglycaemia in acute stroke (THIS) trial, in which a 
larger reduction of 3.6mmol/L from control was observed in patients treated 
with intravenous insulin, there was again no improvement in patients treated 
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with insulin (Bruno et al., 2008).   In the GRASP trial, which was a safety study 
and was therefore not powered to determine efficacy, exploratory efficacy 
analysis revealed that the TGC group had slightly better outcomes than controls 
(Johnston et al., 2009), and therefore supports further investigation of TGC for 
patients with PSH.  Whether insulin treatment can reduce mortality rates and 
improve clinical outcome in patients with PSH therefore remains to be 
determined.   
1.3.3 Pathophysiology of hyperglycaemia in ischaemic stroke 
The mechanisms by which hyperglycaemia mediates its harmful effects during 
ischaemia have not been fully elucidated.  Possible mechanistic explanations 
include: reduction in CBF, impaired recanalisation and increased reperfusion 
injury, increased lactic acidosis, enhancing excitotoxicity and increased 
oxidative stress and inflammation.  These have mostly been investigated in 
animal models of stroke as only a few clinical studies have addressed the 
pathophysiological mechanisms associated with hyperglycaemia. 
1.3.3.1 Reduced CBF 
In the normal rat brain, an intraperitoneal injection of glucose to induce severe 
hyperglycaemia (plasma glucose: 39mmol/L) induced a 24% reduction in regional 
CBF (Duckrow, 1995).  The reduction in CBF could not be fully explained by an 
increase in plasma osmolality as the injection of mannitol to induce a similar 
blood osmolality induced only a 10% reduction in regional CBF.  In rodent models 
of global and focal ischaemia, moderate hyperglycaemia (blood glucose 
~20mmol/L) induced a progressive reduction in CBF after the induction of 
ischaemia (Kawai et al., 1998). Similarly in cats, after 3 hours of focal cerebral 
ischaemia, moderate hyperglycaemia (plasma glucose ~20mmol/L) induced a 70% 
reduction in CBF after occlusion of the MCA compared with a lesser reduction of 
34% in normoglycaemic animals (Wagner et al., 1992). If hyperglycaemia reduces 
CBF following ischaemic stroke this could lead to a significantly larger volume of 
hypoperfused tissue and subsequently to greater ischaemic damage and 
neurological deficits. 
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One way in which hyperglycaemia may reduce CBF is through altering the 
reactivity of the cerebral microcirculation.  Mayhan and colleagues examined 
the response of rat cerebral arterioles In Vivo to various agonists (acetylcholine, 
histamine, NMDA and nitroglycerin) in the presence of increasing concentrations 
of glucose.  They found that in the presence of glucose concentrations of 20 and 
25mmol/L the dilation of the cerebral arterioles to the agonists acetylcholine, 
histamine and NMDA was inhibited but the response to nitroglycerin, a non-
endothelium dependent agonist, was not (Mayhan and Patel, 1995). This 
indicated that acute exposure to high glucose impairs endothelium dependent 
(NO-mediated) vasodilation. Thus, elevated blood glucose levels may reduce CBF 
by impairing NO-mediated vasodilation. This is comparable to the reported 
effects of diabetes on the cerebrovasculature.  Normally, exposure to 5% carbon 
dioxide (CO2) following normocapnia in healthy, non-diabetic patients causes 
cerebral blood vessels to dilate, resulting in an increase in CBF.  However this 
CO2-induced increase in CBF is markedly attenuated in diabetics, in which the 
endothelial production of NO is known to be reduced (Dandona et al., 1978, 
Griffith et al., 1987, Lin et al.).  In addition, the hyperglycaemia-mediated 
increase in ROS production (see below), can neutralise NO in the vessel wall 
which can further compromise cerebrovascular reactivity (Garg et al., 2006). 
Together this suggests that hyperglycaemia may reduce CBF by impairing NO 
production or reducing its availability. 
1.3.3.2 Pre-stroke hyperglycaemia   
As previously mentioned, over 50% of patients without a history of diabetes 
presenting with PSH are found to have diabetes or a related disorder of glucose 
metabolism at follow-up (3 months after stroke) (Gray et al., 2004). It is 
therefore highly possible that prior to their stroke, these patients had elevated 
blood glucose levels that could have induced morphological changes in the 
cerebrovasculature leading to neurovascular dysfunction.  This is a condition in 
which the normal blood flow increases during neural activity are suppressed and 
is thought to be caused by the production of ROS at the level of the vascular 
endothelium (Moskowitz et al., 2010, Iadecola and Davisson, 2008).  
Morphological and functional changes might also occur in cerebral capillaries and 
this has been found to occur in conditions which pre-dispose to stroke such as 
aging, hypertension and diabetes (Bell and Ball, 1981, Tagami et al., 1990, 
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Junker et al., 1985, McCuskey and McCuskey, 1984). The role of such capillary 
changes in the aetiology and pathophysiology of stroke is uncertain at present. It 
is hypothesised that constriction of capillary pericytes (contractile cells that 
wrap around the endothelium of capillaries) during ischaemia could block the 
flow of blood and may explain the lack of reperfusion (no-reflow phenomenon) 
that occurs in some patients (Yemisci et al., 2009, Ostergaard et al., 2013). Prior 
to stroke, changes in capillary morphology could disturb the passage of blood 
through capillary beds, affecting local oxygen delivery. This could contribute to 
the abnormal CBF responses found in neurovascular dysfunction.  During 
ischaemia this could be detrimental to the ischaemic penumbra where the 
survival of tissue depends on effective oxygen extraction to compensate for the 
reduced perfusion (Ostergaard et al., 2013). 
1.3.3.3 Impaired recanalisation and increased reperfusion injury  
Hyperglycaemia is associated with lower recanalisation rates in ischaemic stroke 
patients treated with rt-PA (Ribo et al., 2005). This may be caused by a decrease 
in plasma fibrinolytic activity and elevated plasma levels of plasminogen 
activator inhibitor type 1 (PAI-1), which have been reported to occur in both 
acute (Pandolfi et al., 2001) and chronic hyperglycaemic states (Auwerx et al., 
1988, Juhan-Vague et al., 1989).  Both a decrease is plasma fibrinolytic activity 
and increased levels of PAI-1 can reduce the thrombolytic activity of rt-PA and 
impair its ability to recanalise occluded blood vessels.  The lower recanalization 
rates in stroke patients with PSH may explain the worse outcome observed in 
these patients as this could prevent the restoration of blood flow to the 
potentially viable tissue in the ischaemic penumbra causing this tissue to 
become incorporated into the infarct.  
Evidence from animal models of transient focal cerebral ischaemia indicates that 
hyperglycaemia may exacerbate reperfusion injury (Nedergaard, 1987, Huang et 
al., 1996a, Kamada et al., 2007, Wei et al., 1997).  Reperfusion injury is the 
tissue damage caused by the restoration of blood to previously ischaemic tissue 
and is believed to be caused by the generation of ROS upon restoration of CBF. 
Hyperglycaemia may exacerbate reperfusion injury by increasing the production 
of free-radicals during reperfusion (Wei et al., 1997). This could lead to 
microvascular damage which in turn could impair the return of blood flow to the 
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tissue even after recanalization.  Evidence from animal stroke studies supports 
this hypothesis as studies have shown that the restoration of regional CBF to pre-
ischaemic levels following transient focal cerebral ischaemia was impaired in 
hyperglycaemic but not normoglycaemic animals (Kawai et al., 1997b, Wei et 
al., 2003).  
1.3.3.4 Lactic acidosis 
During ischaemia, the reduction in CBF and the resulting lack of oxygen delivery 
causes a shift from aerobic to anaerobic metabolism of glucose.  This leads to 
the production of lactic acid.  The level of lactic acid production is dependent 
on the amount of glucose available. Therefore, elevated blood glucose levels 
during ischaemia leads to increased levels of lactic acid and subsequently 
intracellular acidosis in the brain tissue.  Tissue acidosis may lead to greater 
ischaemic brain injury through enhancing the production of free radicals, 
activation of endonucleases leading to DNA fragmentation and altering gene 
expression or protein synthesis (Siesjo et al., 1996). Excessive lactate production 
may also cause the hypoperfused, yet potentially viable tissue in the ischaemic 
penumbra to progress to infarction.  Evidence from clinical and experimental 
studies supports this.   Parsons et al (2002) measured brain lactate levels, using 
magnetic resonance spectroscopy, in patients with PSH with evidence of 
perfusion-diffusion mismatch tissue.  They found that higher blood glucose levels 
were associated with increased lactate production in the ischaemic brain, which 
in turn was associated with reduced salvage of mismatch tissue. In addition, 
Anderson et al reported that severe hyperglycaemia (plasma glucose: 28mmol/L) 
worsened tissue acidosis and mitochondrial function in the ischaemic penumbra 
after permanent focal cerebral ischaemia in rabbits. Infarct volume was 
significantly greater in hyperglycaemic animals compared to controls and this 
supports the hypothesis that tissue acidosis leads to the recruitment of ischemic 
penumbra into infarction. In the normal brain, despite the fact that lactate is 
considered to be potentially toxic, it is now recognised that lactate may be a 
valuable energy substrate for neurons in cases of high energy demand (Pellerin, 
2010). Moreover, lactate metabolism is also recognised as an important 
substrate for ATP production during ischaemia (Pellerin and Magistretti, 1994) 
and therefore may be crucial for survival of the ischaemic penumbra. 
Furthermore, reducing brain lactate levels in patients with PSH did not influence 
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infarct growth (McCormick et al., 2010), indicating that brain lactic acidosis is 
not the only mediator of brain injury in hyperglycaemic ischaemia. 
1.3.3.5 Hyperglycaemia-mediated increase in excitotoxicity 
Hyperglycaemia may exacerbate the excitotoxic response after ischaemia.  
Following both global and focal cerebral ischaemia in rodents, the rise in 
extracellular glutamate levels in the ischaemic cerebral cortex was reported to 
be significantly greater in hyperglycaemic compared to normoglycaemic animals 
(Li et al., 2000b, Wei and Quast, 1998, Choi et al., 2010).  Furthermore, the 
increase in extracellular glutamate levels correlated with an increase in 
ischaemic brain injury (Wei and Quast, 1998). Increased extracellular glutamate 
levels during ischaemia could lead to an increase in glutamate receptor 
stimulation which in turn may lead to significantly greater levels of intracellular 
Ca2+ resulting in more Ca2+ mediated cell death. The increase in Ca2+ may also 
increase the activation of calcium-dependent proteolytic enzymes which can 
also lead to increased brain injury.  In particular, an increase in the activation of 
the calcium-dependent cysteine protease calpain has been reported in a rat 
model of chronic hyperglycaemia (Smolock et al., 2011).   
1.3.3.6 Increased oxidative stress and inflammation 
Hyperglycaemia is linked to increased oxidative stress following ischaemia.  The 
production of ROS during ischaemia increases in the presence of elevated 
glucose levels, particularly in combination with reperfusion (Tsuruta et al., 
2010). Hyperglycaemia can increase the production of superoxide through the 
enzyme NADPH oxidase.  During ischaemia/reperfusion, elevated glucose levels 
helps to sustain the production of NADPH, a substrate for the production of ROS, 
through the pentose phosphate pathway (Tang et al., 2012).  The increase in 
superoxide production during hyperglycaemic ischaemia can disrupt the blood 
brain barrier leading to increased vasogenic oedema (Kamada et al., 2007).  
Hyperglycaemia has also been found to have a profound effect on the 
inflammatory response after ischaemia.  In particular, hyperglycaemia has been 
shown to increase several transcription pathways that increase the migration of 
inflammatory cells such as leukocytes into the injured brain (Li et al., 2013).  
The migration of circulating leukocytes into the brain is thought to amplify 
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inflammatory signalling pathways which in turn will enhance ischaemic damage 
(Wang et al., 2007). In addition, the infiltration of leukocytes into the brain 
following transient focal ischaemia is enhanced under hyperglycaemic ischaemia 
(Lin et al., 2000).  
1.3.4 Hyperglycaemia and animal models of stroke 
Understanding the pathophysiology of hyperglycaemia in animal focal cerebral 
ischaemia models could help to inform the design of future clinical trials.  
However, the findings from animal studies show conflicting results.  Most studies 
are consistent with the clinical findings, reporting that hyperglycaemia increases 
ischaemic damage in both permanent (Decourtenmyers et al., 1988, Huang et 
al., 1996b, Prado et al., 1988) and transient (Huang et al., 1996b, Nedergaard, 
1987, Gisselsson et al., 1999) models of focal cerebral ischaemia. Whereas 
others have shown that hyperglycaemia may be beneficial by decreasing the 
extent of ischaemic damage following experimental stroke (Zasslow et al., 1989, 
Ginsberg et al., 1987, Kraft et al., 1990).  Data from a recent systematic review 
of studies assessing the effects of hyperglycaemia on infarct size in animal 
models of MCAO found that most of the previous studies report clinically 
irrelevant models of hyperglycaemia (MacDougall and Muir, 2011). This is 
because in the vast majority of studies included in that review hyperglycaemia 
was induced by either the streptozotocin (STZ) model of type I diabetes or by 
extremely high glucose/dextrose infusions.  The different methods will be 
discussed in the subsequent sections.  
1.3.4.1 Streptozotocin model of hyperglycaemia 
Streptozotocin causes hyperglycaemia by destroying the insulin producing beta 
cells of the pancreas leading to diminished insulin release and failure to control 
blood glucose levels.  Due to its high toxicity to pancreatic beta cells STZ is 
commonly used to simulate experimental type I diabetes and therefore has 
limited pathophysiological relevance to the type of diabetes (type 2), and the 
insulin resistant phenotype, commonly observed in acute ischaemic stroke 
patients (O'Donnell et al., 2010, Rothwell et al., 2004, Gray et al., 2004).  
Despite this, the STZ model of hyperglycaemia has been widely used to study the 
effects of hyperglycaemia in global and focal cerebral ischaemia models.  In the 
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systematic review by MacDougall and Muir, animals in which hyperglycaemia was 
induced by STZ had higher glucose levels and larger infarcts compared to 
animals in which hyperglycaemia was induced by glucose infusions (MacDougall 
and Muir, 2011).  Glucose values exceeding 20mmol/L are typical of STZ induced 
hyperglycaemia, with values approaching or greater than 30mmol/L in some 
studies (Bomont and MacKenzie, 1995, Quast et al., 1997).  In clinical studies 
patients are generally considered to have post stroke hyperglycaemia if blood 
glucose levels on admission are greater than 6.0-8.0mmol/L (Scott et al., 1999b, 
Gray et al., 2007, Shimoyama et al., 2014), with blood glucose levels rarely 
exceeding 15mmol/L (Scott et al., 1999a). Therefore hyperglycaemia induced by 
STZ would be considered severe and not typical of the clinical scenario.  
1.3.4.2 Hyperglycaemia induced by glucose administration 
Glucose administration has also been widely used to study the effects of 
hyperglycaemia in experimental stroke models. Glucose administration protocols 
vary amongst studies with regards to the route and timing of administration, 
dose used and the frequency of dosing.  Due to the variation in protocols it is 
difficult to interpret what effect hyperglycaemia induced by glucose loading has 
on stroke outcome.  
In permanent MCAO models glucose administration to induce hyperglycaemia has 
produced divergent results.   In one of the earliest studies performed in cats, 
hyperglycaemia (~30mmol/L) was reported to reduce ischaemic injury in a study 
in which a 50% glucose infusion was administered before permanent ischaemia to 
induce hyperglycaemia (Zasslow et al., 1989).  However in other studies, which 
have also used permanent MCAO models, hyperglycaemia induced by 
intraperitoneal injection of a 50% glucose solution before ischaemia had no 
influence on infarct size (Nedergaard et al., 1987, Slivka, 1991).  In another 
study, a 20% glucose solution administered 2 hours prior- and 2 hours post-MCAO 
in rats increased infarct volume after permanent MCAO (Bomont and MacKenzie, 
1995).  In contrast to permanent MCAO models, results of glucose-induced 
hyperglycaemia on ischaemic damage are more consistent following transient 
MCAO, with the majority of studies reporting that hyperglycaemia exacerbates 
ischaemic damage (Gisselsson et al., 1999, Martin et al., 2006, Liu et al., 2007, 
Wei et al., 2003, Tan et al., 2015).  
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A wider range of glucose values, between 13-31mmol/L are reported in 
hyperglycaemic animals following glucose administration, with an average of 
~23mmol/L.  Glucose values exceeding 20mmol/L are not typically seen in 
patients with PSH, with one study reporting values >17mmol/L in fewer than 2% 
of patients (Scott et al., 1999a).  In the GIST-UK clinical trial, patients with 
admission hyperglycaemia had only mild to moderate increases in plasma glucose 
levels compared to normoglycaemic patients (normoglycaemia: ~4-6mmol/L).  In 
GIST-UK hyperglycaemia was defined as having a plasma glucose concentration 
between 6.0-17.0mmol/L.  The median plasma glucose level in hyperglycaemic 
patients receiving GKI therapy was 7.6mmol/L, indicating a mild increase 
compared to normal levels (4-6mmol/L) (Gray et al., 2007).  Results from 
experimental rodent studies, in which the majority of studies report blood 
glucose levels in excess of 20mmol/L, are therefore difficult to interpret as they 
are not typical of clinical scenarios with stroke patients.  The establishment of 
an animal model with clinically relevant glucose values is therefore essential for 
future assessment of hyperglycaemia in experimental stroke.  
1.3.5 Summary 
Post-stroke hyperglycaemia is common and is associated with increased 
mortality and poor clinical outcomes.  In addition, it is associated with an 
increased risk of intracerebral haemorrhage in patients treated with rt-PA, the 
only licensed thrombolytic therapy for ischaemic stroke. Several clinical trials 
have investigated the treatment of PSH with insulin but to date there is no clear 
evidence that insulin treatment improves patient outcome. The pathogenic 
mechanisms underlying the harmful effects of hyperglycaemia in ischaemic 
stroke are poorly understood.  Understanding these mechanisms could help to 
guide the development of new therapies for treating PSH, as well as the optimal 
time-window for therapeutic intervention.  The majority of the mechanistic 
proposals to date have been inferred from animal models that are not 
representative of the clinical picture of PSH.  Therefore there is a need for 
further studies with relevant animal models.  One potential mechanism by which 
hyperglycaemia may exacerbate ischaemic damage is through an influence on 
perfusion. The studies in this thesis aimed to test the hypothesis that 
hyperglycaemia leads to a significantly larger volume of hypoperfused tissue, 
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and subsequently to greater ischaemic damage, using an animal model of 
clinically relevant hyperglycaemia.  
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1.4 Thesis Aims 
1. To optimise a clinically relevant animal model for studying the effects of 
hyperglycaemia in experimental ischaemic stroke.  
2. To determine the effects of clinically relevant levels of hyperglycaemia 
on the severity of the initial blood flow deficit using 99mTc-HMPAO blood 
flow autoradiography and MRI perfusion imaging.  MRI was also used to 
assess the effects of hyperglycaemia on acute lesion growth, perfusion-
diffusion mismatch tissue and infarct size after permanent MCAO.  
3. To determine if excitotoxicity induced brain injury pathways play a role in 
hyperglycaemia-mediated damage by examining the protein levels of 
calpain substrates in ischaemic brain tissue. 
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Chapter 2 - Methods 
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2.  
2.1 ARRIVE guidelines 
All experiments in this thesis were performed with strict adherence to the 
National Centre for the Replacement, Refinement and Reduction of Animals in 
Research (NC3R’s) ARRIVE (Animal Research; Reporting In Vivo Experiments) 
guidelines (https://www.nc3rs.org.uk/arrive-guidelines).   
2.2 Animals  
Adult male Sprague-Dawley, Fischer 344 or Wistar rats were obtained from 
Harlan laboratories UK and housed in an animal care facility at the University of 
Glasgow.  On arrival to the University all rats were acclimatised for 1 week 
before experimentation.  Rats were housed in groups of 2-4 rats per cage and 
were maintained on a 12:12 hour light:dark cycle.  Water and food (standard rat 
chow) were available ad libitum until the day before surgery when food was 
removed at the end of the day for fasting.  All experiments were performed 
under license from the UK Home Office (Personal license number 60/12152, 
working under Project license numbers 60/3759 and 60/4449).  All surgical 
procedures in Chapters 3-5 were carried out by Lisa Roy.  In Chapter 6 Lindsay 
Gallagher (Personal license number 60/713) assisted with surgery.  
2.2 Surgery 
Aseptic techniques were maintained throughout all surgical procedures.  All rats 
were fasted for 18 hours prior to surgery.  Fasting was essential as the 
anaesthetic used in this technique induced hyperglycaemia in fed rats but not 
fasted rats (in-house observation; (Saha et al., 2005).  On the day of surgery, 
rats were weighed in the animal housing unit before being transferred to the 
operating theatre.  
2.2.1 Induction and maintenance of general anaesthesia 
Anaesthesia was induced in an anaesthetic gas chamber, with 5% isoflurane 
(Baxter Healthcare Ltd, UK) administered in a 30:70% oxygen:nitrous oxide 
mixture.  The depth of anaesthesia was assessed using the withdrawal reflex, 
47 
 
where the footpad of a hind limb was tightly squeezed to evoke withdrawal of 
the foot.  When the rat showed no reflex the animal was considered deeply 
anaesthetised and it was therefore appropriate to proceed with surgery.  The 
withdrawal reflex was assessed regularly throughout the surgical period to 
determine if the anaesthetic dose required adjustment.  
Once deeply anaesthetised the rat was immediately transferred to a designated 
area within the laboratory and the fur overlying any planned incision sites was 
removed using electric clippers (Wella, Germany) and cleared using a handheld 
vacuum (Black & Decker, USA).  The rat was then transferred to the operating 
table and artificially ventilated via one of two methods: oral intubation or 
surgical tracheotomy.   
Surgical tracheotomy 
In experiments where rats were not recovered following surgery a tracheotomy 
was performed.  Upon transfer to the operating table the rat was positioned on 
its back and a facemask was used to deliver isoflurane at a reduced dose of 2-3% 
in the same gaseous mixture as previously stated.  The neck area, which was 
previously shaved, was cleaned with 70% alcohol.  An incision was made through 
the skin and fascia of the neck using blunt ended scissors and the underlying 
musculature was divided by blunt dissection to expose the trachea.  The 
connective tissue surrounding the trachea was carefully separated using small 
round forceps and two ligatures of 2-0 thread (Davis & Geck, UK) were threaded 
under the trachea and loosely tied around the proximal and distal ends of the 
exposed trachea, approximately 1.5cm apart.  A small incision was made 
between rings of tracheal cartilage using microscissors (World Precision 
Instruments, UK) and a ventilation tube (Linton Instruments, UK) was quickly 
inserted into the trachea and advanced down the trachea, towards the bronchi, 
approximately 2cm.  Prior to insertion of the ventilation tube, a ruler was used 
to measure 2cm from the bottom of the tube and this distance was marked on 
the tube using a permanent marker pen.  When inserting the tube into the 
trachea, care was taken to ensure that it was not advanced beyond this mark as 
this could lead to obstruction of one of the bronchi.  The ventilation tube was 
then quickly connected to the ventilator (Ugo Basile, Linton Instruments, UK) 
where the stroke volume was set to ~3ml at a frequency of 45 strokes per 
minute to maintain anaesthesia.  The two ligatures at the proximal and distal 
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ends of the trachea were then tied firmly around the trachea and ventilation 
tube to hold it in place and the neck was stitched using 4-0 silk suture 
(SoftsilkTM, Covidien, USA). 
Oral Intubation  
 
In experiments where rats were recovered following surgery oral intubation was 
performed for artificial ventilation using a simplified rat intubation method (Jou 
et al., 2000).  Following the initial induction of anaesthesia, animals were 
transferred to a cork board.  A loop of 4-0 silk thread (SoftsilkTM, Covidien, USA) 
attached to the board was placed around the incisors of the animal and used to 
lift the animal into a raised position at an approximate angle of 45°.  A fibre 
optic light (Schott, USA) was positioned over the neck of the animal and the 
tongue was pulled to one side.  An intubation wedge made from a 2ml plastic 
syringe (BD PlastipakTM, Spain, Figure 2.1C) was inserted into the mouth of the 
rat with the bottom of the wedge touching the rat’s tongue and the roof 
touching its palate.  The wedge was fixed firmly in the oropharyngeal cavity by 
natural pressure from the incisors.  The wedge was held in a thumb and index 
finger grip and the tip of the wedge was elevated causing expansion of the 
oropharyngeal cavity and allowing visualisation of the vocal cords and trachea. A 
16 gauge catheter, 45mm in length with a 70mm long wire stylet (MillPledge 
Veterinary, UK) was used as the endotracheal tube.  The 5mm long sharp tip of 
the stylet was cut off to produce a blunt ended guide wire (Figure 2.1A).  The 
wings of the 16 gauge catheter were also removed to enable the catheter to pass 
through the intubation wedge (Figure 2.1B).  Under illumination of the fibre 
optic light the catheter attached to the guide wire was directed into the 
trachea.  The guide wire was removed and the catheter was then further 
advanced 1-2cm into the trachea.  The intubation wedge was then carefully 
removed with the aid of a cotton bud to hold the catheter in place.  The 
catheter was then connected to a ventilator at a stroke volume of 3-4ml and a 
frequency of 55-60 strokes per minute.  The dose of isoflurane delivered to the 
ventilator was set to between 2.5 and 3% to maintain anaesthesia.  Condensation 
in the intubation tube and chest expansion and collapse synchronous with the 
ventilator provided confirmation that the intubation tube was correctly inserted 
into the trachea.  The intubation tube was then secured in place by stitching it 
to the side of the mouth using 4-0 silk suture.  
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Figure 2.1. Rat intubation kit. Composed of a guide wire made from a blunt-ended 70mm 
long wire stylet (A), a 16 gauge catheter (B) and an intubation wedge prepared from a 2ml 
syringe (C).  
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2.2.2 Blood vessel cannulation  
In all experiments the right femoral artery was cannulated to allow for 
continuous recording of mean arterial blood pressure (MAPB) and monitoring of 
blood gases and blood glucose.  The rats’ hind limbs were secured to the 
corkboard using masking tape (Tesa, Germany) to prevent movement during 
cannulation.  The ventral abdomen and inner thigh region, which was previously 
shaved, was disinfected with 70% alcohol.  A small incision was made in the skin 
and fascia over the region of the femoral vessels using blunt ended scissors.  The 
femoral artery was carefully isolated from the femoral vein and saphenous nerve 
(~10mm section) using small curved and straight-edged forceps.   
A 4-0 silk thread was securely fastened around the distal end of the artery and a 
second 4-0 thread was loosely tied around the proximal end.  Tension was 
applied to the proximal and distal ties by using masking tape to secure the ends 
of the ties to the corkboard.  Using microscissors, a small incision was made in 
the artery, mid-way between the two ties.  A 30cm length of polythene catheter 
(external diameter 0.96mm; internal diameter 0.58mm, Smiths Medical 
International Ltd) attached to a 1ml syringe filled with 1% heparinised saline 
(1000units/ml, Wockhardt UK Ltd, UK) was then inserted into the vessel using 
right-angled forceps.  Tension on the proximal tie was then released to allow the 
catheter to be advanced further into the vessel, ~1-2cm, before securing the 
catheter in place with the proximal tie.  Before securing the distal tie, blood 
was withdrawn into the syringe to ensure that the catheter was inserted 
correctly.  Excess thread was then removed and the wound was closed with a 4-0 
suture to prevent the tissue from drying out.  The catheter was connected to a 
blood pressure transducer which in turn was connected to a computer where 
physiological parameters including MABP and heart rate were recorded (Biopac, 
Acknowledge).   
The femoral cannulation procedure was also performed on the right femoral vein 
for radioisotope administration in Chapter 4.  
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2.3 Focal Cerebral Ischaemia 
2.3.1 Intraluminal filament model of middle cerebral artery occlusion 
Permanent occlusion of the middle cerebral artery (MCA) was performed using 
the intraluminal filament model which was first described by Koizumi et al 
(1986) and later modified (Longa et al., 1989).  All surgery was performed under 
a light operating microscope (Zeiss, Germany).  Where a tracheotomy was 
performed for artificial ventilation the common carotid artery (CCA) was 
isolated through the incision site used for exposing the trachea.  Where artificial 
ventilation was achieved through tracheal intubation the neck area was firstly 
shaved and disinfected with 70% alcohol before a midline incision was made 
through the skin and fascia in the neck region overlying the trachea.  The soft 
tissues were carefully pulled apart and retracted to expose the left CCA.  Using 
curved and straight-edged forceps the left CCA was carefully dissected free from 
surrounding nerves.  A 4-0 silk thread was securely tied around the CCA ~15mm 
below the bifurcation of the external carotid artery (ECA) and the internal 
carotid artery (ICA), tying off the vessel at this point.  A 4-0 silk thread was 
loosely tied around the CCA immediately below the bifurcation of the ECA and 
ICA.  A loose tie was placed around the ECA above the occipital artery branch 
but below the ascending pharyngeal artery branch.  Another loose tie was placed 
around the occipital artery and a separate tie was place around the ICA.  The 
pterygopalatine artery was isolated and tied off at its bifurcation from the ICA 
using a 4-0 silk thread (Figure 2.2).  Blood flow through the ECA, ICA and 
occipital arteries was ceased by applying tension to the ties. This was achieved 
by using masking tape to secure the ties to the corkboard.  
The intraluminal filament was prepared from a length of 3-0 or 4-0 nylon 
monofilament (Dermalon, Sherwood Medical, USA).  A small bulb was created at 
one end of the filament using a cauterising pen (Aaron Medical, FL, USA).  The 
diameter of the bulb was measured and this was used to select filaments for use 
based upon the weight of the animal. The length of the filament was also 
measured and a bend was introduced at a point of 20mm from the bulb.  This 
was introduced to ensure that the filament occluded the vessel at the origin of 
the MCA. 
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Figure 2.2.  Diagram illustrating the intraluminal filament model of MCAO.  The proximal end 
of the common carotid artery is tied off with a secure tie (red) and loose ties (black) are 
placed around the external carotid artery at the bifurcation with the internal carotid artery 
and where it meets the ascending pharyngeal artery.  Loose ties are also placed around the 
occipital and internal arteries and a secure tie around the pytergopalatine artery.  Tension is 
placed on these ties to cease blood flow during insertion of the filament.  A small incision is 
made in the common carotid artery and the filament (blue) is advanced along the internal 
carotid artery until it lodges in the narrow proximal anterior cerebral artery, where it blocks 
the origin on the middle cerebral artery.  The filament can be left in place for permanent 
MCAO or can be removed after a specified time to produce transient MCAO. 
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A small incision was made between the two ties on the CCA using microscissors 
and a filament was introduced through the incision and gently advanced through 
the ICA to the origin of the MCA where the filament meets slight resistance.  
After correct insertion of the filament, the loose ties around the ICA and CCA 
were tied firmly around the filament to hold it in place.  Tension in the 
remaining loose ties was released and the ties were removed.  The secure tie 
around the pytergopalatine artery was carefully removed using needle point 
forceps.  The filament was left in position for 24 hours in order to occlude blood 
flow and induce a stroke within the MCA territory.  The wound was closed using 
a 4-0 silk suture. 
2.3.2 Distal diathermy model of MCAO 
Following oral or tracheal intubation the rat was positioned laterally so that the 
left side of the head was clearly visible.  The left eye was sutured closed with a 
6-0 suture (SoftsilkTM, Covidien, USA) to prevent it from drying out and the 
whiskers were carefully taped over to one side.  The area between the left eye 
and auditory canal was shaved and wiped clean with 70% alcohol.  Using sharp-
ended scissors, a small incision was made at the midpoint between the auditory 
canal and the left orbit, and the underlying connective tissue and muscle was 
dissected until the skull was clearly visible.  Retractors were used to pull back 
the muscle in order to expose an area of the skull approximately 5mm2.  Small 
pieces of absorbent sponge (Surgiswabs, John Weiss International, UK) were 
carefully placed within the working area to protect the muscle and surrounding 
connective tissue from drilling.  A craniectomy was performed on the exposed 
skull using a dental drill (Volvere Vmax, Nakanishi Inc) and a round diamond bur 
(Wright Cottrell, UK).  Drilling was performed across the entire area of exposed 
skull in an up and down motion and took approximately 30 minutes to complete.  
The craniectomy site was regularly flushed with sterile saline (0.9%, Baxter 
Healthcare Ltd) during this time to prevent over-heating.  Drilling was continued 
until the MCA and inferior cerebral vein (ICV) were visible through the skull.  The 
remaining layer of bone was removed using needle point forceps.  A dura hook, 
constructed in-house by bending the tip of a 21 gauge needle, was used to pierce 
the dura mater over a region with no visible blood vessels.  Starting from this 
point the dura mater was carefully removed using needle point forceps and any 
bleeding from small vessels of the dura mater or those surrounding the MCA was 
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ceased by flushing the area with sterile saline.  If bleeding continued then 
absorbent sponge was used to apply gentle pressure or the vessels were 
electrocoagulated using bipolar diathermy forceps (110mm angled, Eschmann, 
UK).  The point at which the MCA crosses the ICV was identified and the entire 
portion of the MCA above and below the ICV was electrocoagulated with 
diathermy forceps (Figure 2.3). This was carried out under saline to prevent the 
diathermy forceps from sticking to the vessel.  Mean arterial blood pressure was 
reduced to ~70mmHg during the diathermy step by increasing the concentration 
of isoflurane to 3.5%.  MABP was reduced to this level for approximately 10 
minutes and this step dramatically reduced bleeding from the surrounding 
cerebral vasculature.  Complete occlusion of the MCA was confirmed by cutting 
the vessel using microscissors.  Following this the absorbent sponges and 
retractors were removed from the craniectomy site and a small piece of 
haemostatic gauze (Surgicel, Ethicon, Johnson & Johnson Medical Ltd 2011) 
soaked in saline was placed inside the cavity before the muscle was closed over.  
The wound was then sutured using a 4-0 silk suture and the eye suture was 
removed. 
2.3.3 Physiological monitoring 
Throughout the period of anaesthesia a number of physiological variables were 
monitored and details of these variables were recorded at regular intervals.  
Body temperature was maintained at 37°C using an external heat lamp and 
recorded using a rectal thermometer (Physitemp, New Jersey, USA).  A blood 
sample was taken at the beginning of each experiment (immediately after 
femoral artery cannulation) and at each hour from this point for the duration of 
the experiment for the measurement of blood pH, arterial oxygen tension (PaO2) 
and arterial carbon dioxide tension (PaCO2).  A blood sample (~100µl) was 
withdrawn from the femoral artery cannula into a glass capillary tube and the 
tube was immediately taken to the blood gas analyser (Rapidlab 248/348, 
Siemens).  The animal’s temperature at the moment the sample was obtained 
was entered into the analyser and the blood gas analyser adjusted the blood gas 
and pH values according to the animal’s temperature.   
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Figure 2.3.  Images of the middle cerebral artery before and after the diathermy step 
performed during the distal diathermy MCAO model.  The left image shows the MCA prior to 
the diathermy step.  The inferior cerebral vein regularly crosses the MCA and this can be 
used as a point of reference when occluding and cutting the vessel.  The right image shows 
the MCA after diathermy where approximately 2mm of the vessel is occluded.  The dotted 
line indicates where the vessel is cut to confirm complete occlusion. 
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Blood gases and blood pH were maintained within a defined range (paCO2 35-
45mmHg, pH 7.35-7.45) by adjusting the output parameters of the ventilator.  
PaO2 values were higher than the normal physiological range of 80-100mmHg due 
to the high percentage (30%) of oxygen used to ventilate the animals.  Blood 
pressure was monitored by connecting a femoral artery catheter to a blood 
pressure transducer which was connected to a computer in combination with an 
MP150 Biopac system (Biopac systems Inc, USA) and Acknowledge software 
(Linton) used to display mean arterial, systolic and diastolic blood pressure and 
heart rate throughout surgery.  During all surgical procedures MABP was 
maintained within the range of 85-100mmHg by adjusting the isoflurane 
concentration. 
2.3.4 Animal recovery from surgery 
At the end of surgical procedures where animals were recovered from surgery 
for 24 hours, the arterial cannula was removed and the small incision in the 
artery was closed over using diathermy forceps. The wound was flushed with 
sterile saline and closed using 4-0 suture.  The isoflurane concentration was 
decreased to 0% and the animals were ventilated with 100% oxygen until they 
became responsive to foot pinching and started to breathe without the 
ventilator.  At this point the animal was disconnected from the ventilator and 
the intubation tube was removed.  The animal was supplemented with 50% 
oxygen via a facemask until breathing became steady and the animal started to 
regain consciousness.  At this point the animal was transferred to a clean cage 
lined with soft absorbent pads containing softened food and water available ad 
libitum.  The cage was transferred to a recovery room maintained at ~25°C and 
the animal was housed there until it was killed at 24 hours.  The animal was 
closely monitored for at least 2 hours post-surgery and details of the animals 
condition were recorded on animal recovery sheets. 
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2.4 Induction of hyperglycaemia and glucose 
measurements 
In all experiments rats were randomly assigned to a vehicle or glucose treatment 
group using a randomization plan generator (http://www.randomization.com).  
Glucose treated rats received a 15% glucose solution (10ml/Kg), by 
intraperitoneal (IP) injection, 10 minutes before MCAO.  A fresh glucose solution 
was prepared for each experiment by dissolving 1.5g of D-glucose (Sigma-
Aldrich, USA) in 10ml distilled water.  Vehicle treated rats received the 
equivalent volume of distilled water.   
Blood and plasma glucose levels were measured regularly during experiments.  
Blood glucose levels were measured using the Accu-Chek® Aviva test strip 
system. To measure blood glucose using this system a test strip was placed in 
the meter and then a drop of blood, withdrawn from the femoral artery cannula, 
was placed at the tip of the test strip.  The glucose value in mmol/L was 
displayed on the meter and was recorded.  To ensure the results were reliable a 
control test was performed regularly and each time a new box of test strips was 
opened using Accu-Chek® Aviva control solutions in accordance with the 
manufacturer’s instructions.  
Plasma glucose levels were measured using a GM9 plasma glucose analyser 
(Analox Instruments Ltd, UK).  To measure plasma glucose levels using the 
plasma glucose analyser a small amount of blood (~100µl) was withdrawn from 
the femoral artery cannula into a microcentrifuge tube.  The microcentrifuge 
tube was centrifuged at 1000rpm for 2 minutes to separate the blood into its 
various components and plasma was inserted into the plasma glucose analyser 
using a pipette.  The plasma glucose analyser utilizes an enzymatic assay to 
determine the plasma glucose concentration in mmol/L, which the machine 
produced a printout of.  Before each use the glucose analyser was calibrated 
using an 8.0mmol/L glucose standard (Analox Instruments, UK). Although both 
blood and plasma glucose levels were measured in most studies, only blood 
glucose results are presented in this thesis.  Plasma glucose levels tended to be 
higher than blood glucose levels as shown in Table 2.1, and this was expected 
because it is known clinically that the glucose content of plasma is 
approximately 12% higher than whole blood (Diabetes.co.uk).  In one study 
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included in this thesis (Chapter 4) the glucose content of plasma ranged from 
between 9-28% above blood values (Table 2.1).  
 
Table 2.1.  Comparison of blood and plasma glucose levels. Mean blood and plasma 
glucose levels measured in a group of Wistar rats (n=11) measured at baseline (-20 minutes) 
and 0, 30 and 60 minutes after MCAO. This group of rats received a 15% glucose solution 
(10ml/kg) 10 minutes before MCAO. The difference between blood and plasma glucose 
levels is expressed as a % of blood glucose values. 
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2.5 2,3,5-triphenyltetrazolium chloride staining and 
quantifying ischaemic damage 
2,3,5-triphenyltetrazolium chloride (TTC) has been used for decades to identify 
regions of ischaemic tissue damage and has been validated for assessing infarct 
volume 24 hours after the induction of cerebral ischaemia (Bederson et al., 
1986).  TTC is a water soluble salt which is reduced by dehydrogenase enzymes 
to a lipid soluble, deep red formazan.  Normal undamaged tissue will appear 
deep red after TTC staining as the mitochondria, which contain the necessary 
enzymes to reduce TTC, are still intact.  Damaged tissue will remain unstained 
after TTC staining as the mitochondrial systems become incapacitated.  
Therefore in TTC stained brain slices from rats subjected to MCAO, the 
unstained regions depict the area of ischaemic damage (Figure 2.4). For TTC 
processing of the brain the animal was deeply anaesthetised at 24 hours post-
MCAO using 5% isoflurane before decapitation.  The brain was then rapidly 
removed and immersed in saline at 1-2°C.  The brain was wrapped in tin foil and 
placed in the freezer at -20°C for 20 minutes.  After this time the brain was 
placed into a rat brain matrix (World Precision Instruments, UK) and sectioned 
into 2 mm slices using microtome blades.  The slices were incubated in a pre-
warmed solution of 2% TTC (Sigma-Aldrich, Switzerland) in phosphate buffered 
saline at 37°C for 15 minutes.  The sections were then removed from the TTC 
solution and fixed in 4% paraformaldehyde (PAM, VWR International, Belgium) 
overnight prior to imaging.  For each brain, digital images of six, 2mm thick 
slices were captured using a digital camera.  The areas of the infarct, ipsilateral 
(ischaemic) and contralateral (non-ischaemic) hemispheres were measured on 
both faces of each slice using image analysis software (ImageJ, 
http://rsb.info.nih.gov.ij).  Infarct volume was calculated by summing the 
individual areas and multiplying by the slice thickness.  Infarct volume was 
corrected for ipsilateral brain swelling (Swanson et al., 1990), by computing the 
volume of each hemisphere and using the following equation: 
 
 
 
 Corrected infarct =   Volume of contralateral  -  (Volume of ipsilateral – lesion volume)  
        volume   hemisphere  hemisphere 
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Figure 2.4.  Representative image of a rat brain slice stained with TTC.  Cerebral ischaemia 
was induced using the distal diathermy model of permanent MCAO.  The unstained region 
represents ischaemic damage. 
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2.6 Preparation of 
99m
Tc-HMPAO for autoradiography 
Technetium- 99m hexamethylpropyleamine oxime (99mTc-HMPAO) is an 
established radiopharmaceutical for the study of regional CBF both clinically and 
experimentally.  Clinically 99mTc-HMPAO is used as a tracer to study rCBF using 
single photon emission computed tomography (SPECT).  99mTc-HMPAO is also used 
experimentally to assess CBF in animals using autoradiography (Baskerville et 
al., 2012).  99mTc-HMAPO autoradiography was used in Chapter 4 to assess the 
reduction in CBF 1 hour after MCAO.  The isotope used in this study, [99mTc] 
pertechnetate, has a half life for gamma emission of 6.03 hours.  Radiation 
protection measures were put in place during this experiment and all 
contaminated material was handled with caution and disposed of in accordance 
with the University of Glasgow’s radiation protection policy.   
2.6.1 Reconstitution of Ceretec kit 
HMPAO is supplied in small single use vials under the trade name CeretecTM (GE 
Healthcare, UK).  Each vial contains a freeze-dried mixture of 0.5mg 
exametazime (HMPAO), 7.6µg stannous chloride dehydrate and 4.5mg sodium 
chloride.  For the purpose of experimental rodent work, each vial of CeretecTM 
was reconstituted in 1ml 0.9% sterile saline and 4 x 250µl aliquots were stored in 
sterile nitrogen filled vials at -50°C until further use.  
2.6.2 Preparation and administration of 99mTc-HMPAO 
On the day of the experiment 99mTc-HMPAO was prepared using fresh generator 
eluted sodium [99mTc] pertechnetate ordered from the dispensary at the Western 
Infirmary hospital, Glasgow.  500Mbq in 1ml of 0.9% saline was ordered in for a 
reference injection time of 1pm.  If there was any deviation from this reference 
time the activity of the isotope at a certain time was calculated using the 
following exponential decay equation:  
 
 
Where A(t)= activity at certain time; A0 = activity at reference time; -λ = decay 
constant (ln2 (0.693) / t1/2); t1/2 = half life.   
A(t) = A0e
-λt
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Approximately 10 minutes before the planned injection time an aliquot of 
Ceretec (HMPAO) was removed from the freezer and transferred to a 1.5ml 
eppendorf tube.  The reducing agent stannous chloride (7µg/ml) was added to 
the tube to stabilise the reagent.  The volume of 99mTc-pertechnetate containing 
an activity of 280Mbq was calculated and this volume was added to the tube 
containing the aliquot of HMPAO.  The contents of the tube were thoroughly 
mixed and the volume of 99mTc-HMPAO required to produce a dose of 225Mbq 
(~0.6ml) was withdrawn from the tube into a 1ml syringe.  This step was carried 
out under a fume hood in a designated radioisotope laboratory.  The syringe 
containing 225Mbq 99mTc-HMPAO was then placed in a lead lined container and 
transferred to the operating theatre.   
2.7 Magnetic Resonance Imaging 
MRI scanning took place at the Glasgow experimental MRI centre (GEMRIC) based 
within the University of Glasgow.  MRI scanning was performed by staff within 
the centre: Jim Mullin, Dr Chris McCabe and Dr William Holmes, and technical 
assistance was provided by Lindsay Gallagher.  
2.7.1 Magnet specifications 
Animals were scanned using a Bruker Biospec 7T/30cm system with a gradient 
coil (internal diameter=121mm, 400mT/m) and a 72mm birdcage resonator 
(diffusion weighted imaging, perfusion imaging) or Bruker Pharmascan 7T/30cm 
system with a gradient coil (internal diameter=121mm, 400mT/m) and a 72mm 
birdcage resonator (T2-weighted Imaging). 
2.7.2 Physiological monitoring during MRI scanning 
Following surgery to induce MCAO rats were immediately transferred to the MRI 
scanner and placed prone in a Perspex rat cradle and the head was restrained 
using tooth and ear bars.  A linear phased array surface receiver coil (2cm 
diameter) was placed above the head of the animal.  Body temperature was 
monitored using a rectal thermocouple and maintained within physiological 
range (37±0.5°C) using a temperature controlled water jacket.  MABP was 
monitored via the femoral artery catheter attached to a blood pressure 
transducer, which was in turn connected to Biopac software. In some animals 
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electrocardiogram (ECG) leads were positioned onto the ventral surface of the 
chest and the left hind limb before animals were placed in the scanner.  ECG 
leads were attached for cardiac gating during perfusion imaging when motion 
artefacts appeared in some scans.  ECG gating allows for stop motion imaging by 
acquiring data only during a specified portion of the cardiac cycle (typically 
during diastole when the heart is not contracting) leading to improved perfusion 
images. 
2.7.3 Diffusion Weighted Imaging 
Diffusion-weighted imaging was performed each hour post-MCAO for 4 hours to 
assess the evolution of the ischemic lesion. 
Technical specifications  
Spin Echo-Echo Planar Imaging (SE-EPI) diffusion-weighted scans consisted of 
eight contiguous coronal slices of 1.5mm thickness which were generated with 
an in-plane resolution of 260µm.  The field of view was 25 x 25mm2 and the 
matrix size was 96 x 96mm.  The gradient strengths (B values) were 0 and 1000 
s/mm2 and gradient directions were x, y and z.  The repetition time (TR) was 
4000.3ms and the echo time (TE) was 22.5ms. 
Image Processing 
Quantitative ADC maps (mm2/sec) were generated for each of the 8 contiguous 
coronal slices throughout the brain (Figure 2.5).  Raw datasets were initially 
processed using Paravision v5 (Bruker Biospin).  Subsequent analysis of ADC maps 
was carried out using ImageJ (http://rsb.info.nih.gov.ij) software.  To calculate ADC 
lesion volume an abnormal diffusion threshold was applied to all ADC maps.  ADC 
threshold values are described in detail in Chapter 5.  
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Figure 2.5.  DWI images of 8 coronal slices from a rat brain 4 hours after permanent MCAO.  
B. The equivalent ADC maps for the 8 DWI images.  The region of ischaemic damage 
appears bright on DWI maps and dark on ADC maps.  Scale bar - ADC values expressed as 
0-2 x10
-3
 mm
2
/sec. 
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2.7.4 Perfusion imaging 
Perfusion Imaging was performed each hour post MCAO for 4 hours to assess the 
perfusion deficit. 
Technical specifications 
Quantitative imaging of CBF (expressed as ml/100g/min) was carried out on 6 
coronal slices within the MCA territory (slices 2-7 of DWI scan) during ischaemia 
using a form of pseudo-continuous arterial spin labelling (pCASL) based on a 
train of adiabatic inversion pulses (Baskerville et al., 2012).  The sequence 
employs a SE-EPI imaging module (TE 20ms,TR 7000ms, matrix 96 x 96, FOV 25 x 
25mm2, slice thickness 1.5mm, 16 averages, 4 shots) preceded by 50 hyperbolic 
secant inversion pulses in a 3 second train (Baskerville et al., 2012, Moffat et al., 
2005).  Inversion pulse frequency offset and gradient strength were set to 
provide 10mm label/control bands centred at ±30mm from the centre of the 
imaging slice.  A T1-weighted image was also acquired each hour for four hours 
using an EPI inversion recovery sequence (TE=20ms, TR=10000ms, matrix=96x96, 
FOV=25x25mm, slice thickness 1.5mm, 16 averages, 4 shots, using 16 inversion 
times from 200ms to 7700ms).  Quantitative CBF maps in ml/100g/min were 
calculated using the following formula for continuous labelling (Williams et al., 
1992): 
  
 
Where α is the inversion pulse efficiency (0.79 taken from Moffat et al, 2005), λ 
is the blood tissue partition function (assumed to be 0.9).  Scontrol and Slabel are 
the signal intensity from the control and labelled images acquired with inversion 
pulses applied above the head and in the neck respectively.  
Image processing 
CBF maps were generated for 6 contiguous slices throughout the brain.  Raw 
data sets were processed using ImageJ software. To quantify the CBF images the 
labelled pCASL images were first subtracted from the averaged control images 
(Subtracted pCASL, Figure 2.6A) and the resulting image was divided by the 
control image to generate a relative CBF map (Normalised pCASL, Figure 2.6B).  
 
CBF =  λ    Scontrol  - Slabel 
          T1       2αScontrol 
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Fully quantitative CBF maps (Figure 2.6D) were generated by dividing the 
relative CBF map by the T1 values generated from the T1 map (Figure 2.6C).  A 
perfusion deficit map was produced by applying an abnormal perfusion threshold 
to the CBF map (Figure 2.6E). An absolute perfusion threshold of 30ml/100g/ml 
was applied to pCASL images.  Details of the perfusion threshold are described in 
Chapter 5.   
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Figure 2.6.  Images from the different steps involved in the post-processing of pCASL 
images to produce quantitative CBF maps.  Colour bar units, ml/100g/min, red shading in 
(E), CBF below 30ml/100g/min.   
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2.7.5 T2-Weighted Imaging  
T2-weighted imaging was performed at 24 hours post-MCAO to calculate infarct 
volume. 
Technical specifications 
A RARE (rapid acquisition with refocused echoes) T2 weighted sequence 
(effective TE: 46.8ms, TR: 5000s; in plane resolution of 97 um; 16 slices of 
0.75mm thickness) was used to determine infarct volume 24 hours post MCAO 
(Figure 2.7). 
Image processing 
The infarct was defined as the hyperintense area on T2-weigted images.  ImageJ 
was used to measure the area of the hyperintense region on each of the 16 slices 
in mm2.   Infarct volume was calculated by summing the total area across the 16 
slices and multiplying by the slice thickness. The areas of the ipsilateral and 
contralateral hemispheres on each slice were also measured and these were 
used to calculate the volume of each hemisphere.  Infarct volume was corrected 
for oedema using published equations (see below) that take into account both 
the compression of the contralateral hemisphere (Gerriets et al., 2004), and 
swelling of the ipsilateral hemisphere (Swanson et al., 1990). 
To correct infarct volume for swelling of the ipsilateral hemisphere the following 
equation was used: 
 
To account for compression of the contralateral hemisphere a correction factor 
was established using the following equation: 
 
To correct infarct volume for both ipsilateral swelling and compression of the 
contralateral hemisphere the following equation was used:  
 
 
 Corrected infarct  =   Volume of contralateral  -  (Volume of ipsilateral – lesion volume)  
        volume   hemisphere  hemisphere 
 Compression factor = (ipsilateral volume + contralateral volume)/(2 x contralateral volume) 
    
Infarct Volume = Corrected lesion volume x Compression Factor 
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Figure 2.7. T2-weighted images of 16 coronal slices from a rat brain imaged 24 hours after 
permanent MCAO. Ischaemic damage appears bright on T2-weighted images. From top- 
bottom and left to right the coronal sections lie caudal-rostral. 
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2.8 Protein Analysis 
2.8.1 Materials 
All materials in this section were purchased from either Sigma-Aldrich or BioRad 
Laboratories unless otherwise stated: 
Sigma-Aldrich, UK 
Sucrose, HEPES, protease inhibitor cocktail, sodium orthovanadate, sodium 
pyrophosphate, sodium chloride, Tris-base, Tween 20, Ponceau S solution 
ethylenediaminetetraacetic acid, phenylmethylsulfonyl fluoride. 
BioRad Laboratories Inc, UK 
2x Laemmli sample buffer, dithiothreitol (DTT), pre-cast 4-20% polyacrylamide 
mini-protean TGX gels and Criterion TGX gels, precision plus protein standards, 
10x Tris/Glycine/SDS running buffer, Trans-Blot turbo mini and midi transfer 
packs, Clarity Western ECL substrate.   
2.8.2 Preparation of rat brain tissue lysates 
Brain tissue lysates were prepared from the ipsilateral cortex of rats in which 
permanent MCAO was induced for 2 or 24 hours.  To obtain the ipsilateral cortex 
samples rats were euthanized by decapitation and the brains were rapidly 
removed from the skull and placed onto a chilled glass plate.  The olfactory 
bulbs and cerebellum were removed and discarded and the remaining cerebrum 
was dissected into four: ipsilateral cortex, contralateral cortex, ipsilateral 
subcortex and contralateral subcortex.  Each sample was placed into a sterile 
eppendorf tube and snap frozen in liquid nitrogen.  Samples were stored at          
-80°C until for later use.   
Prior to tissue homogenisation, a homogenate buffer (HB, Table 2.2), 
supplemented with a protease inhibitor cocktail (Table 2.3) was prepared and 
pre-chilled on ice.  Approximately 0.4g of ipsilateral cortex brain tissue was 
transferred to a 15ml tube and homogenised in 2ml HB using a Ultra-Turrax T8 
blender (IKA Labortechnick, USA).  Homogenates were centrifuged at 1000rpm 
for 20 minutes at 4°C, using a Beckman TL-100 centrifuge to remove debris.   
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Table 2.2.  Tissue homogenisation buffer.  The buffer was supplemented with a protease 
inhibitor cocktail (Sigma, UK).  The desired volume of HB was prepared in distilled water. 
Ethylenediaminetetraacetic acid (EDTA), phenylmethylsulfonyl fluoride (PMSF). 
 
 
 
 
 
 
                                   
 
                                                                       Table 2.3.  Protease inhibitor cocktail (100X). A 1X 
dilution of the protease inhibitor cocktail was added to the tissue homogenisation buffer. 
  
Reagent Concentration 
Sucrose 250mM 
Hepes 10mM 
Sodium orthovanadate 1mM 
Sodium pyrophosphate 1mM 
EDTA 1mM 
PMSF 0.2mM 
Component Inhibitory Property Concentration 
AEBSF Serine proteases 104mM 
Aprotinin Serine proteases 80µM 
Bestatin Aminpeptidases 4mM 
E-64 Cystein proteases 1.4mM 
Leupeptin Serine & cystein 
proteases 
2mM 
Pepstain A Acid proteases 1.5mM 
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The resulting supernatant was transferred to a fresh centrifuge tube and 
centrifuged at 30,000 rpm for 30 minutes at 4°C.  After this second, high speed 
spin, the resulting supernatant (cytosolic fraction) was removed and stored at     
-20°C until required.  The pellet (membrane fraction) was resuspended in HB 
and centrifuged at 30,000 rpm for 30 minutes at 4°C.  The resulting supernatant 
was discarded and the pellet was resuspended in HB and stored at -20°C until 
required.  
2.8.3 Protein assay 
The protein concentration in the brain tissue fractions from each rat was 
determined using the Pierce bicinchoninic acid (BCA) protein assay kit (Fisher 
Scientific, UK).  This method is an adaptation of the Lowry method (Smith et al., 
1985), and relies on the reduction of Cu2+ to Cu1+ by protein in an alkaline 
medium. This biuretic reaction generates a purple chromagen that is 
proportional to the amount of protein at a specific absorbance of 562nm.   
Protein assays were performed using a 96 well plate.  For each plate 25µl of 
blank standard (distilled water) and bovine serum albumin (BSA) protein 
standards: 25, 125, 250, 500, 750, 1000, 1500 (µg/ml), and 5µl of each sample 
were loaded in duplicate.  200µl of working reagent (mixture of reagent A&B 
from BCA kit in a 50:1 ratio) was added to each well and plates were covered 
and incubated at 37°C for 30 minutes.  The absorbance of the plate was read on 
a standard spectrophotometer (Cecil Instruments, UK). The protein 
concentration of the samples was determined using a standard curve of the 
562nm absorbance measurements for each albumin standard concentration 
(µg/ml) and correcting for the amount of sample loaded (Figure 2.8).  The 
average 562nm absorbance measurement of the blank standard was subtracted 
from all standard and sample replicates prior to constructing the standard curve.   
2.8.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
To prepare samples for SDS-PAGE the desired amount of protein was determined 
from the protein concentration obtained from the BCA protein assay.  Samples 
were mixed (1:1) with 2x Laemmli sample buffer containing 0.1M DTT and made 
up to a final volume with distilled water. Samples were prepared in equal 
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Figure 2.8.  Typical standard curve using BCA protein assay 
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volumes and with equal amounts of protein (10µg/well).  Samples were 
denatured in a water bath at 95°C for 4 minutes prior to loading the samples on 
to gels. Heating proteins in the presence of DTT linearises the proteins by 
disrupting protein disulphide bonds and the presence of SDS, an anionic 
detergent, imparts a negative charge which facilitates their migration towards 
the anode during PAGE.  
Samples were loaded on to 1.0mm thick pre-cast 4-20% polyacrylamide mini-
PROTEAN TGX gels (10 well) or CriterionTM TGX gels (18 or 26 well, BioRad 
Laboratories, UK).  5µl of Precision Plus ProteinTM standards (10-250kD) were 
loaded into the first well of each gel and the samples were added to the other 
wells.  Empty wells were loaded with a volume of sample buffer equal to the 
volume of the samples.  10 well gels were run in 1x Tris/Glycine/SDS running 
buffer in a BioRad Mini-PROTEAN® tetra Cell at 140 volts. 18 or 26 well gels were 
run in 1x Tris/Glycine/SDS running buffer in a Biorad CriterionTM Cell at 200 
volts.  Both cells were connected to a BioRad PowerPac Basic and gels were run 
until the blue dye had reached the bottom of the gel (approximately 1 hour).  
2.8.5 Gel Staining 
Following SDS-PAGE gels were removed from their plastic cassettes and 
transferred to a clean plastic tray and washed three times, for 5 minutes each 
time, with distilled water.  Gels were stained with 20ml Coomassie blue stain 
(SimplyBlueTM SafeStain, Invitrogen, UK) for 1 hour with gentle agitation.  Gels 
were initially de-stained in distilled water for 1 hour followed by a second 
overnight wash. Gels were then placed in a fixing solution containing 50% 
methanol and 10% glacial acetic acid overnight and stored in a 5% glacial acetic 
acid solution.  The stained gels were dried using a gel dryer (BioRad, UK).  Gel 
staining with Coomassie blue allows the visualisation of proteins as blue bands 
(Figure 2.9), and this reflects the strong covalent binding of the dye with the 
proteins on the gel (which is proportional to the amount of protein). 
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Figure 2.9. Image of a gel stained with Coomassie blue.  Protein molecular weight standards 
were run in the left hand lane. In each subsequent lane 10µg of ischaemic cortex brain 
tissue, collected 2 hours post-MCAO from rats that were hyperglycaemic or 
normoglycaemic at the time of MCAO, was run.  
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2.8.6 Western blot 
Following SDS-PAGE gels were removed from their cassettes, the wells were 
removed using a scalpel blade and the gels were washed in distilled water for 5 
minutes.  The Trans-blot Turbo system from BioRad was used for the transfer 
step.  Gels were placed onto a nitrocellulose membrane which is a component of 
the transfer packs which are supplied with the system.  Mini (7 x 8.5cm) transfer 
packs were used for 10 well gels and midi (8.5 x 13.5cm) transfer packs were 
used for 18 and 26 well gels. The packs were assembled in one of the transfer 
cassettes according to the manufacturer’s instructions and the proteins were 
transferred using the turbo option on the system which takes 7 minutes.  
Following transfer membranes were quickly removed from the cassettes and 
stained with Ponceau S solution to confirm the successful transfer of proteins 
from the gel onto the membrane.  Following removal of the Ponceau S solution, 
membranes were washed in distilled water for 5 minutes followed by two 5 
minute washes in 1x Tris-buffered saline containing Tween-20 (1x T-TBS, Table 
2.4).  Membranes were blocked with 5% milk powder in 1x T-TBS for 1 hour then 
incubated overnight at 4°C in a primary antibody.  The primary antibodies used 
in this thesis were: monoclonal mouse anti-spectrin (MAB1622, Millipore, UK), 
polyclonal rabbit anti-MAP2 (ab32454, Abcam, UK) both at a 1/200,000 dilution 
and monoclonal mouse anti-beta Actin (ab8224, Abcam, UK) at a 1:400,000 
dilution.  Primary antibodies were prepared in 5% milk powder in 1x T-TBS.  
After the overnight incubation membranes were washed in 1x T-TBS three times 
for 10 minutes each and were incubated for 1 hour in a horseradish peroxidise 
(HRP) conjugated secondary antibody.  For the spectrin and β-actin antibodies a 
polyclonal goat anti-mouse HRP conjugated secondary antibody was used (P0447, 
Dako, UK).  For the MAP2 antibody a polyclonal goat anti-rabbit HRP conjugated 
secondary antibody was used (P0448, Dako, UK).    Both secondary antibodies 
were diluted 1/10,000 (5% milk powder in 1x T-TBS).  Membranes were then 
washed three times as before.   
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Table 2.4.  T-TBS (10X) recipe.  The reagents were dissolved in 700ml distilled water and the 
pH was adjusted to 7.4 with concentrated hydrochloric acid before making up to 1 litre with 
distilled water.  1 litre of 1x T-TBS was prepared by diluting 10x T-TBS 1:10 in distilled water. 
 
2.8.7 ECL detection and signal quantification 
BioRad’s Clarity Western enhanced chemi-luminescence (ECL) substrate was 
used in this study.  Membranes were incubated in 2-4ml of the reagent for 1 
minute and excess reagent was removed by placing blots between two sheets of 
filter paper.  Membranes were placed in clear plastic wrap and exposed to X-ray 
film (hyperfilm™ECL™, Amersham Biosciences, UK) in a light tight cassette for a 
range of exposure times (between 1 and 60 seconds) and developed using an 
automatic film processor (Xograph Healthcare, UK).  Membranes were also 
visualised using the BioRad Chemidoc MP system and Image Lab software 
(BioRad, UK).  This system uses a high-resolution charge coupled device camera 
to produce a digital image of the membrane and therefore does not require the 
use of x-ray film.  
The x-ray film images were scanned to produce a digital image and examples of 
an x-ray image and a BioRad Chemidoc image from the same membrane are 
shown in Figure 2.10.  The x-ray images became saturated after an exposure 
time of 1 second which made it impossible to analyse the results. Therefore only 
images from the Biorad Chemidoc system were analysed in this thesis.   
To estimate the amount of protein in each sample images were analysed using 
ImageJ.  The rectangular selection tool in this software was used to select a 
band of interest on the image and a plot profile of the grey levels that represent 
the relative density over the area of each band was generated.  The area under 
each peak was quantified and the values were expressed in arbitrary units of 
optical density (OD).   
  
Reagent Amount 
Tris-Base 60.2g 
Sodium Chloride 87.7g 
Tween 20 10ml 
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Figure 2.10.  Western blot imaging methods.  A. Images of a western blot produced using X-
ray film. The membrane was exposed to the film for 1 second and the bands at 280kD and 
150kD appear saturated.  B. Image of the same blot produced using the BioRad Chemidoc 
system which automatically determines the exposure time (7 seconds in this case).  The 
bands in this image are not saturated.  The primary antibody for this blot was mouse anti-
αIIspectrin (1:200,000). 
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Chapter 3 – Establishing a rodent model of 
clinically relevant hyperglycaemia 
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3.  
3.1 Introduction 
3.1.1 Animal models of hyperglycaemia in experimental stroke 
research 
It is widely accepted that hyperglycaemia is associated with increased mortality 
and disability ischaemic stroke patients (Capes et al., 2001, Parsons et al., 
2002).  The findings from animal models however show diverging results.  Most 
studies are consistent with the clinical findings, reporting that hyperglycaemia 
increases ischaemic damage in both permanent (Decourtenmyers et al., 1988, 
Huang et al., 1996b, Prado et al., 1988) and transient (Huang et al., 1996b, 
Nedergaard, 1987, Gisselsson et al., 1999) models of focal cerebral ischaemia, 
whereas others have shown that hyperglycaemia may be beneficial by decreasing 
the extent of ischaemic damage following experimental stroke (Zasslow et al., 
1989, Ginsberg et al., 1987, Kraft et al., 1990).  Data from a recent systematic 
review of studies assessing the effects of hyperglycaemia on infarct size in 
animal models of MCAO found that most of the previous studies report clinically 
irrelevant models of hyperglycaemia (MacDougall and Muir, 2011). This is 
because in previous studies hyperglycaemia was induced by either streptozotocin 
injection, which is a method used to induce experimental type I diabetes and 
thus does not reflect the most common type of diabetes, type 2, observed in 
acute stroke patients (Air and Kissela, 2007).  In addition hyperglycaemia was 
also induced using glucose loading protocols that induced extremely high glucose 
levels that are rarely observed in patients with PSH.  Therefore the development 
of a model with clinically relevant blood glucose values for the assessment of 
PSH is important for future experimental studies.  
3.1.2 Rodent model of clinically relevant hyperglycaemia 
3.1.2.1 Method of inducing hyperglycaemia 
Recent data established from in-house studies showed that administering a 15% 
glucose solution IP to Wistar Kyoto (WKY) rats or fructose fed spontaneously 
hypertensive stroke-prone (ffSHRSP) rats 10 minutes before MCAO produced 
blood glucose levels of ~12mmol/L at the time of MCAO (Tarr et al., 2013).  In 
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rats that received a vehicle solution at the same time blood glucose levels at the 
onset of MCAO ranged from 5-6mmol/L.  In an acute MRI study using both rat 
strains hyperglycaemia, induced using the above method, was shown to increase 
the diffusion weighted lesion as early as 1 hour post-MCAO when compared to 
rats that received vehicle treatment.  This level of hyperglycaemia is within the 
range of glucose values considered hyperglycaemic in the GIST-UK clinical trial 
(6-17mmol/L) and thus hyperglycaemia at clinically relevant levels was shown to 
increase ischaemic damage after MCAO.  Further studies performed in-house 
using this same method to induce hyperglycaemia in Sprague Dawley (SD) rats 
showed that glucose treatment significantly increased infarct volume 24 hours 
after permanent MCAO (Tarr, 2012).  Prior to glucose or vehicle treatment and 
MCAO, baseline blood glucose values measured in SD rats were approximately 5-
7mmol/L.  Following vehicle or glucose treatment at 1 hour post-MCAO blood 
glucose values remained at baseline levels in vehicle treated rats but rose to 
~16mmol/L in animals that received glucose treatment.  Blood glucose values in 
hyperglycaemic SD rats were higher than those observed in hyperglycaemic WKY 
and ffSHRSP rats but the values could still be considered clinically relevant (Gray 
et al., 2007).  Together these data showed that administering an IP injection of 
a 15% glucose solution 10 minutes before MCAO produced blood glucose levels 
that were clinically relevant and that caused exacerbation of ischaemic damage.  
It was therefore decided to use this method to induce hyperglycaemia. 
3.1.2.2 Rat strain 
In ischaemic stroke patients hyperglycaemia is associated with a worse outcome 
in non-diabetic patients compared to those with a history of diabetes mellitus 
(Capes et al., 2001).  In a more recent study Shimoyama et al (2014), confirmed 
this reporting that hyperglycaemia was associated with infarct volume growth 
and neurological deterioration in non-diabetic patients but not those with a 
diagnosis of diabetes (Shimoyama et al., 2014).  These findings suggest that 
hyperglycaemia may be more harmful to specific sub-groups of ischaemic stroke 
patients and evidence from experimental studies using rodent models of stroke 
support this.  Tarr et al (2013), investigated the effects of hyperglycaemia on 
lesion growth and infarct volume in rats with and without features of the 
metabolic syndrome (Tarr et al., 2013).  Hyperglycaemia accelerated acute 
lesion growth in both rat strains but only increased infarct volume at 24 hours 
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post-MCAO in rats without features of the metabolic syndrome.  A potential 
explanation for this could be due to the increased sensitivity to ischaemia in the 
rats with metabolic syndrome resulting in a severe initial lesion that makes it 
difficult to detect an increase induced by acute glucose treatment. 
Together the data from both clinical and experimental stroke studies suggests 
that the effects of hyperglycaemia are worse in the absence of any underlying 
co-morbidities.  To try and reflect these findings a normotensive rat strain was 
selected for future studies investigating the mechanisms responsible for the 
deleterious effects of hyperglycaemia in ischaemic stroke. The SD rat is an out-
bred rat strain commonly used in medical research which is considered a 
standard, normotensive rat strain.  Hyperglycaemia, has been previously shown 
to increase infarct volume in SD rats (Tarr, 2012).  Therefore this strain of rat 
was selected for Study 1 which aimed to establish a rodent model in which 
ischaemic damage is increased by hyperglycaemia, at clinically relevant levels.  
However, in Study 1 the blood glucose levels observed pre- and post-MCAO in 
normoglycaemic SD rats (vehicle group) were higher than previously recorded 
levels in this strain (Tarr, 2012).  The high blood glucose levels suggest that the 
rats are hyperglycaemic before and after treatment and therefore describing the 
blood glucose levels in rats that receive vehicle treatment as “normoglycaemic” 
would be inaccurate. In a second study (Study 2) blood glucose levels were 
measured in different breeding colonies of SD rats: SDF and SDG, and in two 
other normotensive rats strains, Wistar and Fischer-344 rats, to determine which 
strain had glucose values which closely resembled normoglycaemic levels (target 
glucose range of GIST-UK: 4-7mmol/L)(Gray et al., 2007). Rats from the strain in 
which blood glucose values closely resembled normoglycaemic levels could then 
be used in subsequent mechanistic studies.  
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3.1.3 Study aims 
To study the pathophysiological mechanisms leading to the increased infarct 
volume in hyperglycaemic rats, two studies were performed for the purpose of 
optimising a suitable rat model: 
Study 1: Investigate the effect of hyperglycaemia on infarct volume following 
permanent MCAO in the Sprague Dawley rat 
To develop an animal model in which ischaemic damage is induced in the 
presence of hyperglycaemia at clinically relevant levels.  
Study 2: Compare glucose values pre- and post-MCAO in different rat strains 
To identify a rat strain with clinically relevant ‘normal’ glucose values before 
and after MCAO.  
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3.2 Methods 
All animals were obtained from Harlan Laboratories (UK) and housed in an 
animal care facility at the University of Glasgow. All experiments were carried 
out on adult male rats (250-400g) and all animals were maintained on a 12:12 
hour light/dark cycle.  Water and food were freely available until the night 
before surgery when rats were fasted overnight with free access to water.   
3.2.1 The effect of acute hyperglycaemia on infarct volume following 
permanent MCAO in the Sprague Dawley rat (Study 1) 
Adult male Sprague Dawley rats were randomly assigned to vehicle and glucose 
treatment groups using an online randomization plan generator.  Rats were 
anaesthetised with 5% isoflurane, intubated and mechanically ventilated with 
2.5% isoflurane in a 70% nitrous oxide and 30% oxygen mixture.  The left femoral 
artery was cannulated for continuous recording of mean arterial blood pressure 
and monitoring of blood pH, PaCO2 and PaO2.  Blood gases, with the exception of 
PaO2, were maintained within normal physiological range throughout the 
experiment by adjusting the ventilator settings.  The high percentage of oxygen 
used to maintain physiological stability resulted in PaO2 values that were higher 
than the normal physiological range.  Body temperature was maintained at 
37±0.5°C using an external heat source and recorded using a rectal 
thermometer.  Permanent focal cerebral ischaemia was achieved by occluding 
the left MCA using the ILF method as described in Chapter 2.3.1.  The filament 
was left in position for 24 hours in order to permanently reduce blood flow 
within the MCA territory.  Blood and plasma glucose levels were measured 20 
minutes before MCAO (baseline) and 0, 10, 40 and 60 minutes post-MCAO as 
described in Chapter 2.4.  Ten minutes prior to inserting the filament animals 
received an IP injection of vehicle or glucose solution (10ml/Kg) as described in 
Chapter 2.4.  Animals were recovered for 24 hours following surgery and infarct 
volume was measured at 24 hours post-MCAO using TTC staining as described in 
Chapter 2.5.   
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3.2.2 Comparison of blood glucose values pre- and post-MCAO in 
different rat strains (Study 2) 
Sprague Dawley colony F (SDF, n=4), Sprague Dawley colony G (SDG, n=4), 
Fischer 344 (n=7) and Wistar rats (n=6) were used in this study.  The rats were 
anaesthetised with 5% isoflurane, intubated and mechanically ventilated with 
2.5% isoflurane in a 70% nitrous oxide and 30% oxygen mixture.  The left femoral 
artery was cannulated for continuous recording of MABP and monitoring of blood 
pH, paCO2 and paO2.  Body temperature was maintained at 37°C using an 
external heat source and recorded using a rectal thermometer.  Permanent focal 
cerebral ischaemia was achieved by occluding the distal portion of the MCA using 
the diathermy method adapted from Tamura et al (1981) as described in Chapter 
2.3.2.  Blood glucose levels were measured 20 minutes before occlusion of the 
MCA to obtain a baseline measurement and at 1 hour post-MCAO as described in 
Chapter 2.4.  All glucose measurements were taken while the animals were 
under anaesthesia.  In this study rats did not receive a vehicle or glucose 
injection and infarct volume was not measured.  Rats were recovered for 24 
hours following induction of focal cerebral ischaemia as described in Chapter 
2.3.4.  At 24 hours post-MCAO rats were deeply anaesthetised with 5% isoflurane 
and brains were removed, sectioned and stained with TTC.  The animals in this 
study contributed to the training of the investigator (LR) in the distal diathermy 
method of MCAO therefore TTC staining was only performed to confirm 
successful occlusion of the MCA.  
A separate group of Wistar rats (n=6) underwent identical surgery to that 
described above but these rats received a 15% glucose solution 10 minutes prior 
to MCAO.  Blood glucose values were measured at baseline (20 minutes pre-
MCAO) at the onset of MCAO (0 minutes post-MCAO) and at each hour for 4 hours 
post-MCAO.  Infarct volume was not measured in these rats and therefore after 
the final glucose measurement at 4 hours post-MCAO the rats were killed using 
an overdose of isoflurane. 
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3.2.3 Statistical analysis 
In Study 1 the blood glucose data were plotted over time and the area under the 
curve (AUC) was calculated. The blood glucose data measured over the first 60 
minutes of MCAO were analysed using a repeated measures 2-way ANOVA with 
Bonferroni post-test.  AUC data were analysed using an unpaired Student’s t-
test.   Physiological variables, baseline blood glucose levels (Study 1) and infarct 
volume (were also analysed using an unpaired Student’s t-test.  In Study 2 
baseline blood glucose data (scatterplots) were analysed using a 1-way ANOVA 
with Tukey’s test for multiple comparisons.  Also, blood glucose data in a group 
of Wistar rats was plotted over time and, as a summary measure, the values at 
baseline and 240 minutes post-MCAO were analysed using a paired Student’s t-
test.  Data are expressed as mean ± standard deviation or scatterplots with the 
mean indicated.  
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3.3 Results 
3.3.1 The effect of hyperglycaemia on infarct volume induced by 
intraluminal filament MCAO in the Sprague Dawley rat   
3.3.1.1 Mortality and excluded animals 
A total of 24 Sprague Dawley rats were included in Study 1.  Three rats (two 
from the glucose treatment group and one from the vehicle group) died during 
the 24 hour recovery period.  The brains of these rats were examined and 
showed signs of a subarachnoid haemorrhage.  Two rats from the vehicle group 
died during MCAO surgery.  One rat from the glucose group was excluded 
because of damage to the brain tissue.  The final group sizes for analysis were 
n=9 for both the vehicle and glucose groups. 
3.3.1.2 Physiological Variables 
The physiological variables measured were all within the normal physiological 
range, except PaO2 which was elevated by increasing the % inspired oxygen to 
maintain physiological stability during general anaesthesia.  There were no 
significant differences in body weight, MABP, temperature, blood PaO2, PaCO2 or 
pH measurements between vehicle or glucose treated rats (Table 3.1). 
Group Weight                 
(g)                                                       
MABP 
(mmHg)        
PaCO2 
(mmHg)
PaO2  
(mmHg) 
pH Temperature 
(°C) 
Vehicle 
(n=9) 
303 ± 17 87 ± 4 40 ± 8 125 ± 16 7.4 ± 0.1 37 ± 0.1 
Glucose 
(n=9) 
296 ± 24 86 ± 3 45 ± 15 120 ± 37 7.4 ± 0.1 37 ± 0.1 
Table 3.1.  Pilot study 1 physiological variables.  Body weight was measured prior to MCAO; 
MABP and temperature expressed as mean over entire surgical period; pH, PaCO2, PaO2 
measured at the onset of MCAO.  Values are mean ± standard deviation.  There were no 
significant differences in any of the variables between the two groups (unpaired Student’s t-
test). 
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3.3.1.3 Blood glucose levels 
Blood glucose levels were measured prior to glucose or vehicle treatment 
(baseline) and at 0, 10, 40 and 60 minutes post-MCAO.  Mean baseline blood 
glucose levels were similar between groups (vehicle, 8.6 ± 8mmol/l; glucose, 8.0 
± 3.6mmol/l, P=0.4, Figure 3.1A).  These values were higher than those recorded 
in previous glucose studies using Sprague Dawley rats (Tarr, 2012), with values 
>10mmol/L in some animals.   
Following a single IP injection of either vehicle or 15% glucose solution blood 
glucose levels remained stable around baseline values in the vehicle group and 
rose to a mean level of ~16mmol/L in the glucose group at the onset of MCAO 
(Figure 3.1B).  Glucose values in the glucose treatment group remained at this 
elevated level for the duration of the 60 minute measurement period.  In order 
to test if there were differences between the two groups at each time point the 
data were analysed using a repeated measures 2-way ANOVA with Bonferroni’s 
post-test.  The blood glucose levels in the glucose treatment group at the onset 
of MCAO and at each time point post-MCAO were significantly higher than 
vehicle treated rats.  As a summary measure the area under the blood glucose 
curve was established for each rat in each group (Figure 3.1C).  The AUC data 
demonstrate that the rats that received glucose treatment have a significantly 
greater blood glucose level during the first hour of MCAO compared to those that 
received vehicle treatment (vehicle, 695±75mmol.min.L-1; glucose, 
1288±126mmol.min.L-1, P<0.0001).  
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Figure 3.1.  Blood glucose data from Study 1. Baseline blood glucose levels measured 20 
minutes before ILF MCAO in SD rats (A).  Data are presented as scatter plot with the line 
indicating the mean. There were no differences between groups (P=0.4, unpaired Student’s 
t-test).  The blood glucose response to a vehicle or 15% glucose solution in SD rats (n=9 per 
group) during the first 60 minutes of ILF-MCAO presented as the temporal profile (B) and 
area under the curve (C). The data in B) are presented as mean ± standard deviation.  
*P<0.0001 compared with vehicle group using repeated measures 2-way ANOVA.  The data 
in C) are presented as scatter plot with the line indicating the mean.  The red arrow in B 
indicates the time of glucose or vehicle administration.  *P<0.0001 compared with vehicle 
group using Student’s unpaired t-test. 
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3.3.1.4 Infarct Volume 
Infarct volume was measured 24 hours after ILF MCAO using TTC staining and 
corrected for ipsilateral brain swelling as described in Chapter 2.5.  
Representative TTC stained sections from the median animal of each group are 
presented in Figure 3.2A.  The unstained region on each slice represents the 
area of ischaemic damage.  In both groups the area of ischaemic damage 
induced by MCAO encompassed almost the entire ipsilateral hemisphere.  A 
scatterplot showing the infarct volume data for individual animals in each group 
is presented in Figure 3.2B.  Mean infarct volume was 234.4±145mm3 in the 
vehicle group and 332.5±149mm3 in the glucose group.  The difference in infarct 
size between the two groups was not statistically significant (p= 0.2).  Within 
each group there was notable variation in infarct volume measurements and this 
is reflected in the large standard deviation values.  
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Figure 3.2.  Infarct volume data from Study 1.  A. Photographs illustrating three coronal 
sections of rat brain slices stained with TTC 24 hours after ILF MCAO from the median rat of 
each group.  B. Scatter plot illustrating infarct volume 24 hours after ILF MCAO, in vehicle 
(n=9) and glucose (n=9) treated Sprague Dawley rats. The horizontal line represents the 
mean.  The difference in infarct size between the two groups was not statistically significant 
(P=0.2, unpaired Student’s t-test). 
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3.3.2 Comparison of blood glucose values pre- and post-MCAO in 
different rat strains 
In Study 1 the blood glucose values measured pre- and post-MCAO in 
normoglycaemic SD rats were higher than previously observed in this rat strain, 
indicating that the rats were hyperglycaemic before treatment.  To determine if 
there might be a possible breeding issue within this strain blood glucose levels 
were measured in rats from two different breeding colonies of SD rats: SDF and 
SDG, pre- and post-MCAO.  In addition, blood glucose levels were measured in 
two other normotensive rat strains: Wistar and Fischer-344, to determine if 
another strain had glucose values that were within the target normoglycaemic 
glucose range. 
3.3.2.1 Mortality and excluded animals 
A total of 8 Sprague Dawley rats were included in this study.  Four died during 
recovery from anaesthesia or during the 24 hour recovery period.  Blood glucose 
data were collected from all 8 rats and therefore no SD rats were excluded.  
Nine Fischer-344 rats were included:  two rats died shortly after the induction of 
anaesthesia (suspected overdose of anaesthetic) and two died during the 24 hour 
recovery period following surgery. The two that died following the induction of 
anaesthesia were excluded.  A total of 12 Wistar rats were included in the study.  
Two Wistar rats died following recovery from surgery but the glucose 
measurements from these rats were included in the study.   The final group sizes 
for analysis were n=4 for SDF and SDG groups, n=7 for the Fischer-344 group and 
n=6 per group in each of the two separate studies using Wistar rats. 
3.3.2.2 Blood glucose levels pre- and post MCAO in different strains 
In order to identify a rat strain with clinically relevant normoglycaemic blood 
glucose levels (target glucose range: 4-7mmol/L), blood glucose levels were 
measured in two different breeding colonies of Sprague Dawley (SDF and SDG), 
Fischer-344 and Wistar rats 20 minutes pre-MCAO and 60 minutes post-MCAO.  At 
baseline, blood glucose levels were relatively high in all groups in comparison to 
the target blood glucose range of 4-7mmol/L.  Mean baseline blood glucose 
values were 8.3, 8.6, 6.9 and 8.6mmol/L in SDF, SDG, Fischer-344 and Wistar 
rats respectively (Figure 3.3, top).  In order to test the hypothesis that there 
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were strain differences the data were analysed using a 1-way ANOVA with 
Tukey’s multiple comparisons correction separately at each time point following 
MCAO.   At baseline there were no significant differences in blood glucose levels 
between strains.  Mean blood glucose levels 60 minutes post-MCAO were 9.3, 
8.5, 6.4 and 5.7mmol/L in SDF, SDG, Fischer-344 and Wistar rats respectively 
(Figure 3.3, bottom). The blood glucose levels in Wistar rats at 60 minutes post-
MCAO were significantly lower than the levels in SDF and SDG rats and blood 
glucose levels in Fischer-344 rats were significantly lower than SDF rats. 
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Figure 3.3.  Blood glucose data pre- and post-MCAO in different rat strains.  Blood glucose 
values in two separate breeding colonies of Sprague Dawley (SDF & SDG, n=4 per colony), 
Fischer-344 (n=7) and Wistar rats (n=6) at 20 minutes pre-MCAO and 60 minutes post-
MCAO.  The dotted lines on each graph represent the target blood glucose range for 
normoglycaemic rats: 4-7mmol/L. Data are presented as scatterplots where the line 
indicates the mean.  Data analysed using 1-way ANOVA with Tukey’s multiple comparisons 
test.  *P<0.05, **P<0.01. 
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3.3.2.3 Blood glucose levels in Wistar rats 
Although Fischer-344 rats displayed glucose values within the target blood 
glucose range of 4-7mmol/L, pre- and post-MCAO, two rats from this strain died 
following  the induction of anaesthesia whereas there were no such deaths in 
any of the other strains.  Further consideration was therefore given to the Wistar 
strain as this strain displayed mean blood glucose levels within the target range 
at 1 hour post-MCAO and the scatterplot of the individual blood glucose values 
for each Wistar rat at baseline showed that there were some rats with values 
within or close to the target blood glucose range.  Consequently Wistar rats were 
included in a separate study where MCAO was induced using the DD method and 
glucose levels were measured at baseline and at each hour for 4 hours post-
MCAO. All rats received a 15% glucose solution in this study.   The mean blood 
glucose level at baseline in this group of rats was 6.3mmol/L (Figure 3.4).  
Following glucose treatment mean blood glucose levels rose to ~12mmol/L and 
remained at this elevated level for 4 hours post-MCAO. The difference between 
blood glucose levels measured at baseline and 4 hours post-MCAO was 
statistically significant (Figure 3.4B, P=0.004). 
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Figure 3.4. Blood glucose levels in Wistar rat strain.  A.  Blood glucose values measured at 
baseline (20 minutes pre-MCAO) and at each hour for 4 hours after DD MCAO in Wistar rats 
(n=6). Glucose was administered IP 10 minutes prior to MCAO. Data are presented as mean 
± standard deviation.  B.  As a summary measure blood glucose levels at baseline and at 
240 minutes (4 hours) post-MCAO were compared.  Data are presented as scatterplot with 
the line indicating the mean.  *P<0.01 compared with baseline (-20 minutes) using Student’s 
paired t-test. 
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3.4 Discussion 
The studies included in this chapter were performed to establish a rodent model 
with clinically relevant glucose levels to be used in future studies assessing the 
pathophysiological mechanisms of hyperglycaemia in ischaemic stroke.  They 
demonstrate that administering a 15% glucose solution, ten minutes prior to 
permanent intraluminal filament occlusion of the MCA, to Sprague Dawley rats 
has no significant effect on infarct volume at 24 hours post-MCAO.  The Sprague 
Dawley rats included in this study displayed blood glucose levels pre- and post-
MCAO that were higher than those previously observed in this strain.  Subsequent 
glucose studies using different normotensive rat strains identified the Wistar 
strain as an alternative for future studies.   
3.4.1 Hyperglycaemia did not increase infarct volume in SD rats 
following permanent ILF MCAO (Study 1) 
The aim of the first study was to establish a rodent model in which 
hyperglycaemia, at a clinically relevant level, exacerbates ischaemic damage.  
This was important because although many studies have investigated the effects 
of hyperglycaemia in animal models of stroke, few studies reported model 
systems with blood glucose concentrations relevant to those observed in clinical 
practice.  Previous in-house data have shown that hyperglycaemia (12mmol/L), 
exacerbates ischaemic damage in Sprague Dawley rats at 24 hours following the 
induction of permanent MCAO (Tarr, 2012).  In the previous study the MCA was 
occluded using the DD method, an invasive surgical method which does not allow 
for reperfusion.  The aim of the first study was therefore to try and reproduce 
this result in Sprague Dawley rats using the same method to induce 
hyperglycaemia as the previous study but using a different method of MCAO: the 
ILF method.  This method of MCAO does not require a craniectomy and is 
therefore less invasive compared to the DD method and subsequently requires 
less preparation time allowing for a higher throughput.  It can also produce both 
permanent and transient MCAO as the intraluminal filament can either be left in 
place (permanent MCAO) or removed after a specified time to achieve 
reperfusion (transient).  The effects of hyperglycaemia on ischaemic damage 
may be different in the absence and presence of reperfusion and using a model 
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that can produce both permanent and transient MCAO provides the opportunity 
to study both and draw comparisons.    
3.4.1.1 Hyperglycaemia did not exacerbate ischaemic damage 
In Study 1 the ILF method was used to induce permanent MCAO in male SD rats 
that were either normo- or hyperglycaemic at the time of MCAO.  Although 
hyperglycaemic animals tended to have larger infarcts than normoglycaemic 
animals (Figure 3.2B) the difference between the two groups was not 
statistically significant.  The scatter plot presentation of the infarct volume data 
revealed that there was substantial variation in infarct measurements within 
each group.  There are a number of experimental factors that can affect the size 
and distribution of ischaemic damage induced by ILF MCAO.  For example, 
deviations in body temperature and the blood partial pressure of CO2 can 
significantly affect infarct volume and therefore physiological variables were 
closely monitored in this study to keep them within the normal physiological 
range. There were no differences in any of the physiological variables (Table 
3.1) measured between the two groups that could have significantly influenced 
the results.  Features of the filament used to occlude the MCA, such as the 
length of filament inserted and bulb size, can also have a major influence on 
infarct size.  Filaments were inserted approximately 20mm along the ICA until 
slight resistance was met.  At this point the filament was considered to be 
correctly inserted and left in place for 24 hours.  However, the only way to 
ensure that the filament has successfully occluded the MCA is to measure CBF in 
a region of the brain supplied by the MCA.  Measuring CBF, using a technique 
such as laser doppler flowmetry during ILF MCAO could help to reduce variability 
as criteria could be set so that animals that do not display a specified 
percentage reduction in CBF from baseline are excluded.  The volume of 
ischaemic damage can also be influenced by the diameter of the bulb on the 
intraluminal filament and this should be matched to the weight of the animal. 
Incorrect matching of filament bulb sizes alongside the inherent variation in the 
cerebral vasculature between rats is probably one of the major factors 
contributing to the variation in infarct volume in this study.  Any future studies 
utilizing this method would need to consider this when calculating group sizes 
and should also use laser doppler flowmetry to continuously measure CBF in the 
MCA brain territory to ensure that the vessel is successfully occluded.   
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Different methods of MCAO were considered before planning future studies.  
This is because hyperglycaemia, induced using the same protocol described in 
this Chapter, has repeatedly been shown to increase infarct volume 24 hours 
post-MCAO in different rat strains where the MCA was permanently occluded 
using the distal diathermy method (Tarr, 2012).  The size and location of 
ischaemic damage induced by distal MCAO differs considerably to that induced 
by the ILF method.  Permanent occlusion of the MCA using the ILF method tends 
to produce large infarcts encompassing both cortical and subcortical regions 
(Figure 3.2A). For example in Study 1 infarct volumes, measured 24 hours after 
ILF MCAO, for the median animal of each group were 230mm3 and 304mm3 in 
vehicle and glucose groups respectively.  Conversely, occluding the distal portion 
of the MCA produces infarcts localised to the cerebral cortex and as such infarcts 
induced by DD MCAO tend to be smaller than those induced by the ILF method 
e.g. mean infarct volumes measured 24 hours after DD MCAO in hyperglycaemic 
WKY and SD rats were 150mm3 and 167mm3 respectively (Tarr, 2012).  The larger 
infarcts induced by ILF MCAO could present a problem as they might restrict the 
ability to detect any harmful effect of hyperglycaemia on infarct size due to a 
“ceiling effect”.  This means that the level of ischaemic damage may be at its 
maximum regardless of glycaemic status.  Data from a transient MCAO study 
demonstrates this effect as neuronal damage was found to be significantly 
increased in hyperglycaemic rats after 15 and 30 minutes of ILF MCAO compared 
to normoglycaemic rats, but there was no significant difference between normo-
and hyperglycaemic animals after 60 minutes MCAO (Gisselsson et al., 1999). 
The volume of neuronal damage increased as the duration of ischaemia 
increased and therefore the extent of damage induced after 60 minutes may be 
maximal and as a result it’s not possible to detect additional damage induced by 
hyperglycaemia.  A similar effect may have occurred in Study 1. 
Furthermore, the widespread ischaemic damage caused by ILF MCAO produces 
complex motor, sensory, autonomic and cognitive deficits.  Hypothalamic 
damage has been shown to occur following ILF occlusion of 60 minutes or more 
generating a hyperthermic response (Li et al., 1999).  Hyperthermia can 
exacerbate neuronal cell death (Chen et al., 1991, Azzimondi et al., 1995, Kim 
et al., 1996), which means that fluctuations in temperature induced by the ILF 
method may produce a source of variability in infarct size.  In comparison, 
100 
 
ischaemic damage induced by the DD MCAO method rarely causes damage to the 
hypothalamus and thus does not induce a hyperthermic response.  The size of 
the lesions produced using the DD method are relatively small, encompassing 
approximately 5-20% of the ipsilateral hemisphere.  This is relevant to clinical 
findings as human stroke sizes have been shown to range from 28-80cm3, which 
translates to 5-14% of the ipsilateral hemisphere (Carmichael, 2005).    
Perfusion-diffusion mismatch data collected from previous in-house MRI studies 
(Tarr, 2012), and from the MRI study in Chapter 5, suggests that there is 
substantial penumbra tissue (~20-130mm3) produced following permanent MCAO 
induced using the DD method.  This is greater in comparison to perfusion-
diffusion mismatch data from studies using the ILF method of MCAO where the 
volume of penumbra tissue in WKY rats during the acute 1-4 hours post MCAO 
ranged from 22-65mm3 (Reid et al., 2012). The potentially salvageable, 
hypoperfused tissue within the ischaemic penumbra is the region where any 
acute therapy is likely to have the greatest impact and is also the location where 
hyperglycaemia is likely to have the greatest influence and thus using a model in 
which there is substantial penumbra will benefit future studies.   
Taken together, the evidence from previous in-house glucose studies indicates 
that the distal diathermy method of MCAO is a suitable method of MCAO for 
studying the effects of hyperglycaemia in experimental stroke.  This method will 
therefore be used in all future studies assessing the pathological mechanisms by 
which hyperglycaemia exacerbates ischaemia damage.   
3.4.1.2 Glucose levels were not clinically relevant pre- or post-MCAO 
The blood glucose data (Figure 3.1B) indicates that a rodent model with 
clinically relevant blood glucose levels was not successfully produced in Study 1.  
In rats that received glucose treatment blood glucose levels in individual rats 
ranged from 13.5-21.0mmol/L with an average of 18mmol/L during the first hour 
of MCAO.  This level of hyperglycaemia is high in comparison to values previously 
recorded in this strain of rat following identical glucose treatment (Tarr, 2012), 
and compared to values typically seen in patients (Gray et al., 2007).  In rats 
that received vehicle treatment blood glucose levels remained around baseline 
levels with values ranging from 7-12mmol/L in individual rats.  Blood glucose 
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levels in normoglycaemic stroke patients typically range from 4-6mmol/L (Gray 
et al., 2007), and normal values in fasted SD rats have been shown to range from 
4-7mmol/L (Tarr, 2012, Saha et al., 2005).  Values above this can therefore be 
considered hyperglycaemic and thus within the vehicle group there were animals 
that were potentially hyperglycaemic.  Also, the glucose values measured at 
baseline (Figure 3.1A) were >8.0mmol/L in all rats from both treatment groups.  
These values are high compared to previous baseline blood glucose data from SD 
rats, where values range from 5-7mmol/L, and this suggests that rats in the 
present study were hyperglycaemic at baseline.   The rats in the present study 
were from the same supplier as those from the previous study and therefore 
steps were taken to try to identify the cause of the hyperglycaemia that may 
have developed in the SD strain.  After contacting the animal supplier and 
speaking with staff in the animal unit a change in diet was ruled out.  In order to 
reduce any influence from environmental stress, experiments were not 
performed on the day when cages were cleaned.  There were no issues with the 
blood glucose meter or plasma glucose analyser, both of which were calibrated 
daily to ensure they were reading glucose levels correctly.  Regardless of the 
steps taken, baseline blood glucose values measured in SD rats remained 
elevated.  Further contact with the animal supplier revealed that the Sprague 
Dawley rats used in Study 1 were from a single breeding colony of Sprague 
Dawley rats (SDF).  The animal supplier had two different breeding colonies and 
offered to supply rats from each, asking for a copy of the blood glucose data 
from the two colonies in return.  Consequently, blood glucose levels from both 
strains were analysed pre- and post-MCAO in a second study (Study 2).  Rats from 
two different normotensive rat strains: Wistar and Fischer-344 rats were also 
included in this study.   
3.4.2 Glucose levels were clinically relevant pre- and post-MCAO in 
Wistar rats (Study 2) 
Blood glucose values were measured in two different colonies of Sprague Dawley 
rat: SDF and SDG, Wistar and Fisher-344 rats at baseline (20 minutes pre-MCAO) 
and 60 minutes post-MCAO (Figure 3.3).  At baseline, out of the four groups, 
blood glucose levels tended to be lower in Fischer-344 rats with a mean blood 
glucose level of 6.9mmol/L.  In SDF, SDG and Wistar rats blood glucose levels at 
baseline were >8.0mmol but there were no statistically significant differences 
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between any of the groups.  Published glucose values from normoglycaemic 
Sprague Dawley, Wistar and Fischer-344 strains measured pre-MCAO are 
presented in Table 3.2.  Compared with published glucose levels, the glucose 
values reported in the present study for Sprague Dawley rats are almost double, 
indicating possible hyperglycaemia in this strain.  The blood glucose values 
measured in Wistar rats are slightly higher than published values and those in 
Fischer-344 rats are in close agreement with published values.   
At 60 minutes post-MCAO blood glucose values in the SDF and SDG rats were 
similar to baseline levels (>8.0mmol/L) but blood glucose values in Fischer-344 
rats and Wistar rats were shown to be <7.0mmol/L.  These results suggested that 
either Fischer-344 or Wistar rats could provide an alternative normotensive 
strain to the SD strain for future studies.  Duverger et al (1988), investigated the 
influence of rat strain on the quantification of cerebral infarction following 
permanent focal cerebral ischaemia induced by proximal MCAO (using an 
adaptation of the method by Tamura et al (1981)), and reported that out of the 
three normotensive rat strains included in their study (Fischer-344, WKY and SD), 
infarct size was most standardised and reproducible in the Fischer-344 strain 
(Duverger and MacKenzie, 1988). In contrast, Dittmar et al 2006 reported that 
Fischer-344 rats are not a suitable strain for experimental stroke studies, in 
particular those using the filament MCAO model.  They experienced more 
surgical complications and a higher incidence of subarachnoid haemorrhage in 
Fischer-344 rats compared to other strains.  Using magnetic resonance 
angiography they found that internal carotid arteries from Fishcer-344 rats had 
more “kinks” compared to arteries from Wistar rats which could explain the 
surgical difficulties experienced with Fischer-344 rats.  From my own personal 
experience, Fischer-344 rats were easily stressed and difficult to handle in 
comparison to Wistar and Sprague Dawley rats.  There was also a higher degree 
of mortality with this strain, in particular mortality soon after the induction of 
anaesthesia. It was therefore decided not to use Fischer-344 rats for future 
experiments.   
As some Wistar rats at baseline and all Wistar rats at 60 minutes post-MCAO 
displayed blood glucose levels within the target range of 4-7mmol/L blood 
glucose levels were investigated in a separate group of Wistar rats.    
103 
 
 
 
 
 
 
 
Table 3.2.  Published glucose values measured pre-MCAO in Sprague Dawley, Wistar and Fischer-344 rats. 
Rat strain Glucose (mmol/L, source) Reference 
Sprague Dawley 4.3 (blood) (Kittaka et al., 1996) 
Sprague Dawley 4.5 (blood) (Wei et al., 2003) 
Sprague Dawley 6.1 (blood) (Quast et al., 1997) 
Wistar 7.3 (plasma) (Nedergaard et al., 1987) 
Wistar 5.2 (blood) (Toung et al., 2000) 
Wistar 7.2 (plasma) (Pulsinelli et al., 1982) 
Fischer-344 8.3 (plasma) (Duverger and MacKenzie, 1988) 
Fischer-344 6.1 (plasma) (Li et al., 2004) 
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Baseline blood glucose levels of all the Wistar rats within this group were within 
the target blood glucose range.  Following a single IP injection of a 15% glucose 
solution blood glucose values in Wistar rats rose to a mean level of 
approximately 12mmol/L and remained at this elevated level for 4 hours post-
MCAO.  In comparison to blood glucose levels reported in previous studies 
investigating hyperglycaemia in animal models of MCAO, blood glucose levels in 
hyperglycaemic Wistar rats were relevant to the typical values observed in 
patients with PSH.  As a result it was decided to use rats from the Wistar strain 
in future studies assessing hyperglycaemia in experimental ischaemic stroke.   
3.4.3 Summary 
The results from the studies presented in this Chapter demonstrate that 
administering a 15% glucose solution IP to Wistar rats, 10 minutes prior to MCAO, 
produces clinically relevant levels of hyperglycaemia that were maintained for 4 
hours post-MCAO.  This model of hyperglycaemia and rat strain will be carried 
forward for future studies.   
Infarct volume data from this study demonstrates that permanent occlusion of 
the MCA using the intraluminal filament model produces large ischaemic lesions 
with considerable variation in size.  Large lesions have the potential to mask the 
effects of a relatively small insult, such as acute hyperglycaemia, on infarct 
size.  It was therefore decided that for future studies investigating the effects of 
hyperglycaemia in experimental stroke the distal diathermy model would be 
used which produces smaller and more reproducible ischaemic lesions. 
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Chapter 4 - The effect of hyperglycaemia on the 
severity of ischaemia 1 hour after MCAO 
  
106 
 
4.  
4.1 Introduction 
4.1.1 Hyperglycaemia and cerebral blood flow 
Following ischaemic stroke, the severity of the blood flow deficit is one of the 
main determinants of acute brain damage and anything that reduces CBF further 
could increase this damage. Evidence from rodent studies suggests that 
hyperglycaemia may augment ischaemic brain injury by increasing the perfusion 
deficit in the acute stage of ischaemic stroke (Duckrow et al., 1985, Duckrow et 
al., 1987, Kawai et al., 1998).  If hyperglycaemia does increase the perfusion 
deficit this could potentiate other pathophysiological mechanisms known to 
increase ischaemic brain damage and could help to explain why hyperglycaemia 
results in larger infarct sizes.  In preclinical studies hyperglycaemia has been 
shown to reduce CBF in both the normal, non-ischaemic rat brain (Duckrow et 
al., 1985, Duckrow, 1995, Mayhan and Patel, 1995, Wang et al., 2008), and 
during global and focal ischaemia (Yura, 1991, Kawai et al., 1997a, Kawai et al., 
1998). In addition, regional CBF has been shown to be reduced within cerebral 
regions of interest in hyperglycaemic patients with diabetes, compared to 
normoglycaemic controls (Vazquez et al., 1999). The triggers for such 
hyperglycaemia-induced reductions in CBF have yet to be elucidated. Several 
mechanisms have been proposed from animal studies which include: an osmotic 
mechanism resulting in a higher brain water content and increased cerebral 
vascular resistance (Duckrow, 1995); impairment of nitric oxide-dependent 
dilatation of cerebral arterioles via the activation of protein kinase C (Mayhan 
and Patel, 1995); and a cooperative effect of hyperglycaemia and cortical 
spreading depression on CBF (Wang et al., 2008).  As with much of the previous 
research regarding hyperglycaemia in experimental stroke the effects of 
hyperglycaemia on CBF were investigated in studies using glucose levels that far 
exceed those seen clinically in patients with PSH.  Since the extent of brain 
injury is governed by the severity of the blood flow deficit during ischaemic 
stroke it is important to determine first of all if clinically-relevant levels of 
blood glucose increase ischaemic damage by increasing the reduction in cerebral 
blood flow.  Using a rodent model of permanent focal cerebral ischaemia, Tarr 
et al, (2013) reported that hyperglycaemia (~12mmol/L) accelerated acute 
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lesion growth and increased infarct volume compared to normoglycaemia 
(~6mmol/L).  The effects of hyperglycaemia on lesion growth were evident at 
the earliest time point examined in the study, 1 hour post-MCAO, suggesting that 
the detrimental impact of hyperglycaemia is rapid.  The aim of the present 
chapter was to determine if hyperglycaemia accelerates acute lesion growth by 
increasing the severity the CBF deficit at 1 hour post-MCAO using the animal 
model established in the previous chapter. 
4.1.2 Measuring CBF in vivo using autoradiography 
There are various different techniques which have been developed for the 
assessment of cerebral blood flow in vivo.  Commonly used techniques for the 
clinical assessment of CBF include PET, perfusion computed tomography and 
MRI. In order for a technique to be suitable for use in routine clinical practice it 
must be capable of assessing CBF through the intact skull.  However, for the 
assessment of CBF in rodents more invasive techniques are available.  For 
example, autoradiography using the radioactive substance 99mTc-HMPAO can be 
used experimentally to assess CBF in animals. 99mTc-HMPAO is a lipophilic, low 
molecular weight radiotracer which, following intravenous injection, freely 
crosses the blood brain barrier.  Once in the brain 99mTc-HMPAO rapidly converts 
to a non-diffusible hydrophilic species causing entrapment in the brain 
proportional to regional CBF (Lassen et al., 1988).  For this reason 99mTc-HMPAO 
autoradiography has been widely used to measure CBF in animal stroke studies 
(Bullock et al., 1991, Gartshore et al., 1997, Lythgoe et al., 1999).  Although this 
technique is terminal, allowing measurement of CBF at a single time point, the 
main advantage of using autoradiography to assess CBF is that it produces 
autoradiograms with high spatial resolution as demonstrated in Figure 4.1.  Also, 
compared with other CBF tracers, such as [14C]-iodoantipyrine (IAP) and 
133Xenon, 99mTc-HMPAO has several advantages such as the short 6-hour half-life 
of the radionucleotide 99mTc, and its stable in vivo binding, which lasts for 
several hours. 
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Figure 4.1 Representative 
99m
Tc-HMPAO autoradiogram of a rat brain section (Level 4, 
0.8mm posterior to Bregma).  The pale region indicates a region of reduced CBF induced by 
1 hour of permanent, distal MCAO. 
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One of the main disadvantages of 99mTc-HMPAO autoradiography is that 
quantitative assessment of CBF is challenging.  This is because for quantitative 
assessment of CBF the arterial activity of the lipophilic complex must be known 
but it is difficult to measure this due to the rapid conversion of 99mTc-HMPAO 
from a lipophilic to hydrophilic form in the blood.  Despite this, the use of 99mTc-
HMPAO autoradiography for semi-quantitative assessment of CBF in a rodent 
stroke model has been validated against quantitative autoradiography methods 
([14C]-IAP) and was shown to accurately represent CBF 0.5-72 hours after acute 
cerebral ischaemia (Bullock et al., 1991).  Therefore in the present study a semi-
quantitative assessment of CBF 1 hour post-MCAO was obtained using 99mTc-
HMPAO blood flow autoradiography.  
4.1.3 Study aim and hypothesis: 
To determine the effect of hyperglycaemia on the severity of the blood flow 
deficit at 1 hour following the induction of cerebral ischaemia using 99mTc-
HMPAO blood flow autoradiography.  It was hypothesised that the reduction in 
CBF induced by 1 hour of permanent MCAO would be greater in hyperglycaemic 
compared with normoglycaemic rats.  
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4.2 Methods 
4.2.1 Animals 
This study used adult male Wistar rats (280-360g) obtained from Harlan 
Laboratories (UK). Animals were housed in an animal care facility at the 
University of Glasgow and maintained on a 12:12 hour light/dark cycle.  Rats 
were allowed free access to food and water until the night before the 
experiment when rats were fasted overnight with free access to water.   
4.2.2 Sample size calculation and blinding 
To calculate the number of animals required for each group a sample size 
calculation (Snedecor and Cochran, 1989, Figure 4.2A), was performed using ADC 
data acquired from a previous in-house MRI study.  The calculation was based on 
the change in ADC derived lesion volume, at 1 hour post-MCAO, exhibited in WKY 
rats that were hyperglycaemic compared to normoglycaemic controls (Tarr et 
al., 2013).  ADC lesion volume was used for the sample size calculation as there 
was no CBF data available and therefore ADC lesion volume provided the best 
approximation.  The difference in ADC-derived lesion volume observed at 1 hour 
post-MCAO between normo- and hyperglycaemic WKY rats was 50.8mm3. The 
standard deviation for the normoglycaemic and hyperglycaemic groups was 36.5 
and 12.5 respectively.  The sample size calculation was based on an 80% power 
(1- β = 0.8) and a 95% significance level (α = 0.05) and therefore according to 
Figure 4.2B the C value was 7.85.  The number of animals per group was 
calculated to be 8.5.  From this it was decided that the optimum group size 
would be 10 rats per group.  Rats were randomly assigned to a vehicle or glucose 
treatment group using an online randomization plan generator.  A colleague was 
given a copy of the randomization plan and presented me with a syringe 
containing the correct treatment for each rat.  Blinding presented a problem in 
the case of rat mortality and in order to account for this it was decided to assign 
13 animals to each group and these animals were included in the randomization 
protocol (Figure 4.3). 
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Figure 4.2. Sample size calculation. A. Equation used to compute sample size for 
continuous variables (Snedecor & Cochran, 1989), where d is the difference to be detected 
based on previous findings, s is the standard deviation and C is a constant derived from the 
power and significance level.  B.  Table for determining the value of C for the sample size 
calculation where α is the significance level (95% or 99%) and 1-β = power (80% or 90%). 
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Figure 4.3.  Randomization plan for 
99m
Tc-HMPAO blood flow autoradiography study where 
13 rats were assigned to each group. The randomization plan was generated from 
www.randomization.com. 
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4.2.3 Surgical Procedures 
Rats were anaesthetised initially in an anaesthetic chamber with 5% isoflurane 
delivered in a nitrous oxide: oxygen mixture (70:30).  A tracheotomy was then 
performed and animals were artificially ventilated with 2.5% isoflurane in the 
same gas mixture described above.  The right femoral artery was cannulated for 
continuous recording of MABP and monitoring of blood pH, PaCO2 and PaO2 as 
described in Chapter 2.2.2. The right femoral vein was also cannulated for 
intravenous administration of 99mTc-HMPAO.  Body temperature was maintained 
at 37±0.5°C using an external heat source and recorded using a rectal 
thermometer.  Permanent focal cerebral ischaemia was achieved using the distal 
diathermy model of MCAO as described in Chapter 2.3.2. 
4.2.4 Induction of hyperglycaemia and glucose measurements 
Animals were randomly assigned (see section 4.2.2) to vehicle or glucose 
treatment groups.  Glucose treated rats received an IP injection of a 15% glucose 
solution (10ml/kg) in distilled water, 10 minutes prior to induction of cerebral 
ischaemia. Vehicle treated rats received an equivalent IP injection of distilled 
water.  Arterial blood glucose was measured 20 minutes prior to MCAO to obtain 
a baseline measurement, at the onset of MCAO (0 minutes) and at 30 and 60 
minutes after MCAO as described in Chapter 2.4. The surgeon (LR) was blind to 
group identity of each animal. 
4.2.5 Assessment of CBF using 99mTc-HMPAO autoradiography 
99mTc-HMPAO was prepared as described in Chapter 2.6.  At 1 hour post-MCAO 
225 MBq 99mTc-HMPAO in ~0.6ml saline was injected via the femoral vein 
catheter over 30 seconds. Approximately five minutes following the 
administration of 99mTc-HMPAO, the rat was euthanised by decapitation and the 
brain was removed and immediately frozen in isopentane at -45°C.  The brain 
was sectioned (20µm) in a cryostat maintained at -20°C.  Sections spanning the 
entire MCA territory, over ten coronal levels (rostral to caudal), were mounted 
on to glass slides and dried on a hotplate set at 60°C for 5 minutes.  
Autoradiograms were prepared from these sections by exposing them, alongside 
pre-calibrated 14C standards (21-174x103 nCi/g 99mTc tissue equivalent for 20µm 
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thick sections), to autoradiographic film for 1 hour.  The autoradiograms were 
then developed using an automatic film processor.  
4.2.5.1 Analysis of autoradiograms 
Autoradiograms were analysed for their 99mTc tissue concentration using an MCID 
Basic image analysis system (7.0 Rev 1.0, build 207; Imaging Research Inc).  For 
each autoradiogram a density calibration was established to construct a standard 
curve that compared the MCID system’s internal optical density measurement 
unit (measured grey levels) to the 14C standard values (21-174x103 nCi/g 99mTc 
tissue equivalents). The density calibration was then applied to the 
autoradiograms which allowed the 99mTc-HMPAO tissue concentration to be 
expressed in relative units of nCi/g. The concentration of 99mTc-HMPAO was 
considered to be proportional to CBF. A semi-quantitative assessment of CBF was 
made by measuring the concentration of 99mTc-HMPAO using two different 
analyses as described below. 
Threshold analysis 
A thresholding approach was used to classify CBF in the ipsilateral cortex into 
different levels of severity relative to the homologous region of the contralateral 
hemisphere: most severe (0-15%), severe (0-43%), moderate (43-75%) and mild 
(75-100%). These thresholds were chosen to reflect tissue with severely, 
moderately and mildly reduced blood flow (Tamura et al., 1981b, Shen et al., 
2003, Hossmann, 1994).  Autoradiographic images of ten coronal levels were 
captured for threshold analysis (Figure 4.4). 
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Figure 4.4.  Autoradiographic images from a representative animal showing the ten coronal levels (0-9) analysed.  The pale regions are areas   
of reduced 
99m
Tc-HMPAO tissue concentration and represent areas where blood flow has been reduced by distal diathermy MCAO.
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The stereotaxic co-ordinates for each level were defined using a rat brain atlas 
(Paxinos and Watson, 2007).  Each level and its position in relation to Bregma 
are provided in Table 4.1. 
 
Table 4.1.  Ten coronal levels and their position relative to Bregma (mm).  Levels with 
positive values lie anterior to Bregma and levels with negative values lie posterior to 
Bregma. 
 
After applying a density calibration, the outline drawing tool on the MCID basic 
programme was used to manually delineate the ipsilateral and contralateral 
cortex of each coronal level.  The tissue concentration of 99mTc-HMPAO (nCi/g) 
in the contralateral cortex was measured and values representing 15%, 43% and 
75% of this were calculated.  A threshold was applied to the ipsilateral cortex 
using the scan area tool and setting the segmentation range to the 99mTc-HMPAO 
values corresponding to that threshold (Figure 4.5).  The area of the ipsilateral 
cortex at each threshold was measured and expressed as a percentage of the 
area of the ipsilateral cortex.  For each coronal level the concentration of 99mTc-
HMPAO was measured in three sections and the average was taken.    
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Figure 4.5.  Representative autoradiograms depicting threshold analysis. The ipsilateral 
cortex (outlined in green) and contralateral cortex (red) were manually delineated (top left).  
The pale region in the ipsilateral cortex represents an area with no uptake of 
99m
Tc-HMPAO 
indicating reduced CBF induced by MCAO. In subsequent images the green pixels represent 
the area of the ipsilateral cortex where 
99m
Tc-HMPAO uptake was within 0-15%, 0-43%, 43-
75% and 75-100% of the contralateral cortex. 
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Region of interest (ROI) analysis 
A list of 22 distinct brain structures was derived from a previous 14C- 
iodoantipyrine autoradiography study (Tamura et al 1981).  Like the threshold 
analysis, autoradiographic images depicting the uptake of 99mTc-HMPAO within 
selected brain sections were captured for ROI analysis.  A rat brain atlas (Paxinos 
and Watson, 2007) was used to identify the 22 brain structures in the 
autoradiograms.  The rectangle drawing tool on the MCID Basic system was used 
to place a box over each structure (ROI) in the ipsilateral hemisphere and the 
99mTc-HMPAO tissue concentration (nCi/g) was measured (Figure 4.6).  The same 
tool was used to place an identical sized box over the equivalent ROI in the 
contralateral hemisphere to measure the concentration there.  The 99mTc-HMPAO 
tissue concentration from the ROI in the ipsilateral hemisphere was then 
expressed as a percentage of that in the contralateral hemisphere.  For each ROI 
examined, the 99mTc-HMPAO concentration was measured on three sections and 
the average was taken. 
Some of the threshold analysis (0-15%) and all of the ROI analysis was performed 
by MRes student Kathleen Macdonald (KM) under supervision by Lisa Roy.   For all 
of the analysis the investigators (LR and KM) were blinded to group identity. 
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Figure 4.6.  Example of the ROI analysis in an autoradiographic section (1.8mm posterior to Bregma).  A stereotaxic rat brain atlas (left) was used to identify 
structures in the autoradiographic image (right).  Identical sized boxes were placed over each brain structure in both the ipsilateral and contralateral 
hemispheres and the 
99m
Tc-HMPAO tissue concentration in each was measured.  Values measured in the ipsilateral cortex were expressed as a percentage 
of those in the contralateral cortex. 
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4.2.6 Study exclusion criteria 
Animals were excluded from the study if they died during the surgery to induce 
focal cerebral ischaemia and also if there were any signs of intracerebral 
haemorrhage development in the brain during cryostat cutting, resulting in 
extensive subcortical ischaemia on the autoradiograms. 
4.2.7 Statistical analysis 
Physiological variables, scatterplots of 0-43% threshold data, and CBF ROI 
measurements were analysed using an unpaired Student’s t-test.  Blood glucose 
level data and line graphs of the threshold analysis data were analysed using a 2-
way ANOVA with Bonferroni’s multiple comparisons post-hoc test.  Data are 
expressed as mean ± standard deviation or scatterplots with the mean indicated.  
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4.3 Results 
4.3.1 Mortality and excluded animals 
A total of 26 animals were initially entered into the study.  Out of the 26 rats 5 
were excluded: 2 rats from the glucose treatment group and 3 rats from the 
vehicle treatment group.  Three of the five rats died due to significant blood loss 
during the diathermy step of MCAO.  One of the rats died during the injection of 
99mTc-HMPAO and one rat was excluded from analysis due to a haemorrhage in 
the brain which was detected as it was being sectioned.   Therefore the final 
group sizes for analysis were n=10 in the vehicle group and n=11 in the glucose 
group. 
4.3.2 Physiological variables  
Physiological variables were monitored throughout the surgical period and the 
measured variables were all within the normal physiological range (except PaO2 
due to the concentration of oxygen used to deliver the anaesthetic).  There 
were no significant differences in body weight, MABP, temperature, blood gasses 
and pH between the two groups (Table 4.2). 
 
Group Weight                 
(g)                                                       
MABP 
(mmHg)        
PaCO2 
(mmHg)
PaO2  
(mmHg) 
pH 
 
Temperature 
(°C) 
Vehicle 
(n=10) 
313 ± 23 85 ± 4 39 ± 6 125 ± 13 7.4 ± 0.1 37 ± 0.2 
Glucose 
(n=11) 
322 ± 29 90 ± 4 40 ± 4 120 ± 15 7.4 ± 0.1 37 ± 0.2 
Table 4.2.  Physiological variables for 
99m
Tc-HMPAO study.  Body weight was measured 
prior to MCAO.  Mean arterial blood pressure (MABP), temperature, pH, PaO2 and PaCO2 
were measured approximately every 30 minutes during surgery and the data are expressed 
as the mean ± standard deviation over the entire surgical period.  There were no significant 
differences in any of the variables between the two groups (unpaired Student’s t-test). 
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4.3.3 Administration of glucose resulted in clinically relevant 
hyperglycaemia in the glucose treatment group 
The blood glucose measurements taken 20 minutes prior to MCAO, before the IP 
administration of glucose or vehicle, were 7.3mmol/L and 7.1mmol/L in the 
vehicle and glucose treatment groups respectively (Figure 4.7).  Therefore the 
two groups were comparable, with no significant difference in blood glucose 
levels prior to MCAO (P>0.5). 
Rats received an IP injection of a vehicle or 15% glucose solution 10 minutes 
before MCAO and blood glucose levels were measured at 0, 30 and 60 minutes 
post-MCAO.  At each time point blood glucose levels were significantly greater in 
the rats that received glucose treatment compared with those that received 
vehicle treatment.  Following MCAO blood glucose levels were approximately 
13mmol/L in rats that received glucose treatment and remained close to the 
blood glucose values measured at baseline (6-7mmol/L) in the vehicle treatment 
group. 
 
 
Figure 4.7. Blood glucose data for 
99m
Tc-HMPAO study.  Blood glucose values measured at 
baseline (-20 minutes) and at subsequent time points over the first hour of MCAO in vehicle 
(n=10) and glucose (n=11) treated rats. The red arrow indicates the time of vehicle or 
glucose administration. Data are presented as mean ± standard deviation.  *, p<0.0001 
compared with vehicle group using 2-way-ANOVA with Bonferroni’s post-hoc test. 
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4.3.4 Hyperglycaemia did not exacerbate the reduction in CBF 1 hour 
after MCAO 
4.3.4.1 Threshold analysis results 
For each autoradiogram different thresholds were applied to the ipsilateral 
cortex of ten coronal levels in order to grade the severity of ischaemia into four 
categories: most severely (0-15%), severely (0-43%), moderately (43-75%) and 
mildly (75-100%) reduced relative to the contralateral cortex.  The area of the 
ipsilateral cortex at each threshold, at each coronal level, was measured and 
expressed as a percentage of the area of the ipsilateral cortex (Figure 4.8).  In 
order to test the hypothesis that there were differences between vehicle and 
glucose treated animals the data at each threshold were analysed using a 2-way 
ANOVA with Bonferroni’s post-test.  The differences between groups were not 
statistically significant at any of the thresholds examined.  However, scrutiny of 
the results from the 0-43% threshold revealed there to be a small difference 
between the two groups at every level, with the glucose treatment group 
tending to have a greater % area of the ipsilateral cortex with a severe reduction 
in CBF.  To investigate this in more detail scatterplots of individual rats were 
produced for coronal levels 3, 4 and 5 (0.3mm, 0.8mm and 1.8mm posterior to 
Bregma) at this threshold (Figure 4.9). These levels were selected as there was 
an observable difference between the two groups at the 0-43% threshold in 
Figure 4.8. At coronal level 4 the difference between vehicle and glucose 
treated rats was statistically significant (P=0.046) but the difference between 
groups at levels 3 (P=0.1), and 5 (P=0.07) was not.  From close examination of 
the autoradiograms by eye there was no obvious difference between any of the 
groups at these three levels (Figure 4.10), and because the difference at level 4 
was small and only marginally significant (P=0.046) no conclusions were drawn 
from this result.    
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Figure 4.8.  Threshold analysis results. The line graphs illustrate the % area of the ipsilateral cortex, across ten coronal levels (rostral to caudal), with CBF 
that is: most severely (0-15%) severely (0-43%), moderately (43-75%) and mildly (75-100%) reduced relative to the contralateral cortex in vehicle (n=10) and 
glucose (n=11) treated rats.  Data are presented as mean ± standard deviation.  Differences between groups are not statistically significant: 2-way-ANOVA 
with Bonferroni’s post-test 
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Figure 4.9.  Threshold analysis 0-43% threshold.  Individual scatterplots illustrating the % area of the ipsilateral cortex at coronal levels 3, 4 and 5 from 
within the 0-43% threshold (top inset).  The line on the scatterplots represents the mean.   There was no difference between groups at levels 3 and 5.  At 
level 4, the difference between groups was statistically significant.  *P<0.05, using unpaired Student’s t-test. 
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Figure 4.10.  Autoradiograms showing the 
99m
Tc-HMPAO concentration in coronal 
levels 3, 4 and 5, from a representative vehicle and glucose treated rat.  Ischaemia is 
visible topographically within the ipsilateral cortex in both groups to a similar extent.   
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4.3.4.2 ROI analysis results 
A semi-quantitative assessment of 99mTc-HMPAO tissue concentration in 22 
different brain regions was achieved by measuring the concentration in the 
ipsilateral hemisphere and expressing this as a percentage of that in the 
contralateral hemisphere (Normalised 99mTc-HMPAO concentration, Table 4.3).  
As expected, there were notable decreases in 99mTc-HMPAO measurements in the 
ipsilateral cerebral cortex, brain structures supplied by the distal branches of 
the MCA, within both groups.  There were no statistically significant differences 
in mean 99mTc-HMPAO tissue concentrations in any of the 22 structures in the 
ipsilateral hemisphere between groups.  In addition, there were no differences 
in mean 99mTc-HMPAO tissue concentrations in brain structures in the hemisphere 
contralateral to the occluded vessel between vehicle and glucose treated groups 
(Table 4.4).   
Scatterplots of individual rats were produced for some of the ipsilateral brain 
structures expected to show a considerable reduction in CBF induced by distal 
MCAO (Figure 4.11A).  Normalised 99mTc-HMPAO values were lower, indicating 
low CBF, in regions within the ipsilateral cerebral cortex.  For example mean 
99mTc-HMPAO concentrations in the primary somatosensory cortex were 18% and 
12% of the contralateral regions in vehicle and glucose treated rats respectively.  
Other areas within the cerebral cortex with notable reductions in 99mTc-HMPAO 
concentrations were the secondary somatosensory cortex and motor cortex 
(Figure 4.11B&C). Across the entire ipsilateral cortex, 99mTc-HMPAO 
concentrations ranged from 12-96% of the contralateral region.  There was 
notable variation in values from within the cerebral cortex of both groups.  This 
is evident in both the scatterplots in Figure 4.11 and from the standard deviation 
values in Table 4.3.  This variation could result from biological variation of the 
branching pattern of the MCA between animals leading to slightly different 
occlusions for each animal.  To minimise this potential source of variation rats 
from a single strain were used. 
In ROI’s outside the cerebral cortex there was less variation in 99mTc-HMPAO 
concentration measurements. 99mTc-HMPAO concentrations for every rat were 
close to 100% of the contralateral region in the globus pallidus, hypothalamus 
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and thalamus structures (Figure 4.12), and this was the case for most subcortical 
structures (Table 4.3). 
A few regions of the brain displayed a slight increase in blood flow, most notably 
the globus pallidus and substantia nigra which displayed mean CBF values of 
111% and 105-111% of the contralateral regions respectively (Table 4.3).  
Hyperperfusion within these regions has previously been described in a rodent 
model of focal cerebral ischaemia (Tamura et al., 1981b) and may be explained 
by an increase in metabolic demand in these structures following acute 
ischaemic injury. 
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Table 4.3.  Normalised 
99m
Tc-HMPAO concentration (% contralateral region) in 22 distinct 
structures for vehicle (n=10) and glucose (n=11) treated rats 1 hour after MCAO.  There were 
no significant differences between groups in any region (P> 0.05).  Data are presented as 
mean ± standard deviation.  
 
 
% Contralateral Region 
Region Vehicle 
(mean ± SD) 
Glucose 
(mean ± SD) 
P 
Motor cortex 57 ± 18 60 ± 26 0.81 
Auditory cortex 
 
54 ± 28 53 ± 28 0.89 
Visual cortex 
 
50 ± 15 63 ± 23 0.43 
Primary somatosensory 
cortex 
18 ± 15 12 ± 5 0.22 
Secondary somatosensory 
cortex 
35 ± 19 25 ± 18 0.42 
Anterior cingulate cortex 
 
77 ± 16 81 ± 18 0.53 
Medial cingulate cortex 
 
96 ± 15 87 ± 21 0.29 
Lateral orbital cortex  
 
60 ± 28 62 ± 22 0.88 
Insular cortex 
 
68 ± 28 55 ± 19 0.21 
 
Prelimbic cortex 78 ± 21 80 ± 18 0.80 
 
Piriform cortex 
 
89 ± 21 94 ± 19 0.56 
 
Caudate Putamen Medial 
 
95 ± 17 95 ± 9 0.87 
Caudate Putamen Lateral 
 
103 ± 20 98 ± 26 0.60 
Hippocampus 
 
106 ± 14 102 ± 5 0.31 
Globus pallidus 
 
112 ± 13 111 ± 11 0.85 
Nucleus accumbens 
 
99 ± 12 99 ± 10 0.92 
Amygdala 
 
105 ± 15 105 ± 12 0.95 
Hypothalamus 
 
99 ± 10 98 ± 5 0.88 
Thalamus 
 
103 ± 5 101 ± 7 0.40 
Substantia nigra 
 
105 ± 8 110 ± 11 0.20 
Septum 
 
98 ± 7 99 ± 6 0.56 
Corpus callosum 100 ± 8 89 ± 10 0.40 
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Table 4.4.  
99m
Tc-HMPAO tissue concentrations (nCi/g) of brain structures within the 
hemisphere contralateral to the occluded MCA.  There were no significant differences 
between groups in any region (P> 0.05).  Data are presented as mean ± standard deviation 
(values x10
3
). 
 
99mTc-HMPAO Tissue Concentration (nCi/g) 
Contralateral Region Vehicle 
(mean ± SD x103) 
Glucose 
(mean ± SD x103) 
P 
Motor cortex  69 ± 21 76 ± 26 0.45 
Auditory cortex  
 
65 ± 21 67 ± 31 0.88 
Visual cortex 
 
61 ± 20  65 ± 30 0.70 
Primary somatosensory 
cortex 
73 ± 21 83 ± 26 0.37 
Secondary 
somatosensory cortex 
67 ± 23 67 ± 32 0.94 
Anterior cingulate cortex 
 
64 ± 15 66 ± 23 0.90 
Medial cingulate cortex 
 
68 ± 20 84 ± 38 0.17 
Lateral orbital cortex 
 
74 ± 21 79 ± 25 0.64 
Insular cortex 
 
66 ± 19 72 ± 25 0.48 
Prelimbic cortex 
 
64 ± 15 69 ± 23 0.55 
Piriform cortex 
 
78 ± 25 79 ± 21 0.87 
Caudate putamen medial 
 
80 ± 22 84 ± 25 0.69 
Caudate putamen lateral 
 
77 ± 22 86 ± 27 0.42 
Hippocampus 
 
85 ± 23 86 ± 33 0.85 
Globus pallidus 
 
64 ± 23 68 ± 26 0.75 
Nucleus accumbens 
 
79 ± 23 82 ± 25 0.71 
Amygdala 
 
79 ± 21 83 ± 23 0.73 
Hypothalamus 
 
82 ± 21 87 ± 24 0.84 
Thalamus 
 
83 ± 20 90 ± 24 0.45 
Substantia nigra 
 
81 ± 20 83 ± 32 0.99 
Septum 
 
73 ± 19 79 ± 25 0.61 
Corpus callosum 48 ± 20 60 ± 25 0.23 
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Figure 4.11.  ROI analysis results for primary somatosensory cortex, secondary somatosensory cortex and motor cortex.  Scatterplots illustrating 
normalised 
99m
Tc-HMPAO concentration (% of contralateral region) in cortical brain regions: primary somatosensory cortex, secondary somatosensory 
cortex and motor cortex from vehicle (n=10) and glucose treated rats (n=11).  The line represents the mean.  There were no statistically significant 
differences between groups (unpaired Student’s t-test).  
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Figure 4.12.  ROI analysis results for globus pallidus, hypothalamus and thalamus.  Scatterplots illustrating normalised 
99m
Tc-HMPAO concentration (% of 
contralateral region) in the thalamus, hypothalamus and globus pallidus, from vehicle (n=10) and glucose treated rats (n=11).  The line represents the 
mean.  There were no statistically significant differences between groups (unpaired Student’s t-test).  
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4.4 Discussion 
The pathophysiological mechanisms underlying the harmful effects of 
hyperglycaemia during ischaemic stroke are poorly understood. Hyperglycaemia 
has been shown to reduce CBF in the normal rat brain (Duckrow et al., 1985) and 
since the severity of the blood flow deficit is one of the main determinants of 
acute brain damage it was essential to determine if hyperglycaemia exacerbates 
the early reduction in CBF induced by MCAO.   The purpose of the current study 
was therefore to assess the effect of hyperglycaemia, at clinically relevant 
levels, on the severity of the CBF deficit, induced after 1 hour MCAO, using 
99mTc-HMPAO autoradiography.  Thorough analysis of the 99mTc-HMPAO blood 
flow data using two different methods: threshold and ROI based analyses showed 
that there were no significant differences in the CBF deficit between 
hyperglycaemic and normoglycaemic rats.  This suggests that the harmful effects 
of hyperglycaemia during ischaemia may not be caused by an increase in the CBF 
deficit.   
Using two different methods to analyse the 99mTc-HMPAO blood flow 
autoradiography data was valuable for two reasons.  Firstly it demonstrates that 
the results are robust as both methods produced the same result.  Secondly, the 
data from the ROI analysis helped to confirm the use of the thresholds selected 
for the threshold analysis.  There is a lack of consensus on where to set 
thresholds to define severely, moderately and mildly hypoperfused tissue in 
experimental models of stroke and those used here were based on CBF data from 
MRI (Shen et al., 2003) and [14C]-IAP autoradiography (Tamura et al., 1981b) 
studies in rats and therefore might not be appropriate when applied to 99mTc-
HMPAO blood flow maps. The MCA was occluded distally in the present study and 
by doing so blood flow to regions within the frontal and parietal cortex will be 
most affected.  Thus as expected, the somatosensory cortex displayed the most 
severe reduction in CBF with values that ranged from 12-35% of the contralateral 
region. This range closely fits within the 0-43% threshold used in the threshold 
analysis to calculate the area with severely reduced blood flow. In regions with 
moderately reduced blood flow, such as the motor cortex, insular cortex and 
auditory cortex, CBF was approximately 60% of the contralateral region and this 
was within the threshold range used to define moderately hypoperfused regions 
(43-75%).  
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Overall the results from the ROI analysis suggest that the thresholds selected for 
the threshold analysis were appropriate and could be applied in future studies 
utilising the 99mTc-HMPAO blood flow autoradiography technique.  However, the 
thresholds used in this chapter are in slight disagreement with CBF data from a 
quantitative autoradiography study.  Tamura et al (1981) measured CBF 30 
minutes after proximal MCAO and found that regions with severe and modest 
reductions in CBF had levels that were 15-20% and 20-40% of that in the 
contralateral hemisphere respectively.    However, in the present study regions 
with severe and modest reductions in CBF had levels that were 12-35% and 35-
60% of that in the contralateral hemisphere respectively.  The differences 
between studies could partly be explained by the different autoradiographic 
methods used to measure CBF (quantitative [14C]-IAP vs semi-quantitative 99mTc-
HMPAO) and also by differences in the MCAO model (proximal vs distal MCAO) 
and rat strain (Sprague-Dawley vs Wistar rat).   
4.4.1 Clinically relevant blood glucose levels were observed in normo- 
and hyperglycaemic rats 
Although there was no difference in the severity of the CBF deficit between the 
two groups in the current study, there were statistically significant differences 
in the blood glucose values measured between the two groups at 1 hour post-
MCAO.  The glucose levels measured in both the vehicle and glucose treatment 
groups closely resembled those seen in normoglycaemic (4-7mmol/L) and 
hyperglycaemic (6-17mmol/L) ischaemic stroke patients respectively (Gray et 
al., 2007).  Also, the blood glucose data collected in the Wistar rat strain in this 
study is comparable to that from the previous chapter and reinforces the 
decision to change from the Sprague-Dawley rat strain to the Wistar rat strain 
for the study of hyperglycaemia in experimental stroke. 
The fact that hyperglycaemia did not increase the severity of the CBF deficit in 
this study could be explained by the magnitude of the blood glucose increments 
induced relative to those in previous reports.  Experimental studies reporting 
decreases in CBF had glucose increments of 28 and 29mM above control 
(Ginsberg et al., 1980, Duckrow et al., 1985).  Such high increments in glucose 
levels are rarely seen in patients with PSH.  In clinical trials investigating insulin 
treatment for PSH blood glucose levels on admission ranged from ~7-10mmol/L 
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(Gray et al., 2007, Johnston et al., 2009). Blood glucose values in 
normoglycaemic patients typically range from 4-6mmol/L and therefore only 
minor increments in blood glucose levels (~1-6mmol/L) are observed in patients 
with PSH.  In the present study the blood glucose increment between vehicle 
and glucose treated rats was ~6mmol/L which resembles that seen clinically.  
The present study therefore shows that hyperglycaemia, at clinically relevant 
levels, does not exacerbate the decrease in CBF induced by 1 hour of MCAO.     
4.4.2 Interpretation of results 
The findings from the present study are in agreement with results reported 
previously from studies using animal models of stroke (Gisselsson et al., 1999, 
Siemkowicz et al., 1982, Venables et al., 1985, Marsh et al., 1986, Quast et al., 
1997).  Gisselsson and colleagues investigated the influence of hyperglycaemia 
(20mmol/L) on tissue damage and CBF in rats during and after transient MCAO.  
In hyperglycaemic rats tissue damage after 30 minutes MCAO was significantly 
greater compared to normoglycaemic rats but there was no difference in CBF 
(determined by 14C-IAP autoradiography).  Similarly, Venables et al (1985) 
compared the effects of saline or glucose infusions (achieving blood glucose 
levels ~10 and 20mmol/L in saline and glucose treatment groups respectively) on 
changes in CBF during and after transient MCAO in cats.  They found that there 
was no difference in the severity of the CBF deficit after MCAO between saline 
or glucose treatment groups (Venables et al., 1985).   
The results reported here also agree with those from a recent clinical study of 
80 acute ischaemic stroke patients where the perfusion deficit, determined by 
CT perfusion imaging, was found to be similar between patients with and 
without hyperglycaemia on admission (Luitse et al., 2013).  In this study the 
infarct core area was also measured using CT and the authors found no 
difference in the size of the infarct core area between hyperglycaemic and 
normoglycaemic patient groups.  A point of criticism of their study however is 
that only a single measure of the perfusion deficit area and infarct core area was 
reported by Luitse et al (2013).  Both were obtained within 24 hours of admission 
with a median time between the onset of symptoms and CT imaging of 102 and 
104 minutes for normoglycaemic and hyperglycaemic patients respectively.  The 
ischaemic lesion can continue to evolve for several hours following the onset of 
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symptoms and therefore by measuring the perfusion deficit and infarct core size 
at a single time point Luitse et al (2013) may have missed an effect of 
hyperglycaemia.  Likewise, a potential limitation of the present study might be 
that hyperglycaemia does increase the severity of ischaemia but not at the time 
point examined.  Consideration to this was given when designing this thesis and 
an acute MRI study was proposed that would permit serial measurements of the 
perfusion deficit over the acute 1-4 hours post-MCAO as well as the evolution of 
the acute ischaemic lesion.  A limiting factor in the study by Luitse and 
colleagues is the relatively small number of patients included in their study.  
This is further complicated by the inclusion of patients with and without a 
history of diabetes.  There is evidence that patients without a history of 
diabetes have a worse outcome after ischaemic stroke than patients with a 
known history of the condition (Capes et al., 2001).  Preclinical studies support 
this (Tarr et al., 2013) and it has been suggested that the design of future 
clinical trials of glucose lowering therapies in acute ischaemic stroke should 
include only those that have no history of diabetes or other co-morbidities.  
Although the results from the present suggest that hyperglycaemia doesn’t 
exacerbate ischaemic damage by increasing the perfusion deficit, it is still 
possible the hyperglycaemia enhances ischaemic brain injury via an effect on the 
cerebrovasculature.   There is evidence that hyperglycaemia can impair 
reperfusion after global (Ginsberg et al., 1980, Kagstrom et al., 1983) and focal 
ischaemia (Venables et al., 1985, Kawai et al., 1997b).  Results from a study by 
Kawai et al (1997) indicate that hyperglycaemia has a profound effect on 
reperfusion during transient MCAO, with blood flows returning to only 50% of 
those found in normoglycaemic rats.  Another potential indicator for a vascular 
effect of hyperglycaemia is haemorrhage.  Hyperglycaemia is consistently 
associated with a greater incidence of haemorrhagic transformation on 
reperfusion in animal studies (Kawai et al., 1997b, Decourtenmyers et al., 1989).  
There is also a higher incidence of haemorrhage following reperfusion with t-PA 
in hyperglycaemic patients (Alvarez-Sabin et al., 2003).  The effects of 
hyperglycaemia during reperfusion were not examined in this thesis but may be 
examined in future studies by this department.  This would be valuable to the 
pre-clinical stroke literature as there are few studies, if any, that have 
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investigated the effects of clinically relevant hyperglycaemia during transient 
MCAO.  
4.4.3 Summary 
The present study has shown that hyperglycaemia, at clinically-relevant blood 
levels, did not exacerbate the CBF deficit induced by 1 hour of permanent 
MCAO.  Hyperglycaemia may exert an effect on CBF at a later time-point than 
that investigated in this study and subsequent chapters will use MRI to examine 
the temporal evolution of the perfusion deficit. 
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Chapter 5 – Imaging the acute effects of 
hyperglycaemia on the temporal evolution of 
ischaemic damage and CBF using MRI 
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5.  
5.1 Introduction 
Data in the previous chapter demonstrated that hyperglycaemia did not 
exacerbate the reduction in CBF at 1 hour post-MCAO.  However, it is possible 
that in the previous study an effect of hyperglycaemia did exist but was not 
detected since the reduction in CBF was measured at only a single time point.  
In this chapter MRI was used to acquire repeated measurements of the perfusion 
deficit at hourly intervals over the first 4 hours after MCAO using the non-
invasive method of PI, pCASL.  Using MRI meant that concurrent DWI could also 
be performed to assess the acute evolution of ischaemic damage.  By performing 
PI in combination with DWI it was possible to calculate the volume of perfusion-
diffusion mismatch tissue during the first four hours after MCAO.  PI-DWI 
mismatch tissue, which is typically represented by an area of abnormal perfusion 
surrounding an area of abnormal diffusion, is widely used to identify the 
ischaemic penumbra – hypoperfused, yet viable tissue that is destined to 
progress to infarction unless perfusion is restored.  To my knowledge, no 
previous animal studies have investigated the effect of hyperglycaemia on PI-
DWI mismatch tissue following MCAO.  However MRI studies in acute ischaemic 
stroke patients have shown that larger infarct sizes in patients with admission 
hyperglycaemia are associated with reduced penumbral salvage (Parsons et al., 
2002, Rosso et al., 2011). Parsons et al (2002), examined the association 
between admission hyperglycaemia and the ischaemic penumbra using acute 
perfusion-diffusion mismatch MRI.  They found that in patients with evidence of 
perfusion-diffusion mismatch hyperglycaemia was correlated with reduced 
penumbral salvage, larger final infarct sizes and worse functional outcomes.  In 
patients without PI-DWI mismatch (non-mismatch patients) hyperglycaemia did 
not correlate with outcome imaging or clinical measures.  The difference in 
outcome between patients with and without mismatch in relation to glycaemic 
status suggests that PI-DWI mismatch tissue might be highly susceptible to 
hyperglycaemia through the accelerated conversion of hypoperfused at-risk 
tissue to infarction.  It was therefore interesting to compare the volume of 
perfusion-diffusion mismatch tissue and the loss of this tissue over time between 
glucose and vehicle treated rats in the present study to determine if 
hyperglycaemia exerts an adverse effect on the ischaemic penumbra.  
140 
 
  
The detrimental effect of hyperglycaemia on infarct volume at 24 hours post-
MCAO, which was reported in other rat strains (Tarr et al., 2013), has not yet 
been confirmed in the Wistar strain used in this thesis.  Therefore following 
acute MRI scanning, animals were recovered for 24 hours post-MCAO, at which 
time infarct volume was assessed using T2-weighted MRI.  From T2-weighted 
images the extent of ipsilateral hemispheric swelling between groups could also 
be assessed by measuring and comparing the volumes of the ipsilateral and 
contralateral hemispheres.  Hyperglycaemia has been reported to increase 
cerebral oedema in acute ischaemic stroke patients (Berger and Hakim, 1986) 
and following experimental stroke in rodents (Kawai et al., 1997a).  It was 
therefore interesting to determine if glucose treatment is associated with 
increased cerebral oedema in this animal model.  
5.1.1 MRI perfusion and diffusion thresholds 
In the present Chapter perfusion and diffusion thresholds were applied to 
quantitative CBF and ADC maps respectively in order to calculate the perfusion 
deficit, ADC lesion volume and subsequent PI-DWI mismatch.  There is currently 
no consensus on where to set the perfusion and diffusion thresholds to 
accurately define perfusion and diffusion lesions in rodent models of focal 
cerebral ischaemia (Campbell and Macrae, 2015).  This is particularly important 
for pre-clinical studies of neuroprotective agents targeting the ischaemic 
penumbra.  If the thresholds applied are too high or too low this could lead to 
over- or underestimations of the amount of perfusion-diffusion mismatch tissue, 
leading to the false identification of neuroprotective/neurotoxic agents or 
exclusion of potentially efficacious agents.   
Shen et al (2003) established absolute ADC and CBF thresholds below which 
pixels within respective ADC and CBF maps are destined to become infarcted 
following permanent MCAO (intraluminal filament method).  The ADC threshold 
was established from quantitative ADC maps acquired from DWI scans performed 
at 3 hours post-MCAO.  Likewise, the CBF threshold was derived from CBF maps 
acquired using continuous arterial spin labelling scans performed at 3 hour post-
MCAO.  To generate ADC and CBF thresholds Shen et al (2003) adjusted the ADC 
and CBF values on respective ADC and CBF maps until the ADC- and CBF-defined 
lesion volumes were numerically equal to TTC-derived infarct volumes measured 
141 
 
  
at 24 hours post-MCAO.  The absolute ADC and CBF thresholds established in the 
study by Shen et al (2003) were 0.53 x 10-3 mm2/sec and 0.3mL.g-1.min-1 
(30ml/100g/min) respectively.  In a similar manner Reid et al (2012), established 
absolute ADC and CBF viability thresholds for the Wistar Kyoto (WKY) and 
spontaneously hypertensive stroke prone (SHRSP) rat strains by adjusting ADC 
and CBF thresholds until the ADC-derived and CBF-derived lesion volumes at 4 
hours post-MCAO were numerically equal to infarct volumes measured at 24 
hours post-MCAO by T2-weighted imaging.  In WKY rats the ADC and CBF 
thresholds were 0.61±0.03 x 10-3 mm2/sec and 23±8ml/100g/min respectively.  
The ADC and CBF threshold values for SHRSP rats were 0.59±0.03 x 10-3 mm2/sec 
and 36±13ml/100g/min. In the study by Shen et al (2003) the ADC and CBF 
thresholds were established in Sprague Dawley rats, a normotensive rat strain, 
whereas Reid et al (2012), used hypertensive SHRSP rats and their control strain, 
WKY rats.  The results from these studies suggest that ADC and CBF viability 
thresholds can vary depending on rat strain and therefore may be strain specific.   
In addition to this, an acute MRI study reported differences in the temporal 
evolution of acute ADC lesion volume between different rat strains (Bardutzky et 
al., 2005).  Consequently ADC-derived lesion volumes could be significantly 
underestimated if an absolute ADC threshold established in a rat strain where 
the lesion has fully evolved is applied to define ADC lesion volume in a different 
strain where the lesion has not fully evolved.  It is therefore important that 
viability perfusion and diffusion thresholds are established for each rat strain 
used in experimental stroke studies.  Currently there are no published ADC or 
CBF thresholds to define perfusion and diffusion lesions for the Wistar rat strain; 
the strain used in this thesis.  It is also not clear from the literature if ADC and 
CBF viability thresholds vary depending on the method of MCAO.  Both Shen et al 
(2003) and Reid et al (2012) established thresholds following permanent MCAO 
induced by the intraluminal filament model.  However the distal portion of the 
MCA was occluded by diathermy in the present study and there could be 
differences in the temporal evolution of ischaemic damage between different 
methods.  Therefore the perfusion and diffusion data from the present study 
were used to establish CBF and ADC viability thresholds for the Wistar rat strain 
following permanent distal diathermy MCAO.  
142 
 
  
5.1.2 Study Aims 
The main aims of this study were to: 
1. Establish strain-specific diffusion and perfusion thresholds for Wistar rats 
that could be applied to quantitative diffusion and perfusion data in order 
to measure the perfusion and diffusion deficit over the acute 1-4 hours 
after permanent MCAO. 
2. Determine the effect of hyperglycaemia on the early development of 
ischaemic damage using DWI and the perfusion deficit using pCASL.  
3. Investigate the effect of hyperglycaemia on the acute evolution of 
penumbra tissue using the MRI perfusion-diffusion mismatch model. 
4. Assess the effect of hyperglycaemia on infarct volume at 24 hours post–
MCAO using T2 weighted imaging. 
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5.2 Methods 
5.2.1 Animals  
Adult male Wistar rats (280-360g) were used in this study.  Water and food were 
freely available except from the night before surgery when rats were fasted 
overnight with free access to water.   
5.2.2 Sample size calculation, randomisation and blinding 
To calculate the number of animals required per group a sample size calculation 
was performed based on the mean and standard deviation values of ADC lesion 
volume data and the effect size of glucose administration acquired from a 
previous MRI study using WKY rats (Tarr et al., 2013). The sample size 
calculation was based on an 80% power and 95% significance level as described in 
Chapter 4.2.2.  The number of animals per group was calculated to be 10.  All 
animals were randomised to treatment groups using an online randomisation 
plan generator (www.randomization.com).  Administration of treatment during 
surgery was carried out blind to treatment groups with a colleague not involved 
in the study preparing the appropriate syringe on day of surgery.  Similarly, all 
data analysis was carried out in a blinded manner.  Due to the 20% 
mortality/exclusion rate from the previous study it was decided to include 12 
animals per group in the randomisation plan (Figure 5.1).  A further 3 rats were 
later randomised into the study due to the exclusion of some animals.   
5.2.3 Surgical procedures 
Animals were initially anaesthetised in an anaesthetic chamber with 5% 
isoflurane in a 70% nitrous oxide and 30% oxygen mixture.  Oral intubation was 
performed and animals were artificially ventilated with 2.5% isoflurane in a 
nitrous oxide: oxygen mixture (70:30).  The right femoral artery was cannulated 
for continuous recording of MABP and monitoring of blood pH, PaCO2 and PaO2 as 
described in Chapter 2.2.2.  Body temperature was maintained at 37±0.5°C using 
an external heat source and recorded using a rectal thermometer.  Permanent 
focal cerebral ischaemia was achieved using the distal diathermy method of 
MCAO as described in Chapter 2.3.2.   
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Figure 5.1.  Randomization plan for MRI study where 12 rats were assigned to each group.  
The randomization plan was generated from www.randomization.com. 
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5.2.4 Induction of hyperglycaemia and blood glucose measurements 
Rats were randomly assigned to glucose and vehicle treatment groups.  A single 
dose of a 15% glucose solution (10ml/kg) or the equivalent volume of the vehicle 
solution (distilled water) was administered IP to glucose and vehicle treated 
rats, respectively, 10 minutes prior to MCAO.  Arterial blood glucose levels were 
measured 20 minutes prior to MCAO to obtain a baseline glucose reading, at the 
time of MCAO (0 minutes post-MCAO) and at each hour for four hours post-MCAO 
as described in Chapter 2.4.  
5.2.5 MRI scanning protocol 
MRI scanning was performed as described in Chapter 2.7.  For all MRI scans, after 
transferring the animal to the MRI rat cradle, anaesthesia was maintained with 
2-2.5% isoflurane in a nitrous-oxide: oxygen mixture (70:30) and the rat’s 
physiology was monitored as described in Chapter 2.7.2.  Before the cradle was 
placed inside the scanner a phased array surface receiver coil was placed on the 
rat’s head.  The rat cradle was then secured inside the scanner and a pilot 
sequence was obtained to ensure the geometry was correct. 
To assess the early evolution of ischaemic damage DWI scans were obtained at 1 
hour post-MCAO and at each subsequent hour for four hours post-MCAO using the 
sequence described in Chapter 2.7.3.  DWI scans consisted of 8 contiguous 
coronal slices (1.5mm thick) and quantitative ADC maps were generated for each 
slice.  
Perfusion images were acquired at each hour for 4 hours post-MCAO to assess the 
acute evolution of the perfusion deficit.  A form of pseudo continuous arterial 
spin labelling was used to generate non-invasive cerebral blood flow 
measurements on 6 contiguous coronal slices (1.5mm thick) as described in 
Chapter 2.7.4.   
Unlike the DWI scan which took approximately 2 minutes to generate an ADC 
map of 8 coronal slices, pCASL scans took approximately 7 minutes per coronal 
slice.  A T1 map, across 8 coronal slices was also performed each hour (for 
quantifying CBF maps) and this took approximately 10 minutes.  Therefore 
within each hour pCASL scans could only be generated for 6 coronal slices and 
146 
 
  
the 6 slices which were spatially identical to slices 2-7 of the DWI scan were 
selected.   
5.2.6 Animal Recovery  
At the end of the MRI scanning protocol the rat cradle was removed from the MRI 
scanner and after removing the water jacket, rectal thermocouple and ECG 
leads, the rat was disconnected from the ventilator and blood pressure monitor 
and transferred to the operating theatre.  Once in the operating theatre the rat 
was reconnected to the ventilator and anaesthesia was maintained with 2% 
isoflurane in a nitrous oxide: oxygen mixture (70:30).  Rats were then recovered 
for 24 hours as described in Chapter 2.3.4.   
5.2.7 Infarct volume assessment and collection of brain tissue 
At 24 hours post-MCAO, a RARE T2-weighted MRI scan was carried out to allow 
calculation of infarct volume (Chapter 2.7.5).  Following T2-weighted imaging 
the animals were deeply anaesthetised by increasing the isoflurane 
concentration to 5% for five minutes.   Animals were then removed from the MRI 
scanner and killed by decapitation.  The brain was rapidly removed from the 
skull and placed on a chilled glass plate.  The cerebellum and olfactory bulbs 
were removed and a scalpel blade was used to divide the remaining cerebrum 
into a left (ischaemic) hemisphere and right (non-ischaemic) hemisphere.  Each 
hemisphere was further dissected into cortical and subcortical tissue and all 
samples were snap frozen in liquid nitrogen and stored at -80˚C.  Brain tissue 
lysates were prepared from the ischaemic cortex tissue samples for protein 
analysis by western blotting (Chapter 6). 
A timeline summarising the MRI scanning protocol and experimental design is 
presented in Figure 5.2.   
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Figure 5.2. Timeline for MRI study.  Rats were randomized to vehicle (n=10) and glucose (n=10) treatment groups using an online randomisation plan 
generator.  The vehicle or 15% glucose solution was administered IP 10 minutes prior to MCAO.  Following MCAO rats were transferred to the small animal 
scanner and DWI, pCASL and T1–weighted scans were performed each hour for 4 hours.  Blood glucose levels were measured 20 minutes before MCAO to 
obtain a baseline reading, at the onset of MCAO (0 minutes) and at hourly intervals for 4 hours.   At the end of the 4 hour scanning period animals were 
recovered for 24 hours. After this time a T2-weighted MRI scan was performed to assess infarct volume.  The animals were then killed and brain was 
removed and the tissue was collected, snap frozen in liquid nitrogen and stored at -80°C. 
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5.2.8 MRI data analysis 
5.2.8.1 Generation of MRI diffusion and perfusion thresholds for the Wistar 
strain of rat 
For each animal included in the analysis a diffusion (ADC) threshold was 
established by applying a range of absolute ADC threshold values (0-2 x 10-3 
mm2/sec with 0.01 mm2/sec increments) to the quantitative ADC map generated 
at 4 hours post-MCAO until the ADC-defined lesion volume was within ±5mm3 of 
the oedema corrected T2-derived lesion volume (Reid, 2012).  The 4 hour time 
point was selected as the ADC-derived lesion volume has been shown to be fully 
evolved after this time (Li et al., 2000a, Reith et al., 1995).  
In a similar manner a perfusion threshold was established for each animal in the 
study. A range of increasing CBF thresholds (_100-400ml/100g/min with 1 
ml/100g/min increments) were applied to the pCASL CBF maps acquired at 4 
hours post-MCAO until the pCASL derived lesion volume was within ±10mm3 of 
the T2-derived infarct volume at 24 hours post-MCAO.  Negative perfusion values 
were generated in many of the pixels within the ischaemic cortex where there 
was zero or low CBF.  These negative values resulted from the subtraction step 
during pCASL image processing (Chapter 2.7.4), where the signal difference was 
comparable to image noise. Negative perfusion values were assumed to 
represent zero CBF. 
5.2.8.2 Calculation of ADC lesion volume and perfusion deficit volume 
To calculate ADC lesion volume an absolute ADC threshold of 0.53 x 10-3 mm2/sec 
was applied to the ADC maps generated at each hour post-MCAO.  This threshold 
represented the mean ADC threshold generated from all of the animals included 
in this study and matched the ADC threshold for Sprague-Dawley rats (Shen et 
al., 2003).  
The perfusion threshold generated in this study was not used to calculate the 
perfusion deficit as this threshold tended to underestimate the perfusion deficit 
as described in the results.  Instead, the volume of tissue with a perfusion deficit 
was calculated by applying an absolute perfusion threshold of 30ml/100g/min to 
all CBF maps.  This threshold was chosen because it was the absolute CBF 
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threshold derived by Shen et al (2003) to define the perfusion deficit following 
permanent MCAO in Sprague-Dawley rats using arterial spin labelling.  Also, in a 
study in which CBF was measured 30 minutes post-MCAO using [14C]-IAP 
autoradiography, mean CBF within the cerebral cortex was found to be 
~30ml/100g/min (Tamura et al., 1981b).   
5.2.8.3 Calculation of perfusion-diffusion mismatch 
Spatial assessment of the perfusion-diffusion mismatch was carried out on each 
of the 6 coronal slices of the CBF maps.  ImageJ software was used to apply a 
perfusion threshold of 30ml/100g/min and a diffusion threshold of 0.53 x 10-3 
mm2/sec to quantitative CBF maps and ADC maps respectively.  The ADC-derived 
lesion was then superimposed onto the thresholded CBF map and the remaining 
perfusion deficit (mismatch tissue) was manually delineated and the area of 
mismatch tissue was calculated.  The mismatch area on each of the 6 slices was 
summed and multiplied by the slice thickness (1.5mm) to obtain the volume of 
mismatch tissue.  This was repeated for each time point after MCAO. 
5.2.9 Study exclusion criteria 
Animals were excluded from the study if they died during surgery to induce focal 
cerebral ischaemia, during the MRI scanning protocol or before the 24 hour MRI 
scans. Animals were also excluded if there were any signs of intracerebral 
haemorrhage or subdural haematoma (Figure 5.3) development in the brain 
during T2-weighted imaging and/or tissue collection. 
 
Figure 5.3.  T2 weighted images from an excluded animal which had a subdural haematoma 
(white arrow).  The subdural haematoma appears hypointense on T2 images. 
150 
 
  
5.2.10 Statistical analysis  
Physiological variables, T2-weighted lesion volumes, ADC threshold values, CBF 
threshold values, T2-derived infarct volume, ipsilateral hemispheric swelling 
were assessed using a Student’s unpaired t-test.  Blood glucose values, ADC 
lesion volumes, perfusion deficit volumes, contralateral hemisphere CBF, PI-DWI 
mismatch and ADC-defined penumbra volumes were assessed using a repeated 
measures two-way analysis of variance (RM 2-way ANOVA) with Bonferroni’s 
post-test.  Differences between groups were considered to be statistically 
significant when P<0.05.  Data are expressed as mean ± standard deviation or 
scatterplots with the mean indicated.  Where images are presented from the 
median animal of each group these are the median animals from the T2-derived 
infarct volume results.   
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5.3 Results 
5.3.1 Mortality and excluded animals 
A total of 27 animals were included in this study.  Four animals died (3 vehicle 
treated rats and 1 glucose treated rat) during or after the MRI scanning protocol 
and these animals were excluded.  Three further rats (all glucose treated) were 
excluded from the study due to the presence of subdural haematomas on T2-
weighted images.  The final group sizes for analysis were n=10 for the vehicle 
treatment group and n=10 for the glucose treatment group. 
5.3.2 Physiological variables 
Physiological variables were measured throughout the duration of the 
experiment.  Body weight was measured on the day of surgery and there were no 
differences in body weight measurements between vehicle and glucose treated 
rats (321±25g & 326±17g respectively, P=0.6).  MABP, body temperature and 
blood PaCO2, PaO2 and pH were monitored throughout the surgical period to 
keep them within normal physiological range.  Baseline values, measured 20 
minutes before MCAO, and the values at 1-4 hours post-MCAO are presented in 
Table 5.1.  For each physiological parameter, except PaO2, mean values were 
within normal physiological range. PaO2 values were above the normal 
physiological range due to the elevated percentage of inspired oxygen used to 
maintain physiological stability during general anaesthesia.  There were no 
differences in any of the physiological parameters between the two groups at 
any of the time points measured.  
5.3.3 Blood glucose  
Blood glucose values were measured at baseline and at each hour for four hours 
following MCAO.  There was no significant difference in baseline blood glucose 
levels between vehicle and glucose treatment groups, with values of 
4.9±0.9mmol/L and 5.9±1.1mmol/L respectively.  Following a single IP injection 
of either the vehicle or 15% glucose solution (10ml/kg) blood glucose levels 
remained stable around baseline values in the vehicle group but rose to a mean 
level of 12.6mmol/L in the glucose group (Figure 5.4).  Blood glucose values in 
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the glucose treatment group remained at this elevated level for the duration of 
the 4 hour study.  
Physiological 
parameter 
Baseline 1 hour 2 hours 3 hours 4 hours 
Vehicle (n=10) 
MABP (mmHg)       
PaCO2 (mmHg) 
PaO2  (mmHg) 
pH 
Temperature (°C) 
 
92 ± 9 
35 ± 10 
126 ± 17 
7.41 ± 0.1 
37.0 ± 0.3 
 
91 ± 10 
36 ± 10 
125 ± 16 
7.38 ± 0.04 
37.4 ± 0.4 
 
89.5 ± 10 
41.1 ± 11.3 
121 ± 16 
7.39 ± 0.04 
37.3 ± 0.5 
 
90 ±7.6 
40.8 ± 10.8 
131 ± 26 
7.40 ± 0.03 
37.3 ± 0.3 
 
89 ± 6.4 
39 ± 5 
123 ± 30 
7.35 ± 0.04 
37.1 ± 0.1 
Glucose (n=10) 
MABP (mmHg)       
PaCO2 (mmHg) 
PaO2  (mmHg) 
pH 
Temperature (°C)  
 
97 ± 10 
37 ± 11 
132 ± 22 
7.47 ± 0.04  
37.0 ± 0.2 
 
88 ± 5.1 
38 ± 6 
123 ± 21 
7.37 ± 0.1 
37.2 ± 0.4 
 
86.8 ± 10.7 
37.1 ± 8.9 
122 ± 14 
7.35 ± 0.07 
37.1 ± 0.6 
 
84.5 ±11.2 
35.9 ± 5.4 
131 ± 24 
7.37 ± 0.1 
37.4 ± 0.4 
 
89 ± 7.0 
41 ± 9 
132 ± 28 
7.37 ± 0.04 
37.2 ± 0.6 
Table 5.1.  Physiological variables for MRI study.  Body weight was measured prior to 
MCAO.  MABP, temperature, pH, PaO2 and PaCO2 were measured at baseline (20 minutes 
before MCAO) and at each hour for 4 hours post-MCAO. The data are expressed as mean ± 
standard deviation.  There were no significant differences in any of the variables, at any 
time point, between vehicle and glucose treated rats (Student’s unpaired t-test). 
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Figure 5.4. Blood glucose data for MRI study.  Blood glucose values measured at baseline 
(-20 minutes) and at each hour for four hours post-MCAO in vehicle (n=10) and glucose 
(n=10) treated rats.  Glucose or vehicle solution was administered 10 minutes before MCAO. 
*P<0.0001 compared with vehicle using RM 2-way-ANOVA with Bonferroni’s post-test. Data 
are presented as mean ± standard deviation. 
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5.3.4 Establishing strain specific diffusion and perfusion thresholds 
The mean ADC threshold values of the vehicle and glucose treatment groups 
were 0.51±0.05 and 0.56±0.03 x 10-3 mm2/sec respectively (Figure 5.5A). The 
difference in ADC threshold values between groups was statistically significant 
(P=0.03).  There was no difference in mean ADC values in the contralateral 
hemisphere between groups at 4 hours post-MCAO, with values of 0.75 and 0.76 
x 10-3 mm2/sec (P=0.1) in vehicle and glucose treated rats respectively.  The 
mean ADC threshold value for all 20 rats in the study was 0.53±0.05 x 10-3 
mm2/sec (30% reduction from contralateral hemisphere ADC values, Figure 
5.5B).  Due to the observed difference in the mean ADC threshold between 
groups it was decided to use the mean ADC threshold established for all 20 rats, 
0.53 x 10-3 mm2/sec, to calculate ADC lesion volume for all rats.   
The mean CBF viability threshold values calculated for the vehicle and glucose 
treatment groups were 3±14 and 8±14ml/100g/min respectively (Figure 5.6A).  
The difference between groups was not statistically significant (P=0.5).  The 
mean CBF threshold for all rats included in the analysis was 6±14ml/100g/min 
(Figure 5.6B).  By examining the CBF thresholds values for individual rats it was 
found that more than half had CBF thresholds near to or below 0ml/100g/min, 
with thresholds of -14 and -13ml/100g/min calculated in some animals (Figure 
5.6B).  Negative CBF values resulted from the subtraction step during pCASL 
image processing (Chapter 2.7.4) and are assumed to represent zero flow.  
Therefore by assuming all negative CBF thresholds are 0ml/100g/min the mean 
CBF threshold for all 20 animals became 8±11ml/100g/min (Figure 5.6C).  
However, when using this threshold to define the perfusion deficit on 
quantitative CBF maps (top row of Figure 5.7) the area of the perfusion deficit 
on the thresholded CBF map did not match spatially with the region of 
hypoperfused blood flow on the non-thresholded CBF map (middle row of Figure 
5.7).  If this threshold was then applied to all animals the perfusion deficit could 
be underestimated in many animals.  When a CBF threshold of 30ml/100g/min 
was applied to define the perfusion deficit at 4 hours there was better spatial 
agreement between the perfusion deficit on the thresholded CBF map and the 
hypoperfused region on the non-thresholded CBF map (bottom row of Figure 
5.7).  This absolute CBF threshold of 30ml/100g/min has been used to define the 
perfusion deficit following 3 hours of permanent MCAO in Sprague Dawley rats 
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(Shen et al., 2003) and is in close agreement with pCASL derived perfusion 
thresholds generated in-house for WKY (23ml/100g/min) and SHRSP 
(36ml/100g/min) rats (Reid et al., 2012).  Therefore for calculation of the 
perfusion deficit it was decided to use a threshold of 30ml/100g/min. 
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Figure 5.5.  ADC thresholds for Wistar rat strain.  A.  ADC thresholds calculated for vehicle (n=10) and glucose (n=10) treated Wistar rats following MCAO.  
B.  ADC threshold values for all rats (n=20).  The ADC thresholds were generated by adjusting the ADC values on quantitative ADC maps acquired at 4 
hours post-MCAO until the ADC derived lesion volume matched the T2-derived infarct volume at 24 hours post-MCAO.  Data are presented as scatterplots 
with the line indicating the mean.  *P<0.05 compared with vehicle group using Student’s unpaired t-test. 
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Figure 5.6. pCASL derived CBF thresholds. A. CBF thresholds calculated for vehicle (n=10) and glucose (n=10) treated Wistar rats following MCAO.  B. CBF 
thresholds for all rats (n=20).  C. CBF thresholds for each rat with all negative values assumed to be 0ml/100g/min. CBF thresholds were generated by 
adjusting the CBF values on quantitative blood flow maps acquired at 4 hours post-MCAO until the volume of the perfusion deficit matched the T2-derived 
infarct volume at 24 hours post-MCAO.  Data are presented as scatterplots with the line indicating the mean. 
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Figure 5.7.  CBF deficit at 4 hours post-MCAO defined using different CBF thresholds.  
Quantitative CBF maps at 4 hours post-MCAO in slices 2, 4 and 6 (caudal to rostral) from a 
representative animal (top row).  Perfusion deficit (red) on the same CBF maps defined 
using a threshold of 8ml/100g/min (middle row) or 30ml/100g/min (bottom row).  
8ml/100g/min represents the mean CBF threshold established in the present study for the 
Wistar strain and 30ml/100g/min represents the perfusion threshold calculated in Sprague 
Dawley rats (Shen et al., 2003).  The perfusion deficit defined by an absolute threshold of 
8ml/100g/min tended to underestimate the hypoperfused region on quantitative CBF maps 
whereas the perfusion deficit defined by a threshold of 30ml/100g/min threshold tended to 
match this region.  
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5.3.5 Apparent diffusion coefficient lesion volume  
At 1 hour after MCAO, the earliest time point examined, there was no 
statistically significant difference in the mean ADC lesion volume between 
groups (Figure 5.8).  At all other time points after MCAO the mean ADC lesion 
volume was significantly larger in glucose treated rats compared to vehicle 
treated rats.   
The ADC-derived lesion volume increased significantly over the four hour time 
course in both groups.  In the glucose treatment group the mean ADC lesion 
volume increased significantly from 60±13mm3 at 1 hour to 81±29mm3  at 4 hours 
post-MCAO (P=0.02).  In the vehicle treatment group mean ADC lesion volume 
also increased significantly between 1 and 4 hours but the difference was small 
with values of 50±11mm3 and 56±12mm3 at 1 and 4 hours post-MCAO respectively 
(P=0.03).   
The spatial profiles of the ADC lesions at 1 and 4 hours post-MCAO from the 
median animal of each group are presented in Figure 5.9.  The ADC lesion at 1 
hour (white region) was superimposed on the ADC lesion at 4 hours (red) across 8 
coronal slices.  In most slices the ADC lesion at 4 hours post-MCAO was greater 
than that at 1 hour post-MCAO in both the vehicle and glucose treated rat.  In 
the glucose treated rat the ADC lesion was anatomically more widespread 
compared to the vehicle treated rat.  To examine this further the ADC lesion 
area on each of the 8 ADC map slices was plotted for each group at 1 and 4 hours 
post-MCAO (Figure 5.10). At both time points the most pronounced differences in 
the lesion area between groups were observed in the more caudal slices (ADC 
slices 2-3). 
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Figure 5.8.  ADC-derived lesion volume measured 1-4 hours after MCAO. ADC lesion volume 
was calculated by applying an abnormal diffusion threshold of 0.53 x10
-3 
mm
2
/sec.  Data are 
presented as mean ± standard deviation. *P<0.05 compared with vehicle rats using a 
repeated measures 2-way-ANOVA with Bonferroni’s post-test.  
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Figure 5.9.  ADC-derived lesions at 1 and 4 hours post-MCAO, across 8 coronal slices, from the median animal of each group.  The white region depicts the 
ADC lesion at 1 hour post-MCAO and the red region depicts the ADC lesion at 4 hours post MCAO.  ADC lesions at 1 and 4 hours post-MCAO appear to be 
quite similar in size in these examples but overall there was a significant increase in ADC-derived lesion volume between 1 and 4 hours post-MCAO in both 
vehicle (n=10) and glucose (n=10) treatment groups.  In the glucose treated rat the ADC lesion encompassed nearly all 8 coronal slices whereas in the 
vehicle treated rat the ACD lesion affected only a few coronal slices. 
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Figure 5.10.  The caudal-rostral profile of the ADC lesion at 1 hour and 4 hours post-MCAO.  Slices 1-8 refer to the 8 ADC slices depicted in Figure 5.9.  Data 
are presented as mean ± standard deviation for vehicle (n=10) and glucose (n=10) treated rats.  *P<0.05, ***P<0.001, compared with vehicle rats using a 2-
way-ANOVA with Bonferroni’s post-test. 
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5.3.6 Perfusion deficit volume 
An absolute threshold of 30ml/100g/min was applied to quantitative CBF maps 
acquired 1-4 hours post-MCAO to determine the acute evolution of the perfusion 
deficit for each group.  At all time points after MCAO the mean perfusion deficit 
volume tended to be larger in the glucose treatment group compared to the 
vehicle treatment group (Figure 5.11), but the difference between groups was 
not statistically significant.   
The volume of the perfusion deficit tended to increase over time in both groups.  
In vehicle treated rats the perfusion deficit increased from 140mm3 at 1 hour 
post-MCAO to 151mm3 at 4 hours but the difference was not statistically 
significant (P=0.5).  Similarly, in glucose treated rats the perfusion deficit 
increased from 164mm3 to 192mm3 between 1 and 4 hours post-MCAO 
respectively (P=0.2).  Quantitative CBF maps acquired at 1 and 4 hours post-
MCAO from the median animal of each group are presented in Figure 5.12. 
Darker regions on the CBF maps represent regions of reduced CBF and the region 
of reduced blood flow induced by MCAO was detected in the ipsilateral cortex of 
all 6 coronal slices in both groups, at both time points.   
Mean contralateral CBF was not significantly different between vehicle and 
glucose treated rats at any time point after MCAO (Figure 5.13).  CBF in the 
contralateral hemisphere tended to decrease over the 4 hour time period in both 
groups.  In vehicle treated rats mean CBF in the contralateral hemisphere was 
116±25ml/100g/min at 1 hour and 92±23ml/100g/min at 4 hours post MCAO.  
Similarly in glucose treated rats CBF in the contralateral hemisphere decreased 
from 105±29ml/100g/min at 1 hour to 86±23ml/100g/min at 4 hours post-MCAO.    
The decrease in mean contralateral CBF in each group over the course of the 4 
hour experiment was not significant (P=0.08 and P=0.05 in vehicle and glucose 
groups respectively). 
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Figure 5.11.  Temporal evolution of the perfusion deficit 1-4 hours after MCAO.  The 
perfusion deficit volume was calculated by applying an abnormal perfusion threshold of 30 
ml/100g/min to CBF maps.  Data are presented as mean ± standard deviation.  Differences 
between groups are not statistically significant: RM 2-way-ANOVA with Bonferroni’s post-
test. 
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Figure 5.12.  Quantitative pCASL derived CBF maps.  CBF maps (ml/100g/min) displaying hypoperfused tissue at 1 and 4 hours post-MCAO, across 6 
coronal slices, from the median animal of the vehicle and glucose treatment groups.  The darker regions represent areas with reduced CBF and these were 
predominantly found in the ipsilateral cortex, as a result of distal MCAO. 
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Figure 5.13.  Mean CBF, measured by pCASL, in the contralateral hemisphere 1-4 hours 
after MCAO.  Data are presented as mean ± standard deviation.  Differences between groups 
are not statistically significant: RM 2-way-ANOVA with Bonferroni’s post-test.   
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5.3.7 Perfusion-diffusion mismatch volume 
The volume of tissue with perfusion-diffusion mismatch, an estimate of the 
ischaemic penumbra, was comparable between groups at each time point post-
MCAO (Figure 5.14).  The mean perfusion-diffusion mismatch volume at 1 hour 
post-MCAO was 103±31mm3 and 117±36mm3 in vehicle and glucose treated rats 
respectively.  The volume of perfusion-diffusion mismatch tissue did not change 
significantly over time in either group as the mismatch volume at 4 hours post-
MCAO was 108mm3 and 130mm3 in vehicle and glucose treated rats respectively.   
The spatial distribution of the perfusion-diffusion mismatch tissue across 6 
coronal slices at 1 and 4 hours after permanent MCAO is presented in Figure 
5.15.  In coronal slices 2 and 3 of the representative vehicle treated animal 
there was a perfusion deficit but no ADC lesion.   In such instances the perfusion 
deficit was considered to be mismatch tissue.  
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Figure 5.14. Penumbra defined using MRI perfusion-diffusion mismatch. Perfusion-diffusion 
mismatch volume in vehicle (n=10) and glucose (n=10) treated rats following MCAO. 
Mismatch volume was calculated by superimposing ADC-derived lesion volumes onto 
respective CBF maps and manually delineating the remaining perfusion deficit. Data are 
presented as mean ± standard deviation. Differences between groups are not statistically 
significant: RM 2-way-ANOVA with Bonferroni’s post-test. 
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Figure 5.15.  Spatial distributions of perfusion-diffusion mismatch tissue across 6 coronal slices (caudal to rostral) at 1 and 4 hours after MCAO.  The data 
displayed are from the median animal of each group. The red region depicts the perfusion deficit defined by applying an absolute threshold of 
30ml/100g/min. The white region depicts the ADC lesion defined by applying an ADC threshold of 0.53 x10
-3 
mm
2
/sec.  On slices where there was a 
perfusion deficit but no ADC lesion the perfusion deficit area was considered as mismatch tissue.  
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5.3.8 T2-weighted infarct volume 
T2-derived infarct volume (corrected for oedema using equations in Chapter 
2.7.5) measured 24 hours after permanent MCAO was significantly greater in 
glucose compared to vehicle treated rats (P=0.002, Figure 5.16A). The mean T2-
derived infarct volume was 57±22mm3 and 90±19mm3 in vehicle and glucose 
treated rats respectively.  The correlation between T2-derived infarct volume at 
24 hours post-MCAO and blood glucose levels at 4 hours post-MCAO was also 
assessed (Figure 5.16C) and a significant correlation was found (R2=0.37, 
P=0.004). To assess the extent of ipsilateral hemispheric swelling between 
groups at 24 hours post-MCAO the volume of the ipsilateral and contralateral 
hemispheres for each rat were measured from the T2 map and hemispheric 
swelling was calculated using the following equation: ipsilateral hemispheric 
swelling = (volume of ipsilateral hemisphere – volume of contralateral 
hemisphere)/volume of contralateral hemisphere)(Wali et al., 2012).  
Hemispheric swelling tended to be greater in glucose treated rats but the 
difference between groups was not significant (P=0.07, Figure 5.16B).  
5.3.9 Penumbra volume derived from ADC lesion expansion 
In addition to the perfusion-diffusion mismatch model, the penumbra can also be 
assessed retrospectively by subtracting the ADC lesion volume measured at each 
hour from the T2-derived infarct volume measured at 24 h post-MCAO.  Using this 
method, the volume of the penumbra in the vehicle treatment group was 
7±22mm3 at 1 hour and decreased in size to 0±16mm3 at 4 hours post-MCAO 
(Figure 5.17, P=0.03). In glucose treated rats, penumbra volume was 31±16mm3 
at 1 hour, declining significantly over time to 9±21mm3 at 4 hours post-MCAO 
(Figure 5.17, P=0.02). Penumbra volume was significantly higher in the glucose 
compared to vehicle treatment groups at 1 hour post-MCAO (7±22mm3 vs 
31±16mm3, for vehicle and glucose treatment groups respectively (P<0.05, 
Figure 5.17), but was not significantly different between the groups at later time 
points.  
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5.16.  T2 derived infarct volume, correlation between infarct volume and blood glucose and hemispheric swelling at 24 hours post-MCAO.  Scatter plots 
showing T2-derived infarct volume data measured 24 hours after MCAO in each rat (A) and ipsilateral hemispheric swelling (B). The line on each scatter plot 
represents the mean.  *P<0.05 compared with vehicle group using a Student’s unpaired t-test.  C. The correlation between the T2-derived infarct volume and 
blood glucose measured at 4 hours post-MCAO from all rats in the study.  There was a significant correlation between T2-derived infarct volume and blood 
glucose (R
2
 = 0.37, P=0.004) 
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Figure 5.17.  ADC-defined penumbra.  The ADC-defined penumbra volume as determined by 
subtracting the ADC lesion volume at each hour post-MCAO from the oedema corrected T2-
derived infarct volume.  Data are presented as mean ± standard deviation, n = 10 per group.  
*P<0.05, RM 2-way-ANOVA with Bonferroni’s post-test. 
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5.4 Discussion 
The data from the MRI study presented in the present Chapter demonstrates that 
clinically relevant hyperglycaemia significantly increases the acute evolution of 
ischaemic damage and infarct volume in a rodent model of ischaemic stroke.   
The increase in acute ischaemic damage did not correspond with an increase in 
the evolution of the acute perfusion deficit, suggesting that the detrimental 
effects of hyperglycaemia are not mediated by a corresponding reduction in CBF.  
One of the proposed mechanisms by which hyperglycaemia may be harmful 
during ischaemic stroke is by accelerating the conversion of the ischaemic 
penumbra to infarction. The MRI data in this study show that there was no 
difference in the volume of penumbra tissue, defined by the MRI perfusion-
diffusion mismatch model, between hyperglycaemic and normoglycaemic rats.  
However retrospective analysis of the penumbra using the ADC lesion (ADC-
defined penumbra) revealed that there was a considerable volume of ADC-
defined penumbra tissue in hyperglycaemic rats at 1 hour after stroke compared 
to normoglycaemic animals. This suggests that in hyperglycaemic animals there 
may be a window of opportunity to intervene and alter the progression of the 
infarct.    
5.4.1 Glucose treatment increased the threshold to define ADC-
derived ischaemic damage  
The strain of rat used in this study was Wistar and to my knowledge this is the 
first study to define MRI diffusion thresholds for this strain. The mean ADC 
threshold for all of the Wistar rats included in this study was 0.53 x 10-3 
mm2/sec, which was associated with a 30% reduction in ADC from control.  This 
absolute threshold is identical to that established by Shen et al (2003) to define 
ADC derived ischaemic damage in Sprague-Dawley rats.  Shen and colleagues 
also reported a 30% reduction in ADC from control and similarly, Foley et al 
(2010) reported a reduction in ADC values of 30% compared to control in 
Sprague-Dawley rats (Foley et al., 2010).  Both Wistar and Sprague-Dawley rats 
are normotensive rat strains and as such the ADC threshold was predicted to be 
similar.  In comparison to normotensive rat strains, absolute ADC viability 
thresholds established for hypertensive SHRSP rats and their control strain, WKY 
rats, were higher with values of 0.59 and 0.61 x 10-3 mm2/sec respectively (23% 
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and 21% reduction in ADC from control) (Reid et al., 2012). The data from these 
studies suggests that thresholds to define ischaemic damage may be different 
between strains. The higher ADC thresholds in WKY and SHRSP strains may 
reflect the increased sensitivity to ischaemic injury reported in hypertensive 
compared to normotensive rat strains (Coyle and Jokelainen, 1983, Carswell et 
al., 1999). 
Unlike any of the other studies that have established ADC viability thresholds in 
rodents, a confounding factor in the establishment of the ADC thresholds in the 
present study was that rats received either vehicle or glucose treatment.  When 
ADC thresholds were compared between treatment groups it was found that the 
mean ADC threshold was higher in glucose compared to vehicle treated rats. It is 
not clear if there is any biological significance in this finding and since the 
difference between groups was only small (P=0.03) and there was considerable 
overlap in the data points between groups it seems unlikely that there will be.   
However the higher ADC threshold may indicate that hyperglycaemic rats are 
more sensitive to reductions in ADC values and this could help to explain, in 
part, the larger infarct volumes observed in hyperglycaemic compared to 
normoglycaemic rats. 
5.4.2 Glucose treatment did not influence the pCASL-derived 
perfusion deficit  
Glucose treatment had no significant effect on the volume of tissue with a 
perfusion deficit (CBF <30ml/100g/min) 1-4 hours after MCAO compared to 
vehicle treatment.  This result is in agreement with the results from the previous 
Chapter which showed that glucose treatment had no effect on the reduction in 
CBF at 1 hour post-MCAO, determined by 99mTc-HMPAO autoradiography.  
However, in both of the treatment groups in the present study there was a 
substantial perfusion deficit, at all time points after MCAO, with volumes ranging 
from 130-192mm3.  The perfusion deficit data for each group is presented in 
Figure 5.18 alongside the ADC lesion volume data and the T2-derived infarct 
volume.  It is obvious from this graph that the perfusion deficit was far greater 
than the ADC lesion volume and this explains why there were such high volumes 
of perfusion-diffusion mismatch tissue in both groups.   
175 
 
  
 
 
 
 
 
 
Figure 5.18.  Graph summarising the ADC-derived lesion volume, pCASL-derived perfusion 
deficit and infarct volume data.  For both groups: diamonds indicate ADC lesion volume, 
crosses indicate perfusion deficit (CBF) volume and circles indicate T2-derived infarct 
volume measured at 24 hours post-MCAO.  Data are presented as mean ± standard 
deviation.   
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Despite such a large perfusion deficit at the last measured time point (4 hours 
post-MCAO), infarct volumes measured 24 hours after MCAO were similar in size 
to the ADC-derived lesion volume at 4 hours, indicating that most of the  tissue 
with a perfusion deficit at 4 hours was not incorporated into the infarct at 24 
hours.  A potential explanation for this may be due to the increase in blood 
pressure that occurs on withdrawal of anaesthesia.  Withdrawal of isoflurane, 
which is known to have a cardio-depressant effect (Schappert et al., 1992) will 
inevitably lead to a rise in blood pressure as animals regain consciousness.  This 
increase in blood pressure will cause an increase in CBF within the ischaemic 
hemisphere which reduces the volume of the perfusion deficit and prevents the 
progression of the hypoperfused at-risk tissue to infarction.    
The large perfusion deficit observed in both treatment groups in the present 
study could be partly due to applying an inappropriate CBF threshold.  Voxels 
within the ipsilateral hemisphere of CBF maps with CBF below 30ml/100g/min 
were considered to represent hypoperfused tissue.  This is the absolute 
threshold established by Shen et al (2003) to define the perfusion deficit in 
Sprague Dawley rats and not the absolute threshold established in the present 
study (8ml/100g/min).  The latter threshold did not match spatially with the 
perfusion deficit visualised on quantitative CBF maps and this was presumed to 
be due to the high number of voxels with negative CBF values on the 
quantitative CBF maps that arose during pCASL image processing.  Although the 
applied CBF threshold of 30ml/100g/min matched spatially with the 
hypoperfused region on quantitative CBF maps, some of the tissue below this 
threshold could have recovered spontaneously (benign oligaemia) resulting in an 
overestimation of the perfusion deficit and subsequently perfusion-diffusion 
mismatch tissue. Nevertheless results from studies assessing CBF 
autoradiographically support the use of this threshold (Hoehn-Berlage et al, 
1995).  In their study, Hoehn-Berlage and colleagues measured ADC changes over 
the first 2 hours following permanent MCAO in Wistar rats.  At 2 hours following 
the onset of MCAO regional CBF was measured by quantitative [14C]-IAP 
autoradiography and ATP depletion and tissue pH were determined by 
bioluminescence and fluorescence techniques respectively.  Hoehn-Berlage et al 
(1995) defined the ischaemic penumbra as a hypoperfused region within the ADC 
lesion with tissue acidosis but normal ATP levels and showed that this region 
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corresponded to a CBF threshold of 31±11 ml/100g/min (Hoehn-Berlage et al., 
1995).  This value is almost identical to the threshold of 30ml/100g/ml used in 
the present study to identify hypoperfused at-risk tissue. 
Within both the treatment groups the volume of tissue with a perfusion deficit 
did not change significantly over time.  This data is consistent with previously 
published data from acute MRI studies characterising the time course of the 
perfusion deficit after permanent MCAO in normotensive rat strains (Shen et al., 
2003, Meng et al., 2004, Bratane et al., 2009).  In contrast, the perfusion deficit 
has been shown to increase significantly over time in hypertensive rat strains 
(Reid et al., 2012) and this may be due to impaired collateral blood flow after 
stroke.  The stable volume of tissue with a perfusion deficit in normotensive rat 
strains, such as the Wistar strain used in this thesis, could be explained by tight 
physiological monitoring of the animals under anaesthesia.   
5.4.3 Hyperglycaemia did not influence the temporal profile of 
mismatch tissue 
The mismatch between perfusion and diffusion-weighted MR images is presumed 
to approximate the ischaemic penumbra.  In patients with evidence of perfusion 
diffusion mismatch tissue, hyperglycaemia was associated with reduced salvage 
of mismatch tissue from infarction which suggests that the ischaemic penumbra 
may be susceptible to hyperglycaemic ischaemia.   It was therefore interesting 
to examine the amount of tissue with perfusion-diffusion mismatch at each time 
point after MCAO in the present study.  The results showed that glucose 
treatment did not influence the volume of perfusion-diffusion mismatch tissue 
over the first four hours after MCAO.  This may have important clinical 
implications because if the amount of penumbral tissue is similar between 
normo- and hyperglycaemic patients there may be a window of opportunity for 
therapeutic intervention to prevent the harmful effects of hyperglycaemia 
during ischaemia.  The ADC lesion volume data predicts the optimal time window 
for intervention to be within the acute 0-2 hours after stroke onset and future 
clinical trials of glucose lowering therapies may only see a benefit by targeting 
treatment to this early time-window. 
178 
 
  
The volume of perfusion-diffusion mismatch tissue in both groups was 
approximately 100mm3 at 1 hour post-MCAO and the absolute volume did not 
change over time.  The volume of mismatch tissue observed was comparable to 
values reported in published studies in which permanent MCAO was induced by 
the intraluminal filament model (Shen et al., 2003, Bardutzky et al., 2005, Meng 
et al., 2004, Bratane et al., 2009). However previous studies reported a 
decrease in the amount of perfusion-diffusion mismatch tissue over time which 
correlated with an increase in the acute ADC lesion.  Such findings were not 
observed in the present study.  For example in the glucose treatment group the 
volume of the ADC lesion increased from 1 to 4 hours post-MCAO but the volume 
of mismatch tissue remained constant over this time.  This could be due to a 
number of factors.  Firstly, the thresholds used to define perfusion-diffusion 
mismatch by Shen et al (2003) were established by applying increasing ADC and 
CBF thresholds to respective ADC and CBF maps acquired 3 hours post-MCAO 
until lesion volumes matched the TTC derived infarct volume at 24 hours post-
MCAO.  By doing this the authors have essentially forced both the CBF and ADC 
lesions at 3 hours to equal the TTC infarct and therefore it is no surprise that 
perfusion-diffusion mismatch decreases over time.  The authors state that the 
acute 3 hour time point was selected as the ADC lesion volume has been shown 
to stop evolving after this time although they did not go on to show this.  
Therefore Shen et al (2003) may have introduced inaccuracies in their results as 
they assume that both the ADC lesion and the CBF deficit do not evolve beyond 3 
hours.  The same is true of the present study as it was assumed that the ADC 
lesion does not continue to evolve after 4 hours, yet this was not proven.  
Images were not acquired beyond this time as this would have increased the 
length of time that the animals were under anaesthesia which could have 
compromised animal recovery.  
Secondly, differences between the evolution and extent of ischaemic brain 
damage induced by different methods of MCAO might explain the temporal 
differences in perfusion-diffusion mismatch observed in different studies. To my 
knowledge there are no previously published studies that have investigated the 
evolution of the acute perfusion deficit in a rodent stroke model other than the 
intraluminal filament model of MCAO.   Insertion of the intraluminal filament to 
occlude the origin of the MCA produces a severe reduction in CBF that results in 
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widespread ischaemic damage, incorporating both cortical and subcortical brain 
structures. With such extensive ischaemic damage it is inevitable that the 
collateral blood supply will be unable to maintain perfusion of the hypoperfused 
at-risk tissue which will rapidly progress to infarction over time.  Conversely, 
occluding the distal portion of the MCA by diathermy, the method used in this 
thesis, largely restricts ischaemic damage to the ipsilateral cortex and therefore 
the ischaemic damage induced is not as extensive compared to that induced by 
the intraluminal filament method.  Collateral supply from pial blood vessels 
could help to maintain perfusion of the hypoperfused at-risk tissue surrounding 
ischaemic lesions induced by the distal diathermy method of MCAO, resulting in 
the stable volume of perfusion-diffusion mismatch tissue observed in the present 
study.  It is important to mention here that although the volume of mismatch 
tissue measured at each hour after the onset of MCAO doesn’t significantly 
change between 1 and 4 hours in each group, the tissue within the penumbra 
will inevitably change over time.  Some of the tissue with perfusion-diffusion 
mismatch will become incorporated into the infarct and this is supported by the 
fact that the ADC lesion increased over time in both vehicle and glucose 
treatment groups.  Also, as collateral blood supply decreases over time 
(supported by the decrease in CBF observed in the contralateral hemisphere 
Figure 5.12), some of the benign oligaemic tissue will become incorporated into 
the ischaemic penumbra. Therefore although the volume doesn’t changed over 
time the tissue contributing to the perfusion-diffusion mismatch would have. 
5.4.4 Hyperglycaemia increased the ADC-defined penumbra volume at 
1 hour post-MCAO 
In addition to the perfusion-diffusion mismatch model, tissue at risk of infarction 
may also be determined retrospectively from the growth of the acute ADC lesion 
into the final infarct. Using this method, it was established that there was only a 
small volume of penumbra tissue (~7mm3) in vehicle treated animals at 1 hour 
post-MCAO, but a considerable volume of penumbra tissue (~30mm3) in glucose 
treated animals at this same time. In the vehicle treatment group, there was 
little expansion of the ADC lesion volume over time, indicating that the amount 
of ischaemic damage was almost maximal at 1 hour post-stroke (Figure 5.17).  In 
contrast, there was greater expansion of the ADC lesion volume in the glucose 
treatment group, which corresponded with a decrease in the ADC-defined 
180 
 
  
penumbra volume over time. This data suggests that in the hyperglycaemic 
group there was more tissue at risk of infarction and thus there may be a 
window of opportunity for early therapeutic intervention to recover this tissue. 
However, without intervention, hyperglycaemia could continue to exacerbate 
ischaemic damage resulting in the evolution of brain injury and larger final 
infarcts. Although this method of defining the penumbra is not applicable for the 
acute assessment of the penumbra in stroke patients it has many  useful 
research applications,  for example in determining if there are differences in the 
optimal time window for therapeutic intervention.  
5.4.5 MRI perfusion deficit data confirms previous findings 
Previous studies in this thesis demonstrated that glucose treatment had no 
effect on the reduction in CBF at 1 hour post-MCAO measured by 99mTc-HMPAO 
blood flow autoradiography, suggesting that hyperglycaemia does not exacerbate 
ischaemic damage by altering CBF.  Assessment of ischaemic damage was not 
feasible in the study reported in Chapter 4 due to the nature of the 
autoradiographic procedure.  Interestingly the MRI data in this chapter revealed 
no difference in ADC lesion volume between vehicle and glucose treatment 
groups at 1 hour after MCAO.  However, glucose treatment significantly 
increased ADC-derived lesion volume from 2-4 hours after MCAO compared to 
vehicle treated rats. The increase in ADC lesion volume at these time points was 
not associated with a larger perfusion deficit as there was no difference in the 
pCASL defined perfusion deficit at 2-4 hours between groups.  This supports the 
findings from the autoradiographic study in Chapter 4 and suggests that the 
adverse effects of hyperglycaemia during focal cerebral ischaemia are not 
caused by exacerbating the reduction in CBF.  These results also support those 
reported previously in both clinical (Luitse et al., 2013) and animal studies 
(Gisselsson et al., 1999) where poor functional outcomes in patients and larger 
infarct sizes in hyperglycaemic animals could not be explained by larger 
perfusion deficits.  Together this data suggests that the detrimental effects of 
hyperglycaemia are not predominantly mediated in the cerebrovasculature.  
Alternatively, they may take place within the brain tissue. To determine 
whether the adverse effects of hyperglycaemia on infarct size are associated 
with greater tissue injury the brain tissue collected in this study was processed 
for protein analysis by Western blotting and is presented in Chapter 6.  
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The vascular effects of hyperglycaemia during ischaemic stroke however, cannot 
be entirely excluded.  Firstly, hyperglycaemia is associated with an increased 
risk of haemorrhagic transformation (HT) in ischaemic stroke patients (Paciaroni 
et al., 2009).  HT can occur as a natural consequence of ischaemic stroke and is 
especially common after thrombolytic therapy due to bleeding from 
ischaemically injured blood vessels. Indeed, numerous studies have reported 
that there was a greater risk for HT in hyperglycaemic ischaemic stroke patients 
receiving rt-PA (Hill and Buchan, 2005, Demchuk et al., 1999, Bruno et al., 2002, 
Poppe et al., 2009, Putaala et al., 2011). The association between 
hyperglycaemia and an increased HT is supported by experimental data.  Won et 
al (2011) demonstrated a relationship between hyperglycaemia and the 
increased risk of haemorrhage in an animal model of rt-PA stroke treatment.  
The authors reported that the increased risk of haemorrhage after 90 minutes of 
focal ischaemia in hyperglycaemic rats was associated with an increase in 
superoxide production by NADPH oxidase (Won et al., 2011).  Increased 
superoxide production and its interaction with nitric oxide, producing reactive 
nitrogen species such as peroxynitrite, is thought to play an important role in 
vascular disease pathophysiology (Guzik et al., 2000).   
Secondly, hyperglycaemia could act on the cerebral microvasculature to alter 
CBF following ischaemic stroke.  Pericytes are contractile cells found in almost 
all capillaries as well as arterioles and veins.  They are small cells found on the 
outside of the capillary between the endothelial cell layer and the brain 
parenchyma and have an important range of functions in angiogenesis, 
endothelial cell regulation and maintenance of the blood brain barrier (Lai and 
Kuo, 2005, Hirschi and D'Amore, 1996).  Pericytes may also have an important 
role in capillary blood flow regulation.   In a recent study Hall et al (2014) 
demonstrated that during neuronal activity, in response to excitatory 
neurotransmitters, pericytes relax their grip on capillaries causing them to 
vasodilate and increase blood supply to active neurons.  This pericyte-mediated 
dilation of capillaries has been shown to occur before arterioles and is estimated 
to produce 84% of the resulting blood flow increase (Hall et al., 2014). Thus 
pericytes seem to be major regulators of cerebral blood flow under normal 
physiological conditions.  Evidence from in vitro studies suggests that pericytes 
have a profound effect on CBF under ischaemic conditions.  Hall et al (2014) also 
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carried out live imaging of cerebral cortical slices in response to simulated 
ischaemia (oxygen-glucose deprivation, OGD) and found that 15 minutes of OGD 
caused constriction of capillaries in regions near to pericytes.  OGD resulted in 
the rapid death of these capillaries and it was reported that approximately 90% 
of pericytes died within 1 hour.  This effect was shown to be halved by blocking 
AMPA/kainate or NMDA receptors and suggests that ischaemia-induced 
excitotoxicity may contribute to pericyte cell death.  Death of pericytes during 
ischaemia is thought to irreversibly constrict capillaries, which in turn leads to a  
decrease in cerebral blood flow and promotes brain damage (Hall et al., 2014). 
Constriction of capillaries by pericytes has also been shown to occur in vivo 
following transient MCAO (Yemisci et al., 2009) and after the onset of simulated 
retinal ischaemia (Peppiatt et al., 2006).  In the former study, Yemisci et al 
(2009) reported that suppression of oxidative/nitrative stress relieved pericyte 
contraction and restored microvascular patency after transient cerebral 
ischaemia followed by reperfusion.   This suggests that reactive oxygen and 
nitrogen species formation may also contribute to pericyte constriction of 
capillaries during ischaemia.  
There is evidence to suggest that high glucose concentrations lead to pericyte 
cell death.  In vitro studies revealed that high glucose concentrations (~40mM) 
increased the rate of respiration and ROS production in mouse cerebral pericytes 
which led to pericyte cell death by apoptosis (Shah et al., 2013). 
Hyperglycaemia was also found to increase pericyte death in retinal pericytes 
through a protein kinase C-δ dependent signalling pathway (Geraldes et al., 
2009).  These findings implicate pericytes as potential mediators for the 
injurious effects of chronic hyperglycaemia on the microvasculature in diabetic 
retinopathy.  Such high glucose levels are scarcely seen in ischaemic stroke 
patients with PSH and therefore the effects, if any, of clinically relevant 
hyperglycaemia during ischaemia on capillary constriction and pericyte death 
remains to be elucidated. Future studies investigating the effects of acute 
hyperglycaemia on the microvasculature could reveal important information on 
the pathophysiological mechanisms underlying the detrimental effects of 
hyperglycaemia in ischaemic stroke. 
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5.4.6 Summary 
The data from the MRI study presented in this chapter demonstrates that 
hyperglycaemia at the time of MCAO exacerbates early ischaemic damage and 
infarct volume at 24 hours.  In addition, retrospective assessment of the 
penumbra revealed that there was evidence of a considerable volume of ADC-
define penumbra tissue in hyperglycaemic rats at 1 hour after stroke compared 
to normoglycaemic animals, implicating that in hyperglycaemic animals there 
may be a window of opportunity to intervene and limit further damage.  The 
data from this study also demonstrates that the damaging effects of 
hyperglycaemia did not correspond with an exacerbation of the acute perfusion 
deficit following permanent MCAO and this suggests that the adverse effects of 
hyperglycaemia in ischaemic stroke are not due to an increase in the severity of 
the ischaemic insult. The alternative is that detrimental mechanisms operate in 
the brain parenchyma.  In the next Chapter the brain tissue samples collected 
from the experiment reported above, and from 2 hours after MCAO, were used 
to determine if specific proteins associated with ischaemic damage are altered 
in hyperglycaemic versus normoglycaemic brain tissue. 
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Chapter 6 – The effects of glucose treatment on 
calpain-mediated proteolysis of αII-spectrin and 
MAP2 after permanent MCAO 
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6.  
6.1 Introduction 
Although hyperglycaemia is associated with poor functional outcomes and 
increased mortality in ischaemic stroke patients (Kiers et al., 1992a, Berger and 
Hakim, 1986, Melamed, 1976), the mechanism(s) of hyperglycaemia-induced 
harm are poorly understood.  In the previous Chapter it was demonstrated that 
hyperglycaemia exacerbates acute ischaemic damage over the initial few hours 
and leads to larger infarcts in a rodent model of permanent MCAO.  These results 
are in agreement with previous animal studies (Tarr et al., 2013, Huang et al., 
1996a), and suggest that the detrimental effects of hyperglycaemia occur early 
following the onset of ischaemic stroke.  In Chapter 5, using perfusion MRI, it 
was shown that exacerbation of ischaemic damage by elevated blood glucose 
levels was not associated with more severe initial reductions in cerebral blood 
flow. From this it was hypothesised that the detrimental effects of 
hyperglycaemia predominantly take place within the brain tissue rather than at 
the level of the cerebral vasculature.   To test this hypothesis, brain tissue was 
collected from vehicle and glucose treated rats following 2 hours and 24 hours of 
permanent distal MCAO and processed for Western blot analysis of proteins that 
are known to be markers of ischaemic tissue damage.   
6.1.1 Calpain-mediated brain injury 
Increased extracellular glutamate levels during ischaemia leads to the activation 
of calcium permeable NMDA receptors, resulting in a massive influx of calcium 
into the cell.  One of the damaging effects of this calcium overload is the 
excessive activation of calpain, a cysteine protease which has a wide range of 
important physiological functions including long-term potentiation, neurite 
outgrowth and synaptic remodelling (Sorimachi et al., 1997, Denny et al., 1990).   
The excessive activation of calpain during ischaemia leads to the unregulated 
proteolysis of calpain substrates and calpain-mediated neuronal death (Neumar 
et al., 2001).  Further to this, studies have shown that calpain inhibitors are 
neuroprotective during focal cerebral ischaemia, indicating that calpains are 
important mediators of ischaemic brain damage (Hong et al., 1994a, Hong et al., 
1994b, Li et al., 1998).  Evidence from in vitro studies suggests that calpain 
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activation may be an important intracellular mediator of glutamate excitoxicity.  
For example, Siman et al (1989) demonstrated that neuronal damage induced by  
intensive glutamate receptor stimulation, results in calpain activation, 
manifested as increased levels of the break down products of one of calpains 
substrates, spectrin (Siman et al., 1989). This is supported by in vivo studies 
which show that blocking NMDA receptors reduces the proteolytic activity of 
calpain during transient forebrain ischaemia (Seubert et al., 1988). In addition to 
the cytoskeletal protein spectrin, calpain has a number of other substrates 
including microtubule-associated proteins (MAPs), kinases, phosphatases and 
membrane receptors and transporters.  Of these, microtubule associated protein 
2 (MAP2) has been widely studied in animal models of stroke.  MAP2 protein 
levels and immunoreactivity have been reported to decrease over-time after 
MCAO and therefore MAP2 degradation is regarded as a reliable marker of 
ischaemic brain injury (Pettigrew et al., 1996, Dawson and Hallenbeck, 1996, 
Popp et al., 2009).     
6.1.2 Does hyperglycaemia exacerbate the proteolytic activity of 
calpain? 
The possibility that hyperglycaemia exaggerates ischaemic injury by increasing 
excitotoxic brain damage has been studied in rodent stroke models using 
microdialysis (Li et al., 2000c, Choi et al., 2010, Wei and Quast, 1998).  Li et al, 
(2000) used microdialysis coupled with high-performance liquid chromatography 
techniques to measure extracellular glutamate and other excitatory amino acid 
concentrations in normo- and hyperglycaemic rats subjected to 15 minutes of 
transient forebrain ischaemia.  They found that pre-ischaemic hyperglycaemia 
(target blood glucose level: 20mmol/L) enhanced extracellular glutamate 
release in the cerebral cortex which correlated with exaggerated neuronal 
damage in this region.  Hyperglycaemia (~26mM) also increased extracellular 
glutamate levels in brain dialysate samples collected during ischaemia in a 
transient MCAO stroke model (Wei and Quast, 1998).  The increased glutamate 
levels during ischaemia in hyperglycaemic rats correlated with increased brain 
injury, determined by diffusion weighted imaging.  Based on the results from 
these microdialysis studies, it was postulated that the increase in early 
ischaemic damage and infarct sizes observed in hyperglycaemic rats following 
permanent MCAO in the previous Chapter may be caused by an enhancement of 
187 
 
  
glutamate-mediated excitotoxicity.  Since calpain activation has been shown to 
occur during excitotoxic brain damage it was hypothesised that hyperglycaemia, 
at the time of focal cerebral ischaemia, would significantly increase 
extracellular glutamate levels, and consequently the proteolytic activity of 
calpain, compared to a normoglycaemic model.  
6.1.3 Study aims 
In the previous study brain tissue from the ipsilateral cortex was collected from 
vehicle and glucose treated rats 24 hours after permanent MCAO.  Infarct 
volume, determined by T2-weighted MRI, was found to be significantly greater in 
glucose compared to vehicle treated rats.  The aim of the present study was to 
determine if the larger infarct sizes at 24 hours post-MCAO in the glucose 
treatment group was associated with an increase in the proteolytic activity of 
calpain, manifested as an increase in levels of spectrin breakdown products 
(SBDPs) and a greater extent of MAP2 degradation. 
From the previous MRI study in Chapter 5 the earliest time point at which 
glucose treatment was found to have a harmful effect was 2 hours after MCAO.  
In order to gain a better understanding of the mechanisms of hyperglycaemia-
induced harm at this earlier time point, separate groups of vehicle and glucose 
treated rats were generated in which the MCA was occluded permanently for 2 
hours.  As with the 24 hour MCAO tissue, the levels of αII-spectrin and MAP2 
protein were assessed in the 2 hour MCAO tissue to determine if hyperglycaemia 
exacerbates the proteolytic activity of calpain at this earlier time point.   
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6.2 Methods 
6.2.1 Brain tissue samples  
6.2.1.1 Preparation of 2 hour permanent MCAO samples 
Adult male Wistar rats (310-420grams) were fasted overnight prior to stroke 
surgery.  Anaesthesia was induced in an induction chamber with 5% isoflurane in 
nitrous-oxide: oxygen (70:30).  A tracheotomy was performed for artificial 
ventilation and the right femoral artery was cannulated for blood gas and 
glucose measurements as described in Chapter 2.2.  Permanent focal cerebral 
ischaemia was induced by occluding the left MCA using the distal diathermy 
MCAO method as described in detail in Chapter 2.3.  Rats were randomly 
assigned to vehicle (n=7) or glucose (n=7) treatment groups using an online 
randomization plan generator and treatments were administered 10 minutes 
before MCAO as described in Chapter 2.4.  Blood glucose levels were measured 
20 minutes before MCAO to obtain a baseline glucose reading, at the onset of 
MCAO and at subsequent time points after MCAO.  Body weight was measured 
prior to surgery and arterial blood gases were measured before MCAO, at the 
onset of MCAO and at 2 hours post-MCAO.   
After 2 hours of ischaemia the rat was killed by an overdose of anaesthetic and 
the brain was rapidly removed and placed onto a chilled glass plate.  The 
olfactory bulbs, cerebellum and brainstem were removed and the remaining 
cerebrum was dissected into 4 sub-sections: ipsilateral cortex, contralateral 
cortex, ipsilateral subcortex and contralateral subcortex.  All samples were 
placed into sterile Eppendorf tubes, snap-frozen in liquid nitrogen and stored at 
-80°C.   
The brain tissue from animals used in the previous chapter was collected in an 
identical manner at 24 hours post-MCAO and processed alongside the 2 hour 
MCAO tissue.  Brain tissue collected from a naive rat (adult, male, Wistar) was 
used as a control. 
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6.2.1.2 Preparation of cytosolic and membrane fractions 
Brain tissue lysates were prepared from the ipsilateral cortex tissue samples 
collected from each rat as described in Chapter 2.8.2.  The whole of the 
ipsilateral cerebral cortex was homogenised as the previous MRI study in Chapter 
5 showed that the ischaemic lesion was present on coronal brain slices 
throughout the MCA territory. 
The centrifugation protocol used separated the tissue lysates into crude 
membrane and cytosolic fractions.  The proteins of interest; αII-spectrin and 
MAP2 are cell membrane skeletal proteins and thus are expected to be found 
within the membrane fraction.  However, it was decided to analyse both the 
membrane and cytosolic fractions as MCAO is known to cause cell membrane 
disruption and therefore proteins typically found in membrane fractions could be 
released into the cytosol.  
6.2.2 Protein analysis  
6.2.2.1 Protein concentration and protein loading determination  
The protein concentration of the cytosolic and membrane fractions for each rat 
was determined using a BCA assay as described in Chapter 2.8.3.  To determine 
the optimum amount of protein to load for Western blotting experiments a 
standard curve of protein load versus band optical density (OD) was produced for 
each antibody (Figure 6.1).  The standard curves were prepared using different 
amounts of protein from both the membrane and cytosolic fractions of three 
vehicle treated rats (24 hour MCAO tissue).  Protein bands were most consistent 
and were not oversaturated when loading 10µg of protein, in each of the 
standard curves. In addition, 10µg protein generated sharp, well defined protein 
bands when assessed by Coomassie blue staining, indicating that the gels were 
not overloaded.  Therefore 10µg of protein was loaded in all other Western blots 
in this Chapter. 
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Figure 6.1.  Standard curves of protein load versus protein band OD in three vehicle treated 
rats. Standard curves A (cytosolic fraction) and B (membrane fraction) were produced from 
Western blots probed with an antibody against αII-spectrin and curves C (cytosolic fraction) 
and D (membrane fraction) from blots probed with an antibody against MAP2.  A consistent, 
non-saturated signal was produced in each of the curves when 10µg of protein was loaded 
therefore 10µg of each sample was loaded on to gels for all Western blots.  
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6.2.2.2 SDS-PAGE 
For SDS-PAGE, samples were prepared as described in Chapter 2.8.4 and loaded 
into pre-cast gels. This study was conducted blind and the vehicle and glucose 
groups were allocated a code A and B.  Samples were loaded onto the gel by 
alternating between groups.  Each gel included a molecular weight reference 
sample and a naive rat brain to serve as a positive Western blot control for each 
gel. Data from this sample was not used for analysis. 
6.2.2.3 Coomassie blue staining 
The Coomassie blue stain (SimplyBlueTM SafeStain, Invitrogen, UK) was used to 
assess the protein loading between samples, and the profile of each sample used 
to identify any sample degradation (see Chapter 2.8.5 for details of gel 
staining).  Protein loading between groups was comparable at 2 hours (Figure 
6.2: left) but more variable at 24 hours (Figure 6.2: right).  At 2 hours, there did 
not appear to be any evidence of gross protein degradation, which would be 
indicated by the accumulation of low molecular weight proteins. There were 
some changes at 24 hours although a consistent pattern was observed when 
these gels were repeated using fresh aliquots. 
6.2.2.4 Western blots 
Western blots were performed with primary antibodies against mouse anti-
spectrin (MAB1622, Millipore) and rabbit anti-MAP2 (ab32454, Abcam), both at a 
dilution of 1/200,000, as described in Chapter 2.8.6. Following enhanced 
chemiluminescence signal detection the OD of the protein bands on each 
Western blot were measured using ImageJ (Chapter 2.8.7).  An example of the 
calpain proteolysis of spectrin into 150kD and 155kD fragments is illustrated in 
Figure 6.3.  The fragment at 150kD is reported to be specific to cleavage by 
calpain but the fragment at 155kD can be produced by either calpain or caspase-
3 cleavage (Nath et al., 1996).  
All Western blots were re-probed with a β-acting loading control antibody to 
ensure that the lanes on each gel were loaded evenly with sample.   
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Figure 6.2.  Coomassie blue stained gels of proteins from the cytosolic and membrane fractions of brain tissue from the ipsilateral cortex collected 2 hours 
and 24 hours after MCAO.  In each gel 10ug of each sample was loaded per well.  MW = molecular weight marker, C = control sample, A and B are the codes 
given to the different groups for blinding purposes. 
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Figure 6.3. Western blot illustrating calpain-mediated proteolysis of αII-spectrin in 
ischaemic brain tissue collected 24 hours after permanent MCAO.  Calpain cleaves αII-
spectrin (280kD) producing two spectrin breakdown products at 150kD and 155kD. The  
breakdown product at 150kD is exclusively the result of calpain action and the fragment at 
155kD can result from either calpain or caspase-3 cleavage.  In this example bands can also 
be observed at approximately 120-125kD. These may result from caspase-3 mediated 
proteolysis of αII-spectrin which has been shown to produce a fragment at 120kD. 
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Blots were re-probed with the loading control antibody at least 24 hours after 
the ECL detection step of the Western blot protocol to allow sufficient time for 
the ECL signal to decrease.  For the re-probing step, blots were washed 3 times, 
for 5 minutes each, in 1xT-TBS followed by a 30 minute incubation in blocking 
solution (5% milk powder in 1x T-TBS) at room temperature.  Blots were then 
incubated overnight at 4°C in a mouse anti-beta actin primary antibody (ab8224, 
Abcam) diluted 1/400,000 in blocking solution.  The following day blots were 
washed 3 times, for 10 minutes each in 1xT-TBS and then incubated for 1 hour at 
room temperature in a HRP conjugated anti-mouse secondary antibody (Dako, 
UK) diluted 1/10,000 in blocking solution.  Blots were then washed 3 times, for 
10 minutes each, in 1x T-TBS followed by ECL signal detection and quantification 
as described in Chapter 2.8.7.  Relative protein levels of αII-spectrin and MAP2 
were calculated by dividing the OD values of the αII-spectrin and MAP2 bands by 
the OD values of the β-actin band. 
The Western blots for MAP2 were performed by BMedSci student Michael Burns (2 
hour MCAO tissue) and MRes student Evelina Avizaite (24 hour MCAO tissue) 
under my supervision. 
6.2.3 Statistical Analysis 
Blood glucose level data in the 2 hour MCAO rats were analysed using a 2-way 
ANOVA with Bonferroni’s multiple comparisons post-hoc test.  Physiological 
variables, scatterplots of relative αII-spectrin and MAP2 protein level data and 
scatterplots of β-actin band OD data were analysed using an unpaired Student’s 
t-test. 
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6.3 Results 
6.3.1 Blood glucose & physiological data for rats exposed to 2 hour 
MCAO 
Blood glucose levels measured 20 minutes pre-MCAO (baseline) were comparable 
between vehicle and glucose treated rats, with mean values of 8.2±1.4mmol/L 
and 7.8±1.4mmol/L, respectively (Figure 6.4).  Following a single IP injection of 
a vehicle (distilled water) or 15% glucose solution, 10 minutes before MCAO, 
blood glucose levels at the onset of MCAO and at subsequent time points after 
MCAO remained close to baseline blood glucose levels in vehicle treated rats.  In 
rats that received glucose treatment blood glucose levels increased, with mean 
blood glucose levels of 18.5±3.1mmol/L at the onset of MCAO and 
14.4±2.1mmol/L at 2 hours post-MCAO.  
Physiological variables of the 2 hour MCAO rats are presented in Table 6.1.  Body 
weight was measured on the day of MCAO surgery before the induction of 
anaesthesia.  All other physiological variables were monitored throughout the 
surgical period.  The mean values measured at 2 hours post-MCAO for each group 
are presented in Table 6.1. The differences between groups were not 
statistically significant for any physiological variable measured.     
Group Weight                 
(g)                                                       
MABP 
(mmHg)        
PaCO2 
(mmHg)
PaO2  
(mmHg) 
pH 
 
Temperature 
(°C) 
Vehicle 
(n=7) 
370 ± 30 92 ± 7 46 ± 5 107 ± 12 7.349 ± 0.04 37 ± 0.2 
Glucose 
(n=7) 
367 ± 36 87 ± 7 42 ± 9 126 ± 25 7.395 ± 0.05 37 ± 0.3 
Table 6.1.  Table of physiological variables for 2 hour MCAO animals.  Body weight was 
measured prior to MCAO.  The MABP, temperature, pH, PaO2 and PaCO2 data presented are 
the mean ± standard deviation values measured at 2 hours post-MCAO.  There were no 
significant differences in any of the variables between the two groups (unpaired Student’s t-
test). 
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Figure 6.4. Blood glucose values of 2 hour MCAO rats.  Blood glucose levels were measured 
20 minutes before permanent MCAO in all rats to obtain a baseline value and at subsequent 
time points after MCAO in vehicle (n=7) and glucose (n=7) treated rats.  The red arrow 
indicates the time of vehicle or glucose administration. Data are presented as mean ± 
standard deviation.  *, P<0.0001 compared to vehicle group using 2-way ANOVA with 
Bonferroni’s multiple comparisons post-hoc test. 
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6.3.2 Western blot results 
Following western blot analysis the groups were de-coded. In Western blots from 
the 2 hour MCAO tissue samples V1-7 and G1-7 represent vehicle and glucose 
treated animals respectively.  Similarly, in Western blots from the 24 hour tissue 
samples V1-10 and G1-10 represent vehicle and glucose treated animals 
respectively. 
6.3.2.1 - 2 hour MCAO  
Cytosolic fraction - αII-spectrin  
Calpain cleaves αII-spectrin (280kD) producing two spectrin breakdown products 
(SBDPs) at approximately 150kD and 145kD.  A band representing intact full-
length spectrin was observed at approximately 280kD in all samples (Figure 
6.5A). There were no differences in the relative protein levels of this band 
between vehicle and glucose treatment groups (P =0.4, Figure 6.7A).  A doublet 
band was observed at 150-155kD in most samples (except one – G1, with a single 
band at 155kD) representing SBDPs (Figure 6.5B). After re-probing the blot with 
the loading control antibody against β-actin a band was observed at 42kD in all 
samples (Figure 6.5C).  To estimate the amount of β-actin in each sample the OD 
of the β-actin band for each animal was measured and the values for each group 
are presented as a scatterplot.  There were no significant differences between 
groups (P=0.4), indicating that there were no sample loading differences (Figure 
6.5C).  To determine if there was a difference in calpain-mediated proteolysis of 
αII-spectrin between vehicle and glucose treatment groups the OD value of the 
SBDP doublet band (150-155kD) was expressed as a ratio of the β-actin band to 
give relative SBDP protein levels (Figure 6.5D).  The difference in relative SBDP 
protein levels between vehicle and glucose treatment groups was not 
statistically significant (P= 0.09), indicating that there was no difference in the 
proteolytic activity of calpain at 2 hours post-MCAO in the cytosolic fraction.  In 
addition to measuring the amount of SBDPs, the ratio of the intact αII-spectrin to 
the specific spectrin breakdown products has been shown to be a reliable 
indicator of calpain proteolytic activity (Sebe et al., 2013, Schoch et al., 2012). 
However in this analysis there was no significant difference in the ratio of intact 
αII-spectrin to SBDPs between vehicle and glucose treatment groups (P=0.3).  
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Membrane fraction - αII-spectrin  
The Western blot from the membrane fraction of the 2 hour MCAO tissue was 
similar to that of the cytosolic fraction.  Bands representing intact spectrin and 
SBDPs were observed at 280kD and 150-155kD respectively (Figure 6.6A).  In 
comparison to the cytosolic fraction, a doublet band representing SBDPs was not 
observed in all fractions, with only a single band at 155kD in most samples 
(Figure 6.6A).  After reprobing the blot with the loading control antibody, bands 
representing β-actin were observed at 42kD (Figure 6.6B).  In a pattern similar 
to the cytosolic fraction analysis, there was no difference in β-actin (Figure 
6.6B), relative SBDP (Figure 6.6C) and αII-spectrin (Figure 6.7B) protein levels 
between vehicle and glucose treatment groups (P=0.3, P=1.0 and P = 0.7 
respectively).  There was also no significant difference in the ratio of intact 
spectrin to SBDPs between groups (P=0.9), indicating that there was no 
difference in the proteolytic activity of calpain at 2 hours post-MCAO in the 
membrane fraction.  
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Figure 6.5.  αII-spectrin Western blot analysis from cytosolic fraction of 2 hour MCAO tissue.  A. Bands representing intact αII-spectrin were observed at 
280kD. Sample C = control, naive brain tissue sample.  B.  Doublet bands representing SBDPs, resulting from calpain mediated cleavage of intact spectrin, 
were observed at 150-155kD.  The exposure time was increased for SBDP analysis which resulted in saturation of the 280kD bands (highlighted in red).  C.  
After re-probing the blot with a β-actin loading control antibody, a band was observed at 42kD in each sample.  There was no significant difference in OD 
values of the β-actin bands between the vehicle and glucose groups (unpaired Student’s t-test).  D.  The OD value of the SBDP band was expressed as a 
ratio of the β-actin band for each animal to give the relative SBDP protein levels.  There was no significant difference in relative SBDP protein levels 
between the two groups (unpaired Student’s t-test). 
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Figure 6.6.  αII-spectrin Western blot analysis from membrane fraction of 2 hour MCAO 
tissue. A. Bands representing intact αII-spectrin and SBDPs were observed at 280kD and 
150-155kD respectively.  B.  After re-probing the blot with β-actin, a band was observed at 
42kD in each sample. There was no significant difference in OD values of the β-actin bands 
between vehicle (n=7) and glucose (n=7) treated rats (unpaired Student’s t-test).  C. The OD 
value of the SBDP band was expressed as a ratio of the β-actin band for each animal to give 
the relative SBDP protein levels. There was no significant difference in relative SBDP 
protein levels between the two groups (unpaired Student’s t-test). 
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Figure 6.7.  Intact αII-spectrin protein levels. In all αII-spectrin Western blots the OD values 
of the intact αII-spectrin bands (280kD) were expressed as a ratio of the β-actin bands to 
give the relative αII-spectrin protein levels for each animal. There was no significant 
difference in relative αII-spectrin protein levels between vehicle and glucose treated rats in 
either the cytosolic or membrane fractions in ischaemic cortex tissue collected at both 2 
and 24 hours after MCAO (unpaired Student’s t-test). 
  
Intact αII-spectrin (280kD band) protein levels 
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Cytosolic fraction – MAP2  
There are four isoforms of MAP2 in the mammalian brain:  two high molecular 
weight (HMW) isoforms: MAP2A (280kD) and MAP2B (270kD) that are specifically 
expressed in neurons (dendrites) and two low molecular weight isoforms: MAP2C 
(70kD) and MAP2D (75kD) that are present in glial cells (Dehmelt and Halpain, 
2005).  In all of the 2 hour MCAO cytosolic samples a band was observed at 270-
280kD representing HMW MAP2 expression (Figure 6.8A).  In the control sample 
(C) it was assumed that there would be limited MAP2 degradation since this 
sample was prepared rapidly following brain extraction with a cocktail of 
protease inhibitors present. Therefore as the intensity of the MCAO samples is 
similar to that of the control it appears that there was minimal MAP2 
degradation at 2 hours post-MCAO across the samples.  The intensity of the β-
actin band was also comparable between samples and there was no significant 
difference in β-actin expression levels between groups (P=0.7, Figure 6.8B).  To 
account for sample loading errors the OD value of the HMW MAP2 band was 
expressed as a ratio of the β-actin band to give the relative MAP2 protein levels 
(Figure 6.8C).  There were no significant differences in relative MAP2 protein 
levels between vehicle and glucose treated rats (P=0.8).    
Membrane fraction – MAP2  
The expression of MAP2 in the membrane fraction of the 2 hour MCAO tissue was 
similar to that of the cytosolic fraction.  A band representing HWM MAP2 was 
observed at 270-280kD (Figure 6.9A) in all samples. MAP2 (and spectrin) is 
subject to calpain-mediated proteolysis under physiological conditions (Chan and 
Mattson, 1999b, Fischer et al., 1991) however, under ischaemic conditions the 
level of proteolysis of MAP2 is considered to be extreme.  The level of calpain-
mediated proteolysis of MAP2 in the 2 hour tissue samples appeared to be 
minimal since the band intensities of the ischaemic tissue samples were similar 
to that of the control sample, in which it was assumed that the level of 
proteolysis would be at a physiological level.  When comparing vehicle and 
glucose treated animals there was no significant difference in the relative MAP2 
protein levels between groups (P=0.4, Figure 6.9C). There were some notable 
differences in β-actin protein levels within a couple of the samples (Figure 
6.9B), suggesting some potential sample loading errors.  The most obvious 
difference was observed in sample V4, in which the intensity of the β-actin band 
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at 42kD was less than the others. It is this sample which is responsible for the 
outlier in the vehicle group of the scatterplots in Figures 6.9B&C.  When this 
sample was included in the MAP2 analysis there were no significant differences 
in MAP2 protein levels between the vehicle or glucose treatment groups (P=0.4, 
Figure 6.9C). Similarly, when omitted from analysis there was still no significant 
change (P=0.07).  
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Figure 6.8.  MAP2 Western blot analysis from the cytosolic fraction of the 2 hour MCAO 
tissue. A.  Bands representing HMW MAP2 protein were observed at approximately 270-
280kD.  Sample C = control sample from a naive rat brain.  B.  The expression levels of β-
actin were comparable between samples and there was no significant difference between 
vehicle and glucose treated rats (unpaired Student’s t-test).  C. The relative MAP2 protein 
level for each rat was calculated by dividing the OD value of the HMW MAP2 band by that of 
the β-actin band.  There was no significant difference in relative MAP2 protein levels 
between vehicle and glucose treated rats (unpaired Student’s t-test). 
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Figure 6.9.  MAP2 Western blot analysis from the membrane fraction of the 2 hour MCAO 
tissue. A. Bands were observed at approximately 270-280kD representing HMW MAP2. 
Sample C = control, naive brain tissue sample. B.  The expression levels of β-actin were 
comparable between samples and there was no significant difference between vehicle and 
glucose treated rats (unpaired Student’s t-test).  C.  The relative MAP2 protein level for each 
rat was calculated by dividing the OD value of the MAP2 band by that of the β-actin band.  
There was no significant difference in relative MAP2 protein levels between vehicle and 
glucose treated rats (unpaired Student’s t-test). 
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6.3.2.2 - 24 hour MCAO tissue 
Cytosolic fraction - αII-spectrin  
In all of the 24 hour MCAO tissue samples from the cytosolic fraction a doublet 
band was observed at 280kD (Figure 6.10A).  This doublet band may have formed 
from the intact α (280kD) and β (247-460kD) spectrin subunits but was taken to 
represent intact αII-spectrin. A doublet band was also observed at 150-155kD in 
all samples representing calpain mediated SBDPs.  In the control, naive tissue 
sample the intensity of the doublet band at 280kD was greater than the 
150/155kD doublet band indicating only a small (physiological) amount of calpain 
proteolysis.  Among the ischaemic tissue samples most displayed a similar band 
intensity pattern to the control sample however, in some of the samples from 
glucose treated rats (G1 and G4) the intensity of the band at 280kD was less than 
the band at 150-155kD, indicating a greater extent of spectrin breakdown in 
these samples.  Although the intensity of the 280kD was less in these samples 
there was no statistical difference in the intensity of the intact αII-spectrin band 
between groups (Figure 6.7C).   
There was no difference in β-actin expression between vehicle and glucose 
treated rats (P=0.5, Figure 6.10B).  To determine if the amount of SBDPs 
differed between vehicle and glucose treated rats the OD values of the SBDP 
bands were expressed as a ratio of the β-actin loading control band (Figure 
6.10C).  There tended to be more SBDPs in glucose treated rats compared to 
vehicle treated rats but the difference between groups was not statistically 
significant (P=0.08).  However, there was a significant difference in the ratio of 
intact αII-spectrin to SBDPs between vehicle and glucose treatment groups, with 
values of 1.3±0.5 and 0.9±0.3 respectively (P=0.03).  In the glucose treatment 
group the ratio of intact, full length αII-spectrin to the amount of SBDPs was less 
than the vehicle group suggesting that there was more SBDPs and more calpain 
proteolysis in the glucose treatment group.  
Membrane fraction - αII-spectrin  
The Western blot from the membrane fraction produced similar results to the 
blot from the cytosolic samples (Figure 6.11A).  A doublet band representing 
intact spectrin was observed at 280kD.  This band was present in all samples 
from the vehicle treatment group but was not observed in two rats from the 
207 
 
  
glucose treatment group (G1 and G4).  Despite this, there was no difference in 
the relative expression of the 280kD αII-spectrin band between groups (Figure 
6.7D). A doublet band representing calpain mediated SBDPs was observed at 150-
155kD in all rats.  In the two glucose treated rats, in which a band at 280kD was 
not observed (G1 and G4), an intense band at 150kD was observed suggesting a 
greater extent of calpain-mediated spectrin breakdown in these samples.   
Despite the observed differences in the intensity of the 280kD and 150-155kD 
band intensities between samples, there was no difference in the amount of β-
actin between groups ((P=0.7), Figure 6.11B). When the OD values of the SBDP 
bands were expressed as a ratio of the β-actin bands, to account for sample 
loading differences, the protein levels of SBDPs were significantly greater in 
glucose compared to vehicle treated rats (P=0.03, Figure 6.11C), suggesting that 
glucose treatment increased calpain-mediated αII-spectrin breakdown in the 
membrane fraction.  In addition, the amount of calpain proteolysis was 
significantly greater in the glucose treatment group as measured by the ratio of 
intact αII-spectrin to SBDPs, with mean values of 1.6±0.9 and 0.9±0.5 in vehicle 
and glucose treatment groups respectively (P=0.03). 
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Figure 6.10. αII-spectrin Western blot analysis from the cytosolic fraction of ipsilateral 
cortex tissue acquired 24 hours after permanent MCAO. Bands representing intact αII-
spectrin and SBDPs were observed at 280kD and 150/155kD respectively. Sample C = 
control, naive brain tissue sample.  B.  After re-probing the blot with a β-actin, a band was 
observed at 42kD in each sample.  There was no significant difference in OD values of the β-
actin bands between vehicle and glucose treated rats (unpaired Student’s t-test). C. The OD 
value of the SBDP band was expressed as a ratio of the β-actin band for each animal to give 
the relative SBDP protein levels. There was no significant difference in relative SBDP 
protein levels between the two groups (unpaired Student’s t-test). 
209 
 
  
 
Figure 6.11. αII-spectrin Western blot analysis from the membrane fraction of ipsilateral 
cortex tissue acquired 24 hours after permanent MCAO. A. Bands representing intact αII-
spectrin and SBDPs were observed at 280kD and 150-155kD respectively. Sample C = 
control, naive brain tissue sample. B. There was no significant difference in OD values of 
the β-actin bands between vehicle and glucose treated rats (unpaired student’s t-test).  C. 
The OD value of the SBDP band was expressed as a ratio of the β-actin band for each 
animal to give the relative SBDP protein levels.  *, P<0.05 compared to vehicle group using 
an unpaired Student’s t-test.  
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Cytosolic fraction – MAP2  
In the 24 hour MCAO samples from the cytosolic fraction a HMW MAP2 band was 
observed at approximately 270-280kD in a few samples (Figure 6.12A).  However, 
in the majority of samples this band was absent, indicating MAP2 degradation, 
and this is highlighted in the scatterplot (Figure 6.12C) as the relative MAP2 
protein levels are zero in almost half of the rats from each group.  The 
difference in relative MAP2 protein levels between groups was not statistically 
significant (P=0.7).  In most samples within the cytosolic fraction a band was 
observed at approximately 150kD (Figure 6.12A), the identity of which is not 
known. There was no difference in β-actin expression levels between vehicle and 
glucose treatment groups (P=0.4, Figure 6.12B) indicating that there was no 
sample loading differences in this Western blot.   
Membrane fraction – MAP2  
In samples from the membrane fraction of 24 hour MCAO tissue a band 
representing HMW MAP2 was observed at approximately 270-280kD in most 
samples (Figure 6.13A).  The intensity of the HMW MAP2 band varied among 
samples indicating differing amounts of MAP2 degradation.  The intensity was 
greatest in the control sample (C) where MAP2 proteolysis was expected to be 
minimal.  There was no difference in β-actin expression (P=0.9, Figure 6.13B) or 
relative MAP2 protein levels (P=0.05, Figure 6.13C) between glucose and vehicle 
treatment groups although relative MAP2 protein levels in glucose treated rats 
tended to be lower than vehicle treated rats.  
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Figure 6.12. MAP2 Western blot analysis from the cytosolic fraction of ipsilateral cortex 
brain tissue samples collected 24 hours after permanent MCAO.  A.  Bands were observed 
at approximately 270-280kD representing HMW MAP2.  The identity of the band observed at 
approximately 150kD in not known. Sample C = control, naive brain tissue sample.  B.  The 
expression levels of β-actin were comparable between samples and there was no significant 
difference between vehicle and glucose treated rats (unpaired student’s t-test). C. The 
relative MAP2 protein level for each rat was calculated by dividing the OD value of the MAP2 
band by that of the β-actin band.  There was no significant difference in relative MAP2 
protein levels between vehicle and glucose treated rats (unpaired Student’s t-test). 
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Figure 6.13.  MAP2 Western blot analysis from the membrane fraction of ipsilateral cortex 
brain tissue samples collected 24 hours after permanent MCAO.  A.  Bands were observed 
at approximately 270-280kD representing HMW MAP2. Sample C = control, naive brain 
tissue sample.  B.  The expression levels of β-actin were comparable between samples and 
there was no significant difference between vehicle and glucose treated rats (unpaired 
student’s t-test).  C.  The relative MAP2 protein level for each rat was calculated by dividing 
the OD value of the MAP2 band by that of the β-actin band.  There was no significant 
difference in relative MAP2 protein levels between vehicle and glucose treated rats 
(unpaired Student’s t-test). 
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6.4 Discussion 
To obtain insight into the possible damaging effects of hyperglycaemia within 
the brain tissue the degradation of αII-spectrin and MAP2, known markers of 
calpain-mediated brain injury, were analysed in ipsilateral cortex tissue from 
vehicle and glucose treated rats using Western blotting.  It was hypothesised 
that there would be greater tissue injury in glucose compared to vehicle treated 
animals, manifested as greater amounts of SBDPs and MAP2 degradation in brain 
tissue samples from the glucose treatment group.   
In the tissue collected 2 hours after MCAO there was no difference in the levels 
of SBDPs or MAP2 degradation, between vehicle or glucose treatment groups 
suggesting that glucose treatment did not influence the proteolytic activity of 
calpain at this time.  In each Western blot a sample from a naive rat brain was 
included as a positive control for each antibody.  Both αII-spectrin and MAP2 
have been shown to be expressed in normal rat brain tissue lysates (Nakajima et 
al., 2011, Pettigrew et al., 1996) and as such this was accepted as an 
appropriate control.  It was assumed that there would be minimal (physiological) 
calpain proteolysis in the control sample and therefore the levels of intact αII-
spectrin and MAP2 would be higher in the control compared to ischaemic tissue 
samples.  Although no formal comparison between the OD values of the control 
and MCAO samples could be made, visually there were no obvious differences in 
the levels of αII-spectrin, SBDPs and MAP2 protein between control and MCAO 
samples, which suggests that at 2 hours after MCAO the levels of calpain 
proteolysis were similar to physiological levels. The fact that only a single 
breakdown product at 155kD was observed in most of the MCAO samples on the 
αII-spectrin blots at 2 hours also suggests that there was minimal evidence of 
calpain mediated proteolysis at this time.  This is because the 155kD fragment 
has been reported to be produced when αII-spectrin is cleaved by calpain and 
caspase-3 (Nath et al., 1996).  However, the fragment at 150kD is reported to be 
specific to cleavage by calpain and this is absent in some samples, most notably 
within samples from membrane fraction. Conversely, the calpain specific 
breakdown product at 150kD is present within all the samples at 24 hours (and to 
a greater extent than the 155kD product) and thus there was clear evidence of 
calpain’s proteolytic activity in the 24 hour MCAO tissue.  Compared to the 
expression of αII-spectrin and MAP2 in the control brain sample, αII-spectrin 
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break down products and MAP2 degradation were clearly visible on Western blots 
from the 24 hour MCAO tissue.  There was evidence of a significant effect of 
glucose treatment on the proteolytic activity of calpain on αII-spectrin in the 
membrane fraction of the 24 hour MCAO tissue as the relative levels of SBDPs 
were significantly greater in rats that received glucose treatment compared to 
those that received vehicle treatment.  In addition, the ratio of intact spectrin 
to SBDPs, another method of assessing the proteolytic activity of calpain, was 
lower in the glucose- compared to vehicle treatment group in both the 
membrane and cytosolic fractions at 24 hours which suggests that there was an 
increase in calpain proteolysis in the glucose treatment group.  Taken together 
the results from the present study demonstrate an association between glucose 
treatment and an increase in protein markers of neuronal injury in the 24 hour 
infarcted tissue but not the acute 2 hour ischaemic tissue.  The failure to detect 
an association at 2 hours after MCAO may reflect the limitations of adopting a 
biochemical approach (see below), but may also result from the potential for 
hyperglycaemia to influence multiple pathophysiological mechanisms 
simultaneously that combine to exacerbate ischaemic damage. 
6.4.1 Study limitations 
There are a number of limitations in the present study which could have 
impacted on the results.  Firstly, assessment of the protein levels of SBDPs and 
MAP2 in the same animal at two time different time points is not possible and 
therefore direct comparisons between the 2 hour and 24 hour time points could 
not be made.   Observationally, the results showed evidence of calpain-mediated 
proteolysis of αII-spectrin and MAP2 at 24 hours but not at 2 hours.  This is in 
agreement with results from Western blotting experiments reported by 
Pettigrew et al (1996), who investigated the time-course of αII-spectrin and 
MAP2 following permanent MCAO in the rat.  They showed that after 1 hour of 
permanent MCAO the expression of αII-spectrin and MAP2 in ischaemic brain 
tissue was similar to that in the unaffected hemisphere, with pronounced 
changes in the expression of both proteins observed after 6 and 24 hours 
permanent MCAO (Pettigrew et al., 1996).  Therefore, it might not be possible to 
detect the degradation of αII-spectrin and MAP2 2 hours after MCAO using 
Western blotting. Further experiments are needed to determine if the 
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detrimental effects of hyperglycaemia during the initial hours of ischaemia take 
place predominantly within the brain tissue. 
Secondly, when investigating the time-related neuronal changes in SBDPs after 
permanent MCAO,  Bartus and colleagues dissected out 1-mm blocks of tissue 
from the ipsilateral striatum and cortex for Western blot analysis (Bartus et al., 
1995).  In contrast, the entire ipsilateral cortex was dissected for Western blot 
analysis in the present study.  By doing so it is possible that any significant 
changes that occurred in the ischaemic tissue have been diluted.  Future studies 
might benefit from dissecting out smaller regions of the cortex associated with 
ischaemic damage for analysis. Although it could be argued that if 
hyperglycaemia does indeed have a profound effect it might have been possible 
to detect it in the large (diluted) samples.  
Another limitation of the present study was that direct comparisons between 
different Western blots could not be made.  This is because the measured OD 
value for each protein band on a blot is an arbitrary unit which only has meaning 
within the context of the OD values of other bands within that blot.  This 
therefore impacts on the amount of samples that can be analysed together and 
subsequently the questions that can be asked.   For example, whether glucose 
treatment increases the proteolytic activity of calpain in the ipsilateral cortex, 
relative to that in the contralateral cortex, compared to vehicle treatment was 
not investigated.  The expression of αII-spectrin and MAP2 in the contralateral 
cortex was not examined at any stage in the present study.  The important 
question that this study set out to answer was whether there was a difference 
between vehicle or glucose treatment on ischaemic tissue injury and due to the 
limited number of samples that could be loaded on a single gel it was important 
to select the brain region where ischaemic injury would take place.  
6.4.2 Summary 
By measuring the proteolytic activity of calpain on two of its substrates in 
ischaemic brain tissue the aim was to gain an indirect measurement of 
hyperglycaemia on glutamate excitotoxicity. This is because in vivo microdialysis 
studies have shown that hyperglycaemia increases extracellular glutamate levels 
during ischaemia (Li et al., 2000c, Wei and Quast, 1998, Choi et al., 2010), and 
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there is evidence that stimulation of glutamate receptors in vitro leads to 
calpain activation and subsequent substrate proteolysis (Siman et al., 1989).  
The Western blot results reported in the present study suggest there might be an 
association between the harmful outcomes of acute hyperglycaemia and 
enhanced calpain proteolysis 24 hours after permanent MCAO.  However, there 
was no association at 2 hours after MCAO.  This was identified as the earliest 
time point where glucose treatment significantly increased acute lesion volume 
in the previous study.  It was important to include this earlier time point as 
hyperglycaemia has been shown to accelerate acute ischaemic damage and 
therefore establishing the acute pathological mechanisms of hyperglycaemia 
induced damage are essential in terms of therapeutic intervention.   
It is therefore still not clear why hyperglycaemia is harmful during ischaemia. 
The most likely explanation is that a moderate glucose insult affects many 
different pathological mechanisms simultaneously, that cumulatively exacerbate 
ischaemic damage.  Of these many mechanisms, the anaerobic metabolism of 
glucose through the lactic acid cycle was the first and is the most persistent 
hypothesis used to explain the relationship between hyperglycaemia and worse 
clinical outcomes from ischaemic stroke.  In the absence of oxygen glucose is 
metabolised anaerobically producing lactate as a by-product.  Elevated lactate 
levels can acidify cells and the surrounding environment leading to tissue 
acidosis. This is potentially damaging and can lead to the production of free 
radicals and mitochondrial dysfunction (Anderson et al., 1999, Rehncrona et al., 
1989), both of which would be detrimental during ischaemia.  Both clinical and 
experimental studies have revealed an association between hyperglycaemia and 
increased brain lactate levels.  Furthermore elevated lactic acid concentrations 
have been shown to correlate with worse outcomes (Parsons et al., 2000, 
Anderson et al., 1999, LaManna et al., 1992). Although there appears to be 
strong evidence indicating increased lactate as an important mediator of 
hyperglycaemia induced brain damage, the fact that lactate metabolism is 
important for ATP production during ischaemia (Pellerin and Magistretti, 1994) 
and that inhibiting lactate production during ischaemia exacerbates, rather than 
reduces, ischaemic damage (Cassady et al., 2001) suggests that it is not the only 
contributor.  Nevertheless it would have been interesting to compare the lactate 
levels in glucose and vehicle treated rats in this thesis.  Magnetic resonance 
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spectroscopy can be used to assess brain lactate levels during ischaemia and 
lactate measurements were considered as part of the previous MRI study.  
Unfortunately this could not be achieved due to MR signal inference from the 
craniectomy required for occlusion of the distal portion of the MCA by 
diathermy.  Future studies could consider investigating the effect of glucose or 
vehicle treatment on brain lactate levels using a subset of animals in which the 
MCA is occluded by an alternative method that does not require a craniectomy. 
  
218 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7 – General Discussion 
  
  
219 
 
  
7. General Discussion 
Hyperglycaemia at the onset of ischaemic stroke is strongly associated with 
worse clinical outcomes (Baird et al., 2003, Capes et al., 2001, Bruno et al., 
1999, Candelise et al., 1985). Despite this, the pathophysiological mechanisms 
underlying this association are poorly understood.  An increase in the severity of 
the blood flow deficit following ischaemic stroke has been implicated in 
hyperglycaemia-induced brain damage (Duckrow, 1995, Kawai et al., 1998, Wang 
et al., 2008). However, the studies in this thesis demonstrate that an increase in 
the severity of ischaemia is not the primary mechanism by which hyperglycaemia 
exacerbates ischaemic damage following permanent MCAO. This suggests that 
the detrimental effects of hyperglycaemia are not predominantly mediated in 
the cerebrovasculature. Alternatively, the damaging effects of hyperglycaemia 
may occur within the brain parenchyma. However, additional studies are 
required to confirm this.  
The studies reported in this thesis represent one of the few to examine 
hyperglycaemia at levels typically encountered in acute ischaemic stroke, 
demonstrating that hyperglycaemia exacerbates acute lesion volume and infarct 
volume in a normotensive rat strain.  Furthermore, the damaging effects of 
hyperglycaemia were found to occur early after the onset of cerebral ischaemia, 
suggesting that hyperglycaemia accelerates the evolution of ischaemic damage.  
The findings from this thesis will now be put into clinical context to discuss the 
pathophysiological mechanisms that relate hyperglycaemia to poor clinical 
outcomes.   Some of the future strategies for pre-clinical stroke research along 
with the current practices for managing hyperglycaemia in acute ischaemic 
stroke patients will also be discussed.  Firstly some of the limitations of this 
research will be considered. 
7.1.1 Study limitations 
One of the primary aims of this thesis was to establish a clinically relevant 
animal model for studying the effects of hyperglycaemia during experimental 
ischaemic stroke. To induce hyperglycaemia a single IP injection of a 15% 
glucose solution was administered 10 minutes prior to permanent MCAO.  A 
limitation of this approach is that it does not model all of the features of human 
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PSH. The clinical presentation of PSH is far more complex in terms of the 
etiology of hyperglycaemia and the temporal profile of hyperglycaemia seen in 
acute ischaemic stroke patients. However in terms of the preclinical picture of 
PSH, the studies reported in this thesis are novel as they are one of the very few 
to report that hyperglycaemia, at levels comparable to those in patients 
presenting with PSH, increases acute ischaemic damage and infarct size in a 
rodent model of ischaemic stroke. The results from previous preclinical stroke 
studies investigating the effects of hyperglycaemia on infarct size have been 
inconsistent and the glucose levels induced in hyperglycaemic animals greatly 
exceed those seen clinically.  The animal model described in this thesis is 
therefore an important addition to the preclinical literature and could be used in 
the future to study the effects of glucose lowering therapies 
The necessary use of anaesthetics in animal models may also be a limiting factor 
in this research because anaesthetic agents have the potential to induce 
hyperglycaemia. Saha et al (2005) demonstrated that anaesthetics such as 
isoflurane and ketamine/xylazine (KX) induced acute hyperglycaemia in fed rats.  
In contrast, neither agents were found to induce hyperglycaemia in rats that had 
been fasted for 18 hours. The authors investigated the mechanism of KX induced 
hyperglycaemia in fed rats and showed that the effect was mediated through the 
modulation of glucoregulatory hormones (insulin, growth hormone and 
corticosterone) via stimulation of α2-adrenergic receptors (Saha et al., 2005). To 
reduce any influence of isoflurane anaesthesia on blood glucose levels all of the 
animals reported in this thesis were fasted for 18 hours prior to the induction of 
anaesthesia.  However isoflurane may have had some influence on blood glucose 
levels in glucose treated rats.  For instance in experiments where rats were 
maintained under anaesthesia for 4 hours, blood glucose levels in glucose 
treated rats increased and remained elevated for 4 hours. This is a longer time 
than predicted for an acute glucose insult and therefore it seems that 
isoflurane, like KX-induced anaesthesia, may influence the glucoregulatory 
hormones that would normally act to normalise blood glucose levels.  However 
this does not present a disadvantage to the model as blood glucose levels in 
patients with admission hyperglycaemia can remain elevated for several hours 
after symptom onset (Yong and Kaste, 2008).   
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The use of distilled water as a vehicle solution in this thesis also presents a 
potential limitation. IP injections of water can alter the concentration of 
electrolytes in the intraperitoneum which can potentially be cytotoxic leading to 
tissue fibrosis (Levine and Saltzman, 2001).  Although the volume administered 
in a single injection was unlikely to have a significant effect on fluid balance it 
would be preferable to use isotonic saline as the vehicle in future studies. 
7.1.2 Pathophysiology of PSH 
Hyperglycaemia-associated reduction in cerebral blood flow 
Evidence from clinical studies suggests that hyperglycaemia during ischaemic 
stroke is particularly detrimental in patients without a history of diabetes (Capes 
et al., 2001, Shimoyama et al., 2014).  Recent in-house studies support this as 
hyperglycaemia increased infarct volume in rats without features of the 
metabolic syndrome such as hypertension and insulin resistance (Tarr, 2012, Tarr 
et al., 2013).  In light of these findings a standard normotensive rat strain was 
selected for studying the mechanisms by which hyperglycaemia exacerbates 
ischaemic damage.  It was essential to establish from the outset whether 
clinically relevant hyperglycaemia induces a reduction in cerebral perfusion.  
This is because any further reduction in CBF during MCAO could increase the 
volume of hypoperfused tissue leading to larger infarcts and greater penumbral 
loss.  The blood flow data generated from the autoradiography study in Chapter 
4 and the MRI study in Chapter 5 demonstrate that hyperglycaemia does not 
exacerbate ischaemic damage by increasing the perfusion deficit.  It should be 
mentioned here that if hyperglycaemia increased the perfusion deficit it would 
have been important to determine the effects of glucose treatment on plasma 
osmolality.  This is because the treatment groups in this thesis did not control 
for differences in osmotic load between vehicle and glucose treated rats and 
studies have shown that an increase in plasma osmolality can reduce regional 
CBF (Duckrow, 1995, Duckrow et al., 1985). Therefore if hyperglycaemia 
increased the perfusion deficit it would have been difficult to exclude the 
influence of an osmotic mechanism.   
Clinically, few studies have investigated the influence of admission 
hyperglycaemia on the severity of the perfusion deficit after ischaemic stroke.  
In one recent study, Luitse et al (2013) reported that patients with admission 
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hyperglycaemia did not have larger perfusion deficits compared to 
normoglycaemic patients during the acute stage of ischaemic stroke.  These 
results are in agreement with the findings from this thesis and suggest that the 
detrimental effects of hyperglycaemia in ischaemic stroke are not associated 
with larger perfusion deficits.  However, they found that patients with admission 
hyperglycaemia had worse functional outcomes (Luitse et al., 2013), an outcome 
measure that was not examined in this thesis. The association between 
hyperglycaemia and poor functional outcomes observed in their study might be 
explained by the fact that ~50% of patients in each group were treated with 
intravenous thrombolysis and there is an increased risk of intracerebral 
haemorrhage with thrombolysis treatment in patients with PSH (Bruno et al., 
2002, Bruno et al., 1999).  From personal correspondence with the authors of 
this study I learned that they found no difference in the size of the perfusion 
deficit between normo- and hyperglycaemic patients that were not treated with 
thrombolysis, although it was noted that the group sizes were relatively small.  
This was of interest because the animal model established in this thesis is most 
relevant to that particular subset of patients. Whether hyperglycaemia 
exacerbates the perfusion deficit in ischaemic stroke patients needs to be 
examined in a larger patient cohort and Luitse and colleagues recognise this as 
they are planning to perform a larger, prospective study examining perfusion 
deficits in patients with and without admission hyperglycaemia.  
If hyperglycaemic patients do have larger perfusion deficits this could lead to 
larger infarcts and reduced penumbral salvage.  To date, only a few clinical 
studies have investigated the effects of hyperglycaemia on the penumbral tissue 
(Parsons et al 2002, Rosso et al 2011).  These studies demonstrated that the 
volume of tissue-at-risk that progressed to infarction was larger in 
hyperglycaemic compared to normoglycaemic patients groups and suggests that 
the ischaemic penumbra is particularly vulnerable during hyperglycaemic 
ischaemia.  In contrast, the data presented in Chapter 5 demonstrate that 
hyperglycaemia does not influence the volume of the perfusion-diffusion 
mismatch-defined ischaemic penumbra.  Therefore, the observed increase in 
acute lesion volume in hyperglycaemic rats did not correspond with a smaller 
volume of mismatch tissue in the acute phase after MCAO.  This could have 
important clinical implications because the ischaemic penumbra is the target of 
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most therapeutic interventions. Therefore, if there are equal amounts of 
penumbral tissue in normoglycaemic and hyperglycaemic patients there might be 
a window of opportunity for therapeutic intervention in patients with PSH. In 
addition, calculation of the ADC-defined penumbra in Chapter 5 demonstrated 
that hyperglycaemic rats may have a greater amount of penumbra following the 
onset of ischaemia in comparison to normoglycaemic rats, suggesting that there 
may be a window of opportunity for therapeutic intervention in hyperglycaemic 
ischaemia. Further pre-clinical studies are needed to clarify the effects of 
hyperglycaemia on the tissue within the ischaemic penumbra.  Together, with 
the results from this thesis, these studies would help to inform the design of 
future clinical trials investigating the treatment of PSH. 
Other mechanisms of hyperglycaemia-mediated brain injury 
There are many different ways in which hyperglycaemia could be harmful during 
ischaemia.  Some of the possible mechanisms proposed from animal studies 
include: changes in cerebral metabolism (Folbergrova et al., 1992), increased 
local oedema (Berger and Hakim, 1986), an increase in NMDA receptor mediated 
calcium entry into neurons (Li et al., 2000b) and an increase in glucose mediated 
oxidative stress and inflammation (Mohanty et al., 2000, Dhindsa et al., 2004).  
Although the findings from this thesis do not implicate a definitive mechanism, it 
is clear from the MRI data presented in Chapter 5 that the harmful effects of 
hyperglycaemia occurred during the acute 1-2 hours after the onset of cerebral 
ischaemia. During this acute time period glutamate-mediated neuronal 
excitotoxicity contributes to ischaemic brain damage (Brouns and De Deyn, 
2009). Therefore it is possible that hyperglycaemia could exacerbate ischaemic 
damage by increasing glutamate-mediated excitotoxicity. The study presented in 
Chapter 6 aimed to measure this mechanism indirectly by estimating the protein 
levels of αII-spectrin and MAP2.  These proteins are well-defined markers of 
neuronal brain injury and are also substrates for calpain, the activity of which 
has been reported to increase in vivo during experimental ischaemic stroke 
(Neumar et al., 2001, Pettigrew et al., 1996, Bartus et al., 1995) and in vitro 
following glutamate receptor stimulation (Seubert et al., 1988). The data in 
Chapter 6 suggested that hyperglycaemia might increase the amount of calpain 
proteolysis. Future studies in our laboratory will continue to determine if 
hyperglycaemia exacerbates excitotoxic ischaemic damage by examining 
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whether neuronal death, induced by intracerebral injection of NMDA, is 
increased by hyperglycaemia. This model of neuronal brain injury has been 
widely used to test the protective effects of pharmacological agents against an 
excitotoxic brain insult and could provide important information on the effects 
of a clinically relevant glucose insult during excitotoxic processes. 
It is conceivable that acute hyperglycaemia, at the levels induced in this thesis, 
could exacerbate some, if not all of the proposed pathophysiological 
mechanisms of hyperglycaemia during ischaemia to a small degree that only  
when combined together have a significant effect on infarct size. This might be 
true of the studies in this thesis.  In Chapter 5 glucose treated rats tended to 
have a larger volume of tissue with a perfusion deficit compared to 
normoglycaemic rats.  Likewise, in Chapter 6 ischaemic brain tissue from 
hyperglycaemic rats tended to have more spectrin break down products than 
normoglycaemic rats, which could indicate a greater amount of calpain activity 
resulting from an increase in calcium influx during neuronal excitotoxicity.  
Neither the perfusion deficit data nor western blot data alone is sufficient to 
explain the significant increase in acute ADC lesion volume and infarct size 
observed in hyperglycaemic rats, yet a combination of these different 
mechanisms might.  This could be a problem for future pre-clinical mechanistic 
studies as it may never be possible to pin point a single definitive 
pathophysiological mechanism.   
7.1.3 Future investigation of hyperglycaemia in experimental stroke 
The studies performed in this thesis, as well as previous in-house studies (Tarr, 
2012), demonstrated the effects of hyperglycaemia on acute lesion volume and 
infarct size using identical methods to induce hyperglycaemia and focal cerebral 
ischaemia. Although our results appear to be reproducible they are only 
applicable to a single stroke model which may be a limiting factor.  Further 
studies are therefore needed to determine if hyperglycaemia has the same 
effect on lesion volume in alternative stroke models.  Consideration should be 
given to the embolic stroke model.  This model more closely mimics human 
stroke but it is seldom used as it produces ischaemic lesions that are more 
variable in size and location than other MCAO models. This makes it difficult for 
assessing neuroprotective therapies as large group sizes are required to 
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overcome this inherent variation.  Despite this, the embolic model is the most 
suitable for assessing the safety and efficacy of antithrombotic drugs and 
combination therapies.  As such, the embolic model would be the most suitable 
model for assessing the detrimental impact of hyperglycaemia during 
thrombolyisis. Clinical studies have demonstrated an association between 
admission hyperglycaemia and an increased risk of haemorrhage with rt-PA 
induced thrombolysis (Bruno et al., 2002, Alvarez-Sabin et al., 2003, Kase et al., 
2001, De Silva et al., 2010).  This is supported by the observation that 
hyperglycaemia induces rt-PA induced haemorrhage after focal cerebral 
ischaemia in rodents.  Since thrombolyisis with rt-PA is currently the only 
licensed treatment for ischaemic stroke patients it is important to determine the 
mechanisms underlying this association.  Further to this, it is important that 
novel therapies for PSH are tested in combination with rt-PA to determine 
whether such therapies can reduce the risk of haemorrhage associated with rt-
PA.  Fan et al (2013) recently investigated the feasibility of early glycaemic 
control with insulin combined with rt-PA thrombolysis in a focal embolic stroke 
model of type 1 diabetic rats.  They demonstrated that a combination therapy 
with insulin and rt-PA significantly reduced brain infarction and swelling and 
ameliorated rt-PA-associated haemorrhagic transformation 24 hours after stroke 
(Fan et al., 2013). Similar studies are needed to assess the outcome of 
hyperglycaemia and rt-PA in non-diabetic rats.   
Further studies are also required to assess the impact of hyperglycaemia on CBF 
in animal models with pre-diabetic status.  This is essential because although the 
effects of hyperglycaemia during ischaemic stroke are reported to be worse in 
non-diabetic patients, at follow-up many of these patients are found to have 
underlying dysglycaemia such as impaired glucose tolerance and insulin 
resistance (Kernan et al., 2005, Matz et al., 2006, Vancheri et al., 2005).  
Similar to diabetes, these pre-diabetic conditions could lead to changes in the 
cerebrovasculature that may influence vascular tone and integrity which can 
ultimately affect CBF and the magnitude of ischaemic injury. 
7.1.4 Clinical management of post-stroke hyperglycaemia 
Current European and American guidelines for the management of PSH 
recommend intervention with insulin to treat hyperglycaemia. The European 
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Stroke Initiative guidelines recommend treatment of hyperglycaemia with insulin 
when blood glucose levels exceed 10mmol/L (European Stroke Organisation 
Executive and Committee, 2008), whereas the American Stroke Association state 
that it is reasonable to treat hyperglycaemia in acute ischaemic stroke to 
achieve  blood glucose levels in the range 140-180mg/dL (7.8-10mmol/L)(Jauch 
et al., 2013).  Despite these recommendations, there is limited evidence from 
clinical trials that treatment of PSH with insulin improves patient outcome.  To 
date, the GIST-UK trial is the only large-scale trial that has prospectively 
investigated the influence of glycaemic control on clinical outcome after stroke.  
The results from GIST-UK show that there was no influence of insulin infusion 
therapy on the primary outcome measure: 90-day mortality rate, compared to 
saline infusion although there were several limitations to the study.  Firstly 
GIST-UK enrolled only 933 patients out of the original target of 2355 and was 
therefore underpowered to enable accurate conclusions about clinical outcome 
to be made.  Secondly, the study enrolled a heterogeneous population of 
patients, including patients, with lacunar and haemorrhagic strokes as well as 
patients with a wide range of comorbidities including those with a history of 
diabetes, hypertension and previous stroke. Lastly, insulin treatment was 
administered for 24 hours, with the median time to treatment beginning 
approximately 13 hours after the onset of stroke symptoms.  By including such a 
heterogeneous population the GIST-UK trial could have diluted any treatment 
effect as studies have shown that the relationship between hyperglycaemia and 
patient outcome differs between stroke subtypes and the absence or presence of 
existing comorbidities (Uyttenboogaart et al., 2007, Capes et al., 2001, Kruyt et 
al., 2008).  Furthermore, the results presented in this thesis suggest that insulin 
treatment in GIST-UK may have been initiated outside the therapeutic time-
window.  By using MRI we found that the harmful effects of hyperglycaemia 
occurred during the acute 1-2 hours after stroke onset.  If future glucose 
lowering protocols are to be effective, studies should aim to initiate treatment 
within this time-window. Although this is a challenging target to meet, if 
hyperglycaemia does indeed accelerate ischaemic brain damage there will be no 
benefit of glucose lowering/neuroprotective therapies if they are administered 
after the damage has been done.  
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Although the results from GIST-UK were neutral the trial did provide useful data 
that will aid the design of future clinical trials of which a large multicentre, 
randomized controlled trial for PSH is currently ongoing.  Stroke Hyperglycaemia 
Insulin Network Effort (SHINE) was established to evaluate the safety and 
efficacy of targeted glucose control (intravenous insulin with target 4-7mmol/L) 
versus control therapy (subcutaneous insulin plus basal insulin with a target 
blood glucose <10mmol/L) in patients with diabetes or admission hyperglycaemia 
(>6.0mmol/L) within 12 hours of symptom onset.   The primary outcome of the 
trial is functional outcome at 3 months as measured by the modified Rankin 
Scale score.  This trial is in the process of enrolling patients at present and the 
results won’t be available until 2018.  The results from SHINE are expected to 
have a considerable impact on the management of stroke patients with 
hyperglycaemia.  The eligibility criteria for SHINE will result in a stroke 
population that is less heterogeneous compared to GIST-UK.  In addition, the 
trial also recommends that insulin therapies are given within 3 hours of 
admission. Therefore subsequent post-hoc analyses from the trial could provide 
valuable information on the importance of this early time window for treatment. 
SHINE will also administer insulin treatment for 72 hours after symptom onset.  
Increasing the length of time that insulin is administered for in comparison to 
GIST-UK could benefit patients with persistent hyperglycaemia.  Blood glucose 
levels have been reported to decline during the first 24 hours after stroke (Gray 
et al., 2007, Yong and Kaste, 2008), but can rise again after 24 to 88 hours, 
regardless of diabetic status (Allport et al., 2006).  Administering insulin therapy 
beyond 24 hours could therefore benefit a wider range of patients.  However, 
active treatment in the acute phase can only be successful as long as there is 
viable tissue. At present it is still unclear how long the ischaemic penumbra 
exists for in stroke patients, and whether this time window is influenced by high 
glucose levels. Therefore although the administration of insulin for 72 hours may 
lower blood glucose levels it may not have any benefit if there is no viable tissue 
to salvage. Thus, future clinical trials of glucose lowering therapies for PSH 
could consider recruiting only patients with evidence of a penumbra, as 
determined by either perfusion CT or MRI perfusion-diffusion mismatch 
techniques.  
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7.1.5 Future strategies for preclinical stroke research:  
Experimental stroke research 
To date, the neuroprotective effects of more than 1000 interventions for 
experimental stroke have been published.  Of these, only 1 pharmacological 
treatment: thrombolysis with rt-PA, has successfully translated from the bench 
to bedside (Figure 7.1, (O'Collins et al., 2006)). There are a number of 
experimental factors which may explain why so many neuroprotective agents 
showed efficacy in vivo but failed to translate to the human stroke population.  
Differences between the complexity of the human stroke population and animal 
populations in experimental stroke studies may be an important factor.  
Preclinical studies usually involve MCAO in young, healthy animals under 
anaesthesia with tightly controlled temperature, blood pressure and blood 
gasses. In contrast, clinical trials permit multiple stroke subtypes and elderly 
patients with a range of associated variables that can affect prognosis including: 
comorbidities such as diabetes and hypertension, prior strokes, polypharmacy 
and poor collateral circulation. Future preclinical studies could address some of 
these issues by including older animals with comorbidities. For example, an 18 
month old rat with diabetes and hypertension would provide a more accurate 
representation of the clinical stroke population than the 3-4 month old healthy 
rats used in many previous studies.  As well as the need to include aged animals, 
pre-clinical studies should also incorporate more female animals as the 
susceptibility and responses to stroke can be different between genders 
(Wiszniewska et al., 2011, Liu et al., 2009). Females are highly 
underrepresented in experimental stroke research despite the fact that there 
are more total incidences of stroke and a higher 30-day mortality rate in woman 
compared to men (Roger, 2011). In addition to the appropriateness of the 
experimental animals, discrepancies between the stroke model (transient or 
permanent), outcome measures (histology vs functional outcomes), study quality 
(randomization, blinding, consideration of statistical power) therapeutic 
windows and drug-dosing schedules have also been linked to the failure of 
neuroprotection strategies to translate from the laboratory to the clinical setting 
(O'Collins et al., 2006) 
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Figure 7.1.  1026 interventions in experimental stroke.  A review of pre-clinical stroke 
studies identified 1026 interventions which had been tested in in vitro and in vivo 
experimental stroke models (O'Collins et al., 2006).  Of these, 603 were tested in focal 
ischaemia.  374 were effective in focal ischaemia and of these 97 were tested in clinical 
trials.  To date, only one intervention, thrombolysis with rtPA, has been approved for the 
treatment of ischaemic stroke (Figure adapted from (Dirnagl, 2015)).  
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In particular, the higher proportion of studies using transient rather than 
permanent MCAO models may have contributed significantly to the failure to 
translate neuroprotective therapies from the bench to bedside. The evolution of 
ischaemic injury is very different between transient and permanent or gradually 
reversed focal ischaemia models (embolic MCAO occlusion).  In permanent MCAO 
or gradually reversed focal ischaemia models the evolution of injury follows a 
similar pattern to that observed clinically.  Damage to the core ischaemic region 
is irreversible but the progression of the penumbra to infarction can be 
prevented by intervention, but only within a short therapeutic time window of 
approximately 3 hours after the onset of focal ischaemia (Hossmann, 2012). 
However in transient focal ischaemia models some damage to the core ischaemic 
region can recover following prompt reperfusion, but is followed by delayed 
secondary injury or reperfusion injury that occurs after an interval of as long as 
6 to 12 hours (Hossmann, 2012).  Intervention within this interval can reduce 
ischaemic injury but this longer therapeutic time-window is not clinically 
relevant (Saver et al., 2010).  This could explain the failure of many clinical 
trials which have been designed on the basis of transient MCAO studies and 
therefore have a therapeutic window which is far too long.  For example, a 
meta-analysis of pre-clinical studies investigating the effects of NXY-59, a 
neuroprotective drug that showed promise in animal studies but not in the 
Stroke–Acute Ischaemic NYX Treatment I (SAINT I) trial, reported that the design 
of SAINT I was heavily biased on successful studies which used transient focal 
ischaemia models and treatment delays ranging from 15 minutes to 5 hours after 
ischaemia/reperfusion (Bath et al., 2009).  
The poor translational power of preclinical stroke studies led to the 
establishment of the Stroke Therapy Academic Industry Roundtable (STAIR), 
which issues guidelines to improve the quality of pre-clinical stroke research 
((STAIR), 1999). Some of the recommendations from STAIR highlight the 
importance of study design factors such as randomization, blinding and sample 
size calculations as many neuroprotection studies appeared to show selection 
bias by not including or reporting randomization of treatments and blinding of 
investigators (van der Worp et al., 2005).   
These recommendations from STAIR were considered when designing the 
experiments in this thesis.  For example, rats were randomized to glucose or 
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vehicle treatment groups using an online randomization plan generator and the 
investigator was blinded to the treatment groups in each study. Despite this it is 
possible that some degree of bias was introduced as it was obvious which group 
received glucose from taking regular blood glucose measurements.  
It has also been recognised that many neuroprotective studies using animal 
models of stroke may have been underpowered to detect the effect they report, 
as most studies use group sizes with fewer than 10 animals per group (Howells et 
al., 2014). Power calculations were performed to calculate the number of rats 
required to determine the effects of hyperglycaemia on the 99mTc-HMPAO blood 
flow deficit after MCAO in Chapter 4 and on acute lesion volume in Chapter 5.  
These calculations were based on the standard deviation and change in infarct 
volume between glucose and vehicle treated WKY rats from previous in-house 
studies as this data set was considered the most appropriate.  
In order to overcome the translational problems encountered in pre-clinical 
stroke research (in fact, pre-clinical research as a whole as many of the 
translational issues in stroke research also apply to other research fields) effort 
is required, not just from the research community, but also from funding bodies 
and publishers.  If they do not advocate strict adherence to the STAIR guidelines, 
and continue to fund and publish research which does not adhere to these 
recommendations, the problem will only continue. 
Practical solutions to overcoming the translational failures are being taken and 
one of these is the establishment of Multi-PART, the first randomized controlled 
pre-clinical trial network.  The key objective of Multi-PART is to bring the rigour 
of the randomized, controlled, multicentre clinical trial design to the pre-
clinical setting. Such a design will help to reduce biases related to individual 
laboratory practises and conditions and ultimately provide strong, evidence 
based criteria to inform the decision on whether to move a novel therapeutic 
into clinical development. 
7.1.6 Conclusion 
Post-stroke hyperglycaemia is common and associated with worse clinical 
outcomes.  The pathophysiology underlying this association is poorly understood 
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and most of the proposed pathophysiological mechanisms have been inferred 
from animal models which are clinically irrelevant.  The findings reported in this 
thesis demonstrated, using a clinically relevant model of PSH, that 
hyperglycaemia does not exacerbate ischaemic damage by increasing the 
severity of the ischaemic insult. Therefore the mechanism by which 
hyperglycaemia exacerbates acute ischaemic damage remains to be determined.  
The results further demonstrate that hyperglycaemia is harmful to the ischaemic 
brain during the acute 1-2 hours after the onset of ischaemia, which indicates 
that there may be a narrow window of opportunity for the treatment of PSH. 
Future pre-clinical and clinical studies are needed to confirm this as the effects 
of glucose-lowering therapies given after this time-window could provide no 
benefit, only the risk of further damage by inducing hypoglycaemia.   
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